Other Sites:
Robert J. Robbins is a biologist, an educator, a science administrator, a publisher, an information technologist, and an IT leader and manager who specializes in advancing biomedical knowledge and supporting education through the application of information technology. More About: RJR | OUR TEAM | OUR SERVICES | THIS WEBSITE
RJR: Recommended Bibliography 22 Nov 2026 at 01:36 Created:
Alzheimer Disease — Current Literature
Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer's, symptoms first appear in their mid-60s. Alzheimer's is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to such an extent that it interferes with a person's daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person's functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Scientists don't yet fully understand what causes Alzheimer's disease in most people. There is a genetic component to some cases of early-onset Alzheimer's disease. Late-onset Alzheimer's arises from a complex series of brain changes that occur over decades. The causes probably include a combination of genetic, environmental, and lifestyle factors. The importance of any one of these factors in increasing or decreasing the risk of developing Alzheimer's may differ from person to person. This bibliography runs a generic query on "Alzheimer" and then restricts the results to papers published in or after 2017.
Created with PubMed® Query: 2024:2026[dp] AND ( alzheimer*[TIAB] ) NOT pmcbook NOT ispreviousversion
Citations The Papers (from PubMed®)
RevDate: 2026-11-21
CmpDate: 2026-11-21
Integration of Neuroimaging and Histopathology in a Squirrel Monkey Model of Spontaneous Cerebral Amyloid Angiopathy and Amyloid-Related Imaging Abnormalities.
bioRxiv : the preprint server for biology.
Cerebral amyloid angiopathy (CAA) is a prevalent cerebrovascular pathology in AD and contributes to amyloid-related imaging abnormalities (ARIA), a major complication of current anti-amyloid immunotherapy. Despite its growing clinical importance, critical gaps remain in the development of reliable biomarkers for antemortem diagnosis of CAA. Squirrel monkeys (SQMs) are a valuable non-human primate model with translational relevance due to their universal propensity to develop abundant CAA and spontaneous ARIA in geriatric animals. The present study employed R 2 * , the apparent transverse relaxation rate, which is sensitive to susceptibility-related tissue properties, including iron content and blood oxygenation levels, to monitor age-related brain pathology in SQMs with varying CAA severity. Young, early geriatric, and late geriatric SQMs underwent 7T MRI using a dual-purpose T 2 * -w 3D multi-gradient-echo sequence for high-resolution anatomy and quantitative R 2 * mapping, alongside T 2-w/FLAIR imaging. Whole-brain and gray matter R 2 * increased with age. In contrast, white matter R 2 * showed an initial increase followed by a late-life reversal, likely reflecting age-related changes in myelin integrity, tissue microstructure, and tissue water content. MRI-histopathology correlation linked T 2 * -w MRI hypointensities to CAA-positive iron-laden vessels associated with perivascular inflammation and, in some cases, hemosiderin deposits. Here we confirmed the occurrence of ARIA-H and ARIA-E events in geriatric animals. SQMs provided a valuable opportunity to examine the underlying pathology of spontaneous ARIA-E, revealing distinctive tissue signatures associated with its manifestation. ARIA-E hyperintensities were characterized by reactive gliosis and BBB disruption, whereas more advanced lesions exhibited perivascular lymphocytic infiltration and evidence of myelin and axonal injury. The current study presents compelling evidence linking R 2 * alterations with CAA severity and ARIA-related tissue injury, providing a foundation for further advancing early detection of CAA, ARIA risk assessment, and treatment strategies.
Additional Links: PMID-42999189
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid42999189,
year = {2026},
author = {Wadghiri, YZ and Khan, S and Soliman, MT and Szabo, J and Murray, A and Patel, AG and Kingsley, C and Swain, J and Nehete, PN and Veraart, J and Mulholland, MM and Hopkins, WD and Wisniewski, T and Scholtzova, H},
title = {Integration of Neuroimaging and Histopathology in a Squirrel Monkey Model of Spontaneous Cerebral Amyloid Angiopathy and Amyloid-Related Imaging Abnormalities.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
pmid = {42999189},
issn = {2692-8205},
support = {R21 NS153418/NS/NINDS NIH HHS/United States ; U24 NS135568/NS/NINDS NIH HHS/United States ; P40 OD010938/OD/NIH HHS/United States ; P30 CA016672/CA/NCI NIH HHS/United States ; R01 NS128190/NS/NINDS NIH HHS/United States ; R33 AG073305/AG/NIA NIH HHS/United States ; },
abstract = {Cerebral amyloid angiopathy (CAA) is a prevalent cerebrovascular pathology in AD and contributes to amyloid-related imaging abnormalities (ARIA), a major complication of current anti-amyloid immunotherapy. Despite its growing clinical importance, critical gaps remain in the development of reliable biomarkers for antemortem diagnosis of CAA. Squirrel monkeys (SQMs) are a valuable non-human primate model with translational relevance due to their universal propensity to develop abundant CAA and spontaneous ARIA in geriatric animals. The present study employed R 2 * , the apparent transverse relaxation rate, which is sensitive to susceptibility-related tissue properties, including iron content and blood oxygenation levels, to monitor age-related brain pathology in SQMs with varying CAA severity. Young, early geriatric, and late geriatric SQMs underwent 7T MRI using a dual-purpose T 2 * -w 3D multi-gradient-echo sequence for high-resolution anatomy and quantitative R 2 * mapping, alongside T 2-w/FLAIR imaging. Whole-brain and gray matter R 2 * increased with age. In contrast, white matter R 2 * showed an initial increase followed by a late-life reversal, likely reflecting age-related changes in myelin integrity, tissue microstructure, and tissue water content. MRI-histopathology correlation linked T 2 * -w MRI hypointensities to CAA-positive iron-laden vessels associated with perivascular inflammation and, in some cases, hemosiderin deposits. Here we confirmed the occurrence of ARIA-H and ARIA-E events in geriatric animals. SQMs provided a valuable opportunity to examine the underlying pathology of spontaneous ARIA-E, revealing distinctive tissue signatures associated with its manifestation. ARIA-E hyperintensities were characterized by reactive gliosis and BBB disruption, whereas more advanced lesions exhibited perivascular lymphocytic infiltration and evidence of myelin and axonal injury. The current study presents compelling evidence linking R 2 * alterations with CAA severity and ARIA-related tissue injury, providing a foundation for further advancing early detection of CAA, ARIA risk assessment, and treatment strategies.},
}
RevDate: 2026-11-20
Long-term exposures to low concentrations of fine particles (PM2.5) from vehicular exhausts and residential wood combustion and the incidence of dementia and Alzheimer's disease.
Environmental research pii:S0013-9351(26)02542-9 [Epub ahead of print].
BACKGROUND: Long-term exposure to fine particulate matter (PM2.5; aerodynamic diameter ≤ 2.5μm) has been associated with dementia and Alzheimer's disease (AD). However, little is known about whether low levels of source-specific PM2.5 are associated with cognitive decline.
STUDY AIMS: We investigated associations between long-term exposure to low concentrations of PM2.5 from key local sources, i.e., vehicular exhausts and residential wood combustion, and dementia and AD incidence.
METHODS: We followed adults from Helsinki and Vantaa, Finland, who participated in the FINRISK population surveys in 1992, 1997, 2002, 2007, or 2012, until 2022 using register data. Modelled outdoor PM2.5 concentrations (3- to 15-year averages) were linked to participants' residential addresses. We used Cox proportional hazards models and adjusted for potential confounders.
RESULTS: Of the participants (N = 5487), 601 developed dementia and 500 developed AD during the follow-up. The annual mean outdoor concentrations (standard deviations) of PM2.5 from vehicular exhausts and residential wood combustion were 1.06 μg/m[3] (0.95) and 0.45 μg/m[3] (0.21), respectively. We found no association between PM2.5 from vehicular exhausts or from residential wood combustion and dementia incidence. The hazard ratios (HRs) for a 0.1 μg/m[3] increase in PM2.5 were 0.95 (95% CI: 0.85, 1.05) and 1.23 (95% CI: 0.79, 1.92), respectively. However, HRs for the latter were consistently elevated in different models. No associations were observed for AD.
CONCLUSIONS: Exposure to PM2.5 from vehicular exhausts or residential wood combustion was not associated with dementia or AD in this study. Air pollution levels may have been too low to cause significant health effects.
Additional Links: PMID-43064223
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43064223,
year = {2026},
author = {Allaouat, S and Yli-Tuomi, T and Tiittanen, P and Kukkonen, J and Mikkonen, S and Ngandu, T and Männistö, S and Lanki, T},
title = {Long-term exposures to low concentrations of fine particles (PM2.5) from vehicular exhausts and residential wood combustion and the incidence of dementia and Alzheimer's disease.},
journal = {Environmental research},
volume = {},
number = {},
pages = {126205},
doi = {10.1016/j.envres.2026.126205},
pmid = {43064223},
issn = {1096-0953},
abstract = {BACKGROUND: Long-term exposure to fine particulate matter (PM2.5; aerodynamic diameter ≤ 2.5μm) has been associated with dementia and Alzheimer's disease (AD). However, little is known about whether low levels of source-specific PM2.5 are associated with cognitive decline.
STUDY AIMS: We investigated associations between long-term exposure to low concentrations of PM2.5 from key local sources, i.e., vehicular exhausts and residential wood combustion, and dementia and AD incidence.
METHODS: We followed adults from Helsinki and Vantaa, Finland, who participated in the FINRISK population surveys in 1992, 1997, 2002, 2007, or 2012, until 2022 using register data. Modelled outdoor PM2.5 concentrations (3- to 15-year averages) were linked to participants' residential addresses. We used Cox proportional hazards models and adjusted for potential confounders.
RESULTS: Of the participants (N = 5487), 601 developed dementia and 500 developed AD during the follow-up. The annual mean outdoor concentrations (standard deviations) of PM2.5 from vehicular exhausts and residential wood combustion were 1.06 μg/m[3] (0.95) and 0.45 μg/m[3] (0.21), respectively. We found no association between PM2.5 from vehicular exhausts or from residential wood combustion and dementia incidence. The hazard ratios (HRs) for a 0.1 μg/m[3] increase in PM2.5 were 0.95 (95% CI: 0.85, 1.05) and 1.23 (95% CI: 0.79, 1.92), respectively. However, HRs for the latter were consistently elevated in different models. No associations were observed for AD.
CONCLUSIONS: Exposure to PM2.5 from vehicular exhausts or residential wood combustion was not associated with dementia or AD in this study. Air pollution levels may have been too low to cause significant health effects.},
}
RevDate: 2026-11-20
Brain variation underlying genetic factors linked to psychiatric and neurodegenerative disorders.
Biological psychiatry. Cognitive neuroscience and neuroimaging pii:S2451-9022(26)00343-5 [Epub ahead of print].
BACKGROUND: Psychiatric and neurodegenerative conditions have both shared and distinct symptomatology, but the brain mechanisms underlying diagnostic similarities and differences remain unclear.
METHODS: Using genome-wide association data, we analyzed 12 psychiatric disorders and four neurodegenerative diseases, assessing polygenic overlap, shared loci, and genetic causal relationships linking their genetic latent factors with 3,935 brain imaging-derived phenotypes (IDP).
RESULTS: Using genomic structural equation modeling, we identified an internalizing factor (F1), an addiction factor (F2), a factor related to schizophrenia and bipolar disorder (F3), a neurodevelopmental factor (F4), and a factor related to Alzheimer's disease and amyotrophic lateral sclerosis (F5). These showed shared transcriptomic enrichments for frontal and anterior cingulate cortical regions, while F1-specific depletion in substantia nigra and F3-specific enrichment in nucleus accumbens appeared to be specific. Fine-mapping identified 99 variants, including shared loci (e.g., VRK2: F1, F2, F3; TSHZ3: F1, F2; TCF4: F1, F3) and factor-specific loci (e.g., DRD2-F2; SCN2A-F3; FOXP2-F4; TNIP1-F5). The brain-wide analysis of fine-mapped loci identified 1,480 IDP associations (false discovery rate q<0.05). Among these, BANK1 rs1813006, related to F2, was associated to >400 brain IDPs (mostly related to cortical area, cortical grey-white contrast, cortical thickness, and regional and tissue volume). Similarly, MOBP rs1768190 related to F5 was associated with >200 brain IDPs, with about half of them related to cortical thickness.
CONCLUSIONS: The present study provides new insights into cross-diagnostic mechanisms linking genetic variation and molecular changes to the brain structural and functional variation across psychiatric and neurodegenerative conditions.
Additional Links: PMID-43064242
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43064242,
year = {2026},
author = {Xu, Z and Mao, Z and Qiu, D and Cabrera-Mendoza, B and Liu, H and He, J and Polimanti, R},
title = {Brain variation underlying genetic factors linked to psychiatric and neurodegenerative disorders.},
journal = {Biological psychiatry. Cognitive neuroscience and neuroimaging},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.bpsc.2026.11.005},
pmid = {43064242},
issn = {2451-9030},
abstract = {BACKGROUND: Psychiatric and neurodegenerative conditions have both shared and distinct symptomatology, but the brain mechanisms underlying diagnostic similarities and differences remain unclear.
METHODS: Using genome-wide association data, we analyzed 12 psychiatric disorders and four neurodegenerative diseases, assessing polygenic overlap, shared loci, and genetic causal relationships linking their genetic latent factors with 3,935 brain imaging-derived phenotypes (IDP).
RESULTS: Using genomic structural equation modeling, we identified an internalizing factor (F1), an addiction factor (F2), a factor related to schizophrenia and bipolar disorder (F3), a neurodevelopmental factor (F4), and a factor related to Alzheimer's disease and amyotrophic lateral sclerosis (F5). These showed shared transcriptomic enrichments for frontal and anterior cingulate cortical regions, while F1-specific depletion in substantia nigra and F3-specific enrichment in nucleus accumbens appeared to be specific. Fine-mapping identified 99 variants, including shared loci (e.g., VRK2: F1, F2, F3; TSHZ3: F1, F2; TCF4: F1, F3) and factor-specific loci (e.g., DRD2-F2; SCN2A-F3; FOXP2-F4; TNIP1-F5). The brain-wide analysis of fine-mapped loci identified 1,480 IDP associations (false discovery rate q<0.05). Among these, BANK1 rs1813006, related to F2, was associated to >400 brain IDPs (mostly related to cortical area, cortical grey-white contrast, cortical thickness, and regional and tissue volume). Similarly, MOBP rs1768190 related to F5 was associated with >200 brain IDPs, with about half of them related to cortical thickness.
CONCLUSIONS: The present study provides new insights into cross-diagnostic mechanisms linking genetic variation and molecular changes to the brain structural and functional variation across psychiatric and neurodegenerative conditions.},
}
RevDate: 2026-11-20
Sleep characteristics, glymphatic proxies, and ATN biomarkers in Alzheimer's disease.
NeuroImage pii:S1053-8119(26)00674-9 [Epub ahead of print].
BACKGROUND: Sleep and glymphatic dysfunction are increasingly recognized as contributing factors to Alzheimer's disease (AD) pathology. This study examined both the main and interactive effects of sleep characteristics and glymphatic proxies on ATN biomarkers across the AD continuum.
METHODS: This cross-sectional study included 325 participants (50-86 years, 36% male) who underwent 18F-Florbetapir and 18F-Flortaucipir PET/MRI. We assessed sleep characteristics by obtaining habitual sleep duration and the Pittsburgh Sleep Quality Index (PSQI). Neuroimaging-derived glymphatic proxies were choroid plexus volume fraction (CPVF), perivascular space volume fraction (PVSF), and free water within cerebral white matter (WMFW). Linear regression was used to examine the main and interactive associations of sleep characteristics and glymphatic proxies with ATN biomarkers.
RESULTS: Prolonged sleep duration was associated with greater temporal tau burden (β = 0.25) and thinner cortical thickness (CTh, β = -0.19, both p < 0.01). Higher WMFW was associated with greater global Aβ burden (β = 0.20), greater temporal tau burden (β = 0.22), and thinner CTh (β = -0.41, all p < 0.01). Higher CPVF was associated with greater temporal tau burden (β = 0.15), and higher PVSF was associated with thinner CTh (β = -0.14, both p < 0.05). Notably, WMFW consistently moderated the associations between sleep duration and ATN biomarkers (|t| range = 2.61 to 2.78, q < 0.05).
CONCLUSIONS: These findings support a role for sleep-glymphatic interactions in shaping AD pathology and suggest that this interplay warrants further investigation in longitudinal studies.
Additional Links: PMID-43064328
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43064328,
year = {2026},
author = {Xie, H and Gan, R and Wu, X and Li, Y and Lin, H and Wang, H and Gao, H and Zhao, Z and Chen, T and Chen, Q and Jia, Z},
title = {Sleep characteristics, glymphatic proxies, and ATN biomarkers in Alzheimer's disease.},
journal = {NeuroImage},
volume = {},
number = {},
pages = {122360},
doi = {10.1016/j.neuroimage.2026.122360},
pmid = {43064328},
issn = {1095-9572},
abstract = {BACKGROUND: Sleep and glymphatic dysfunction are increasingly recognized as contributing factors to Alzheimer's disease (AD) pathology. This study examined both the main and interactive effects of sleep characteristics and glymphatic proxies on ATN biomarkers across the AD continuum.
METHODS: This cross-sectional study included 325 participants (50-86 years, 36% male) who underwent 18F-Florbetapir and 18F-Flortaucipir PET/MRI. We assessed sleep characteristics by obtaining habitual sleep duration and the Pittsburgh Sleep Quality Index (PSQI). Neuroimaging-derived glymphatic proxies were choroid plexus volume fraction (CPVF), perivascular space volume fraction (PVSF), and free water within cerebral white matter (WMFW). Linear regression was used to examine the main and interactive associations of sleep characteristics and glymphatic proxies with ATN biomarkers.
RESULTS: Prolonged sleep duration was associated with greater temporal tau burden (β = 0.25) and thinner cortical thickness (CTh, β = -0.19, both p < 0.01). Higher WMFW was associated with greater global Aβ burden (β = 0.20), greater temporal tau burden (β = 0.22), and thinner CTh (β = -0.41, all p < 0.01). Higher CPVF was associated with greater temporal tau burden (β = 0.15), and higher PVSF was associated with thinner CTh (β = -0.14, both p < 0.05). Notably, WMFW consistently moderated the associations between sleep duration and ATN biomarkers (|t| range = 2.61 to 2.78, q < 0.05).
CONCLUSIONS: These findings support a role for sleep-glymphatic interactions in shaping AD pathology and suggest that this interplay warrants further investigation in longitudinal studies.},
}
RevDate: 2026-11-20
Symptomatic amyloid-related imaging abnormalities following lecanemab treatment in a patient with Alzheimer's disease-related mild cognitive impairment.
BMJ case reports, 19(11): pii:19/11/e275192.
Additional Links: PMID-43064495
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43064495,
year = {2026},
author = {Kutoku, Y and Homma, T and Mihara, M},
title = {Symptomatic amyloid-related imaging abnormalities following lecanemab treatment in a patient with Alzheimer's disease-related mild cognitive impairment.},
journal = {BMJ case reports},
volume = {19},
number = {11},
pages = {},
doi = {10.1136/bcr-2026-275192},
pmid = {43064495},
issn = {1757-790X},
}
RevDate: 2026-11-20
"We take care of ours": Dementia Care Partner Perspectives on Consumer- vs Agency-Directed Care.
The Gerontologist pii:9108415 [Epub ahead of print].
BACKGROUND AND OBJECTIVES: Medicaid-funded personal care provides essential support enabling persons with dementia to remain in the community. This care is managed either by an agency (agency-direction) or by the care recipient or their designee (consumer-direction). Persons with dementia are more likely to use consumer-direction, but little is known about what drives care model choice, or how the motivations for seeking care and resulting care experiences differ for users of each model.
RESEARCH DESIGN AND METHODS: We conducted semi-structured interviews with care partners of community-living persons with dementia receiving personal care through New York Medicaid (n = 18), using directed content analysis to identify key themes.
RESULTS: Three common goals guided the choice of consumer- vs agency-direction: maximize care quality, ensure provider continuity, and minimize care partner burden. The same goal could lead families to opposite decisions: some chose consumer-direction believing family provided higher-quality care, whereas others chose agency-direction trusting that aides were better trained. Ensuring continuity was most salient for consumer-direction users; minimizing burden most salient for agency-direction users. Regardless of care model, cultural norms and negative experiences with institutional care were primary motivators for using home-based personal care. Common challenges included service hours lagging escalating care needs, administrative obstacles to managing care, and insufficient support from the broader social network.
DISCUSSION AND IMPLICATIONS: Personal care recipients and their families need flexible Medicaid policies enabling them to choose arrangements-including care setting and model-that best align with their needs and preferences, alongside resources to navigate a complex benefits system.
Additional Links: PMID-43064686
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43064686,
year = {2026},
author = {Burgdorf, JG and Fabius, C and Reckrey, JM and Russell, D},
title = {"We take care of ours": Dementia Care Partner Perspectives on Consumer- vs Agency-Directed Care.},
journal = {The Gerontologist},
volume = {},
number = {},
pages = {},
doi = {10.1093/geront/gnag261},
pmid = {43064686},
issn = {1758-5341},
abstract = {BACKGROUND AND OBJECTIVES: Medicaid-funded personal care provides essential support enabling persons with dementia to remain in the community. This care is managed either by an agency (agency-direction) or by the care recipient or their designee (consumer-direction). Persons with dementia are more likely to use consumer-direction, but little is known about what drives care model choice, or how the motivations for seeking care and resulting care experiences differ for users of each model.
RESEARCH DESIGN AND METHODS: We conducted semi-structured interviews with care partners of community-living persons with dementia receiving personal care through New York Medicaid (n = 18), using directed content analysis to identify key themes.
RESULTS: Three common goals guided the choice of consumer- vs agency-direction: maximize care quality, ensure provider continuity, and minimize care partner burden. The same goal could lead families to opposite decisions: some chose consumer-direction believing family provided higher-quality care, whereas others chose agency-direction trusting that aides were better trained. Ensuring continuity was most salient for consumer-direction users; minimizing burden most salient for agency-direction users. Regardless of care model, cultural norms and negative experiences with institutional care were primary motivators for using home-based personal care. Common challenges included service hours lagging escalating care needs, administrative obstacles to managing care, and insufficient support from the broader social network.
DISCUSSION AND IMPLICATIONS: Personal care recipients and their families need flexible Medicaid policies enabling them to choose arrangements-including care setting and model-that best align with their needs and preferences, alongside resources to navigate a complex benefits system.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Innate Immunity in the Oral-Brain Axis: Trained Immunity as a Candidate Link Between Periodontitis and Alzheimer's Disease.
Molecular neurobiology, 63(1):.
Alzheimer's disease (AD) is a complex neurodegenerative disorder shaped by aging, genetic susceptibility, and environmental factors. Observational studies have associated periodontitis with cognitive impairment and dementia, but its causal contribution to AD remains uncertain. This review examines trained immunity as a potential mechanism through which chronic periodontal inflammation might modify neuroinflammatory susceptibility. Trained immunity refers to persistent functional reprogramming of innate immune cells following an initial stimulus, supported by metabolic and epigenetic remodeling and altered responses to subsequent challenges, and is distinct from inflammatory activation during ongoing periodontitis. Studies suggest that experimental periodontal inflammation can reprogram bone marrow myelopoiesis, and separate studies demonstrate that peripheral inflammatory stimulation can alter microglial memory and amyloid pathology. These findings establish different components of the proposed pathway. However, clinical evidence for periodontitis-associated training is preliminary and inconsistent, and direct demonstration that such training mediates AD biomarker changes or clinical progression is lacking. Therefore, we distinguish human associations, genetic causal-inference studies, periodontal experiments, and mechanisms established in non-periodontal models. Shared risk factors, reverse causation, exposure heterogeneity, and potentially protective or tolerant immune responses provide important alternative interpretations. We propose stimulus-removal experiments, lineage-resolved perturbation studies, and longitudinal human investigations to test persistence and mediation. Supportive periodontal care remains indicated for oral health; its neuroprotective efficacy, oral-fluid biomarkers of AD, and oral-brain prediction models require prospective validation. The framework positions periodontitis as a potential modifier while retaining systemic inflammatory aging and shared susceptibility as competing explanations.
Additional Links: PMID-43064881
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43064881,
year = {2026},
author = {Jia, Y and Ding, J and Wu, J and Wang, H and Wang, X and Cao, Z},
title = {Innate Immunity in the Oral-Brain Axis: Trained Immunity as a Candidate Link Between Periodontitis and Alzheimer's Disease.},
journal = {Molecular neurobiology},
volume = {63},
number = {1},
pages = {},
pmid = {43064881},
issn = {1559-1182},
support = {82571093//National Natural Science Foundation of China/ ; 2023YFC2506300//National Key Research and Development Program of China/ ; },
mesh = {Humans ; *Alzheimer Disease/immunology ; *Trained Immunity ; Animals ; *Immunity, Innate/immunology ; *Brain/immunology/pathology ; *Periodontitis/immunology/complications ; *Mouth/immunology/pathology ; },
abstract = {Alzheimer's disease (AD) is a complex neurodegenerative disorder shaped by aging, genetic susceptibility, and environmental factors. Observational studies have associated periodontitis with cognitive impairment and dementia, but its causal contribution to AD remains uncertain. This review examines trained immunity as a potential mechanism through which chronic periodontal inflammation might modify neuroinflammatory susceptibility. Trained immunity refers to persistent functional reprogramming of innate immune cells following an initial stimulus, supported by metabolic and epigenetic remodeling and altered responses to subsequent challenges, and is distinct from inflammatory activation during ongoing periodontitis. Studies suggest that experimental periodontal inflammation can reprogram bone marrow myelopoiesis, and separate studies demonstrate that peripheral inflammatory stimulation can alter microglial memory and amyloid pathology. These findings establish different components of the proposed pathway. However, clinical evidence for periodontitis-associated training is preliminary and inconsistent, and direct demonstration that such training mediates AD biomarker changes or clinical progression is lacking. Therefore, we distinguish human associations, genetic causal-inference studies, periodontal experiments, and mechanisms established in non-periodontal models. Shared risk factors, reverse causation, exposure heterogeneity, and potentially protective or tolerant immune responses provide important alternative interpretations. We propose stimulus-removal experiments, lineage-resolved perturbation studies, and longitudinal human investigations to test persistence and mediation. Supportive periodontal care remains indicated for oral health; its neuroprotective efficacy, oral-fluid biomarkers of AD, and oral-brain prediction models require prospective validation. The framework positions periodontitis as a potential modifier while retaining systemic inflammatory aging and shared susceptibility as competing explanations.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/immunology
*Trained Immunity
Animals
*Immunity, Innate/immunology
*Brain/immunology/pathology
*Periodontitis/immunology/complications
*Mouth/immunology/pathology
RevDate: 2026-11-21
CmpDate: 2026-11-21
Data-driven clustering of atrophy patterns in Alzheimer's disease.
Alzheimer's research & therapy, 18(1):.
BACKGROUND: To enable early detection and treatment of Alzheimer's disease, a better understanding of the heterogeneous disease progression is needed. Longitudinal MRI data has been utilized by previous studies to uncover patterns of brain atrophy. In this work, we aimed to improve upon previous methods by combining a continuous modeling of disease stages with a data-driven clustering algorithm.
METHODS: We developed an algorithm that primarily stages subjects on a continuous latent-time disease scale and subsequently finds clusters of atrophy patterns in a completely data-driven manner. The core of the algorithm is a set of non-linear mixed-effects models, which includes both subject-specific random effects and cluster-specific fixed effects. We applied our algorithm to longitudinal MRI data from the ADNI and OASIS databases and analyzed the found clusters rigorously by studying biomarkers, indicators of co-pathologies, and connections with previously established subtypes. We also utilized the BioFINDER-2 cohort as an independent validation dataset.
RESULTS: We found four clusters of longitudinal atrophy patterns; A: Progressive atrophy, B: Slow progression, C: Delayed atrophy and D: High atrophy. The D (High atrophy) exhibited higher amounts of atrophy, primarily in the typical regions affected in AD. The delayed atrophy group C remained relatively spared until the final stages of the disease, where we saw rapid neurodegeneration. The B (Slow progression) group displayed the least atrophy, and the A (Progressive atrophy) group showed a typical AD-like progression. However, the clusters could only be somewhat reproduced in perturbations of the discovery cohort. In the validation cohort, two clusters were found, which to a certain degree resembled some characteristics of the ADNI/OASIS clusters.
CONCLUSION: Our method combines a continuous disease staging model with a data-driven clustering algorithm, which mitigates some limitations of previous attempts at modeling brain atrophy patterns in Alzheimer's disease. We found four clusters of atrophy patterns, which expressed different clinical profiles. However, the clusters are likely mixes of previously found AD subtypes, and are produced from continuous progression patterns rather than discrete subtypes.
Additional Links: PMID-43065059
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43065059,
year = {2026},
author = {Winzell, F and Raket, LL and Overgaard, NC and Åström, K and Stomrud, E and Spotorno, N and Janelidze, S and Palmqvist, S and Heyden, A and Arvidsson, I and Mattsson-Carlgren, N},
title = {Data-driven clustering of atrophy patterns in Alzheimer's disease.},
journal = {Alzheimer's research & therapy},
volume = {18},
number = {1},
pages = {},
pmid = {43065059},
issn = {1758-9193},
mesh = {*Alzheimer Disease/diagnostic imaging/pathology ; Humans ; Atrophy/pathology ; Magnetic Resonance Imaging ; Clustering Algorithms ; *Brain/pathology/diagnostic imaging ; Disease Progression ; Cluster Analysis ; Female ; Longitudinal Studies ; Male ; Algorithms ; Aged ; },
abstract = {BACKGROUND: To enable early detection and treatment of Alzheimer's disease, a better understanding of the heterogeneous disease progression is needed. Longitudinal MRI data has been utilized by previous studies to uncover patterns of brain atrophy. In this work, we aimed to improve upon previous methods by combining a continuous modeling of disease stages with a data-driven clustering algorithm.
METHODS: We developed an algorithm that primarily stages subjects on a continuous latent-time disease scale and subsequently finds clusters of atrophy patterns in a completely data-driven manner. The core of the algorithm is a set of non-linear mixed-effects models, which includes both subject-specific random effects and cluster-specific fixed effects. We applied our algorithm to longitudinal MRI data from the ADNI and OASIS databases and analyzed the found clusters rigorously by studying biomarkers, indicators of co-pathologies, and connections with previously established subtypes. We also utilized the BioFINDER-2 cohort as an independent validation dataset.
RESULTS: We found four clusters of longitudinal atrophy patterns; A: Progressive atrophy, B: Slow progression, C: Delayed atrophy and D: High atrophy. The D (High atrophy) exhibited higher amounts of atrophy, primarily in the typical regions affected in AD. The delayed atrophy group C remained relatively spared until the final stages of the disease, where we saw rapid neurodegeneration. The B (Slow progression) group displayed the least atrophy, and the A (Progressive atrophy) group showed a typical AD-like progression. However, the clusters could only be somewhat reproduced in perturbations of the discovery cohort. In the validation cohort, two clusters were found, which to a certain degree resembled some characteristics of the ADNI/OASIS clusters.
CONCLUSION: Our method combines a continuous disease staging model with a data-driven clustering algorithm, which mitigates some limitations of previous attempts at modeling brain atrophy patterns in Alzheimer's disease. We found four clusters of atrophy patterns, which expressed different clinical profiles. However, the clusters are likely mixes of previously found AD subtypes, and are produced from continuous progression patterns rather than discrete subtypes.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
*Alzheimer Disease/diagnostic imaging/pathology
Humans
Atrophy/pathology
Magnetic Resonance Imaging
Clustering Algorithms
*Brain/pathology/diagnostic imaging
Disease Progression
Cluster Analysis
Female
Longitudinal Studies
Male
Algorithms
Aged
RevDate: 2026-11-21
CmpDate: 2026-11-21
Traditional Chinese Medicine Regulates Microglia for the Treatment of Alzheimer's Disease: A Paradigm Shift From Phenotypic Modulation to Metabolic Reprogramming and Molecular Regulation.
Journal of immunology research, 2026(1):.
Alzheimer's disease (AD) remains the most prevalent neurodegenerative disorder, and current pharmacotherapies provide only limited symptomatic relief without meaningful disease modification. Microglia-mediated neuroinflammation is a central driver of AD progression, yet conventional research on traditional Chinese medicine (TCM) has largely framed its effects as M1/M2 phenotypic modulation. This descriptive framework cannot capture the high heterogeneity of microglia in vivo or identify direct molecular targets. Phenotypic modulation and metabolic reprogramming are mechanistically distinct: M1/M2-associated markers are phenotypic readouts, whereas metabolic reprogramming refers to the causal rewiring of glycolysis, oxidative phosphorylation/TCA-cycle flux, lipid metabolism, and mitochondrial dysfunction. Recent advances in single-cell/spatial transcriptomics, multiomics, chemical proteomics, structural biology, and genetic validation are driving a paradigm shift from phenotypic description toward molecular targeting by accelerating TCM target discovery and mechanistic dissection. To avoid overstating target specificity, we apply a three-level evidence framework-direct target, target-dependent, and pathway-dependent-and emphasize that molecular docking and network pharmacology are hypothesis-generating rather than direct target evidence. TCM-derived compounds and formulas regulate an interconnected microglial metabo-inflammatory network across four modules: metabolic enzymes (e.g., isocitrate dehydrogenase 1 (IDH1), multifunctional enzyme type 2 [MFE-2], glutaminase 1 [GLS1], hexokinase 2 [HK2], and phosphodiesterase 4B [PDE4B]), metabolic sensors (e.g., triggering receptor expressed on myeloid cells 2 [TREM2] and succinate receptor 1 [SUCNR1]), cell-fate regulators (e.g., ferroptosis and autophagy/mitophagy), and transcriptional/inflammatory execution nodes (e.g., peroxisome proliferator-activated receptor gamma [PPARγ], nuclear factor erythroid 2-related factor 2 [Nrf2], and NOD-like receptor family pyrin domain-containing 3 [NLRP3]). These modules are linked by reciprocal feedback rather than a unidirectional causal cascade. Targeted delivery systems further support translational development by overcoming the blood-brain barrier (BBB) and enabling microglial targeting. Future mechanism-oriented trials should use chemically standardized TCM products and integrate target-engagement biomarkers with pharmacokinetic/pharmacodynamic (PK/PD) assessment to bridge preclinical and clinical research. Overall, precise intervention in the microglial metabo-inflammatory network represents a promising frontier for TCM modernization and next-generation AD therapeutics. Trial Registration: ClinicalTrials.gov identifier: NCT06534723; WHO ICTRP Primary Registry: ITMCTR2023000014.
Additional Links: PMID-43065222
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43065222,
year = {2026},
author = {Lai, G and Hu, B and Duan, S and Yang, X and Xie, G and Wu, X},
title = {Traditional Chinese Medicine Regulates Microglia for the Treatment of Alzheimer's Disease: A Paradigm Shift From Phenotypic Modulation to Metabolic Reprogramming and Molecular Regulation.},
journal = {Journal of immunology research},
volume = {2026},
number = {1},
pages = {},
doi = {10.1155/jimr/4142717},
pmid = {43065222},
issn = {2314-7156},
support = {2026-Q-XZ-05//Medical & Health Leading Academic Discipline Project of Zhenhai District/ ; 2025Z159//Ningbo Major Research and Development Plan Project/ ; LTGY24B050001//Natural Science Foundation of Zhejiang Province/ ; 2024Z184//Key Project of Ningbo Science and Technology/ ; 2023Z196//Ningbo Key Research and Development Program/ ; },
mesh = {Humans ; *Alzheimer Disease/drug therapy/metabolism/etiology ; *Microglia/drug effects/metabolism/immunology ; Animals ; Metabolic Reprogramming ; *Medicine, Chinese Traditional/methods ; *Drugs, Chinese Herbal/therapeutic use/pharmacology ; Phenotype ; },
abstract = {Alzheimer's disease (AD) remains the most prevalent neurodegenerative disorder, and current pharmacotherapies provide only limited symptomatic relief without meaningful disease modification. Microglia-mediated neuroinflammation is a central driver of AD progression, yet conventional research on traditional Chinese medicine (TCM) has largely framed its effects as M1/M2 phenotypic modulation. This descriptive framework cannot capture the high heterogeneity of microglia in vivo or identify direct molecular targets. Phenotypic modulation and metabolic reprogramming are mechanistically distinct: M1/M2-associated markers are phenotypic readouts, whereas metabolic reprogramming refers to the causal rewiring of glycolysis, oxidative phosphorylation/TCA-cycle flux, lipid metabolism, and mitochondrial dysfunction. Recent advances in single-cell/spatial transcriptomics, multiomics, chemical proteomics, structural biology, and genetic validation are driving a paradigm shift from phenotypic description toward molecular targeting by accelerating TCM target discovery and mechanistic dissection. To avoid overstating target specificity, we apply a three-level evidence framework-direct target, target-dependent, and pathway-dependent-and emphasize that molecular docking and network pharmacology are hypothesis-generating rather than direct target evidence. TCM-derived compounds and formulas regulate an interconnected microglial metabo-inflammatory network across four modules: metabolic enzymes (e.g., isocitrate dehydrogenase 1 (IDH1), multifunctional enzyme type 2 [MFE-2], glutaminase 1 [GLS1], hexokinase 2 [HK2], and phosphodiesterase 4B [PDE4B]), metabolic sensors (e.g., triggering receptor expressed on myeloid cells 2 [TREM2] and succinate receptor 1 [SUCNR1]), cell-fate regulators (e.g., ferroptosis and autophagy/mitophagy), and transcriptional/inflammatory execution nodes (e.g., peroxisome proliferator-activated receptor gamma [PPARγ], nuclear factor erythroid 2-related factor 2 [Nrf2], and NOD-like receptor family pyrin domain-containing 3 [NLRP3]). These modules are linked by reciprocal feedback rather than a unidirectional causal cascade. Targeted delivery systems further support translational development by overcoming the blood-brain barrier (BBB) and enabling microglial targeting. Future mechanism-oriented trials should use chemically standardized TCM products and integrate target-engagement biomarkers with pharmacokinetic/pharmacodynamic (PK/PD) assessment to bridge preclinical and clinical research. Overall, precise intervention in the microglial metabo-inflammatory network represents a promising frontier for TCM modernization and next-generation AD therapeutics. Trial Registration: ClinicalTrials.gov identifier: NCT06534723; WHO ICTRP Primary Registry: ITMCTR2023000014.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/drug therapy/metabolism/etiology
*Microglia/drug effects/metabolism/immunology
Animals
Metabolic Reprogramming
*Medicine, Chinese Traditional/methods
*Drugs, Chinese Herbal/therapeutic use/pharmacology
Phenotype
RevDate: 2026-11-21
CmpDate: 2026-11-21
Antipsychotic drug sensitivity in Alzheimer's disease due to blood-brain barrier breakdown with considerations for clinical prescribing: a narrative review.
Frontiers in drug delivery, 6:1957314 pii:1957314.
Alzheimer's Disease (AD) is a neurodegenerative condition that affects cognitive function, memory and behaviour. Antipsychotics are used to manage psychosis and agitation in AD, through antagonism of dopamine (D2/3) receptors. However, AD patients exhibit an increased sensitivity to antipsychotics that is not shared with patients of other neuropsychiatric disorders. Importantly, older AD patients using antipsychotics show a clinical response and experience parkinsonian side effects at reduced doses with high D2/3 receptor occupancies and lower blood drug concentrations. Consequently, these patients have higher morbidity and mortality risks. A critical component in AD pathophysiology is the blood-brain barrier (BBB), a highly selective cellular monolayer separating blood from parenchyma. This narrative mini-review aims to explore current literature on the role of BBB dysfunction in altering antipsychotic drug sensitivity in AD and the clinical implications to prescribing. We investigate the relationship between BBB dysfunction in AD, involving tight junction protein loss and change in function and expression of transporters, and an increase in brain antipsychotic bioavailability and hypersensitivity. We note that regulatory agencies discourage antipsychotic drug usage in AD through black box warnings and recommendations of avoidance where possible, and only the lowest dose and shortest duration to be prescribed. We conclude that further BBB and receptor occupancy studies in elderly AD patients are essential to ensure a more tailored approach that integrates biomarkers of BBB integrity and drug sensitivity for optimal and targeted pharmacotherapy.
Additional Links: PMID-43065708
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43065708,
year = {2026},
author = {Nwalema, N and Thomas, SA},
title = {Antipsychotic drug sensitivity in Alzheimer's disease due to blood-brain barrier breakdown with considerations for clinical prescribing: a narrative review.},
journal = {Frontiers in drug delivery},
volume = {6},
number = {},
pages = {1957314},
doi = {10.3389/fddev.2026.1957314},
pmid = {43065708},
issn = {2674-0850},
abstract = {Alzheimer's Disease (AD) is a neurodegenerative condition that affects cognitive function, memory and behaviour. Antipsychotics are used to manage psychosis and agitation in AD, through antagonism of dopamine (D2/3) receptors. However, AD patients exhibit an increased sensitivity to antipsychotics that is not shared with patients of other neuropsychiatric disorders. Importantly, older AD patients using antipsychotics show a clinical response and experience parkinsonian side effects at reduced doses with high D2/3 receptor occupancies and lower blood drug concentrations. Consequently, these patients have higher morbidity and mortality risks. A critical component in AD pathophysiology is the blood-brain barrier (BBB), a highly selective cellular monolayer separating blood from parenchyma. This narrative mini-review aims to explore current literature on the role of BBB dysfunction in altering antipsychotic drug sensitivity in AD and the clinical implications to prescribing. We investigate the relationship between BBB dysfunction in AD, involving tight junction protein loss and change in function and expression of transporters, and an increase in brain antipsychotic bioavailability and hypersensitivity. We note that regulatory agencies discourage antipsychotic drug usage in AD through black box warnings and recommendations of avoidance where possible, and only the lowest dose and shortest duration to be prescribed. We conclude that further BBB and receptor occupancy studies in elderly AD patients are essential to ensure a more tailored approach that integrates biomarkers of BBB integrity and drug sensitivity for optimal and targeted pharmacotherapy.},
}
RevDate: 2026-11-21
CmpDate: 2026-11-21
Ultrasound-Assisted Enzymatic Extraction of Flavonoids from Pouteria caimito Leaves: Process Optimization, Mechanistic Investigation, and Bioactivity Evaluation.
ACS omega, 11(45):70355-70374.
To enhance the resource utilization value of Pouteria caimito leaves, this study employed ultrasound-assisted enzymatic extraction (UAE) to extract flavonoids from Pouteria caimito leaves (PCL). The UAE process was optimized using single-factor experiments combined with response surface methodology. Scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), and X-ray diffraction (XRD) were used to investigate structural changes in leaf tissues and the synergistic extraction effects of ultrasound and enzymatic hydrolysis. UHPLC-HRMS/MS was used to characterize extracts obtained by different extraction methods, and seasonal variations in flavonoid content and biological activity were also evaluated. The optimal extraction conditions were as follows: solid-liquid ratio of 1:50, ethanol concentration of 50%, pH 3.6, enzyme addition of 1.6%, enzymatic hydrolysis temperature of 50 °C, enzymatic hydrolysis time of 51 min, ultrasonic temperature of 50 °C, and ultrasonic time of 39 min. Under these conditions, the flavonoid extraction yield by UAE was higher than that achieved by ultrasonic extraction (UE) or enzymatic extraction (EE) alone. SEM, FT-IR, and XRD results demonstrated more extensive cell wall disruption and higher extraction efficiency with UAE. After purification using AB-8 macroporous resin, flavonoid purity increased from 32.84% to 73.15%. Activity evaluation showed that the purified product (MRP) exhibited strong antioxidant and multienzyme inhibitory activities: DPPH IC50 = (0.0197 ± 0.0014) mg/mL, ABTS[+]• IC50 = (0.0560 ± 0.0016) mg/mL, tyrosinase IC50 = (0.2911 ± 0.0022) mg/mL, acetylcholinesterase IC50 = (0.5303 ± 0.0101) mg/mL, and α-amylase IC50 = (0.3328 ± 0.0100) mg/mL. Network pharmacology further identified catechin, dihydrotricetin, and kaempferol 3,5,7-trimethyl ether as key candidate compounds and suggested that their potential effects against Alzheimer's disease may involve AChE-related regulation within the "Neuroactive ligand signaling" pathway. January was identified as the optimal harvest period. This study demonstrates the potential of UAE for the high-value utilization of PCL flavonoids.
Additional Links: PMID-43066164
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066164,
year = {2026},
author = {Li, X and Li, W and Ma, Q and Gao, X and Liu, Q and Xu, R and Li, J},
title = {Ultrasound-Assisted Enzymatic Extraction of Flavonoids from Pouteria caimito Leaves: Process Optimization, Mechanistic Investigation, and Bioactivity Evaluation.},
journal = {ACS omega},
volume = {11},
number = {45},
pages = {70355-70374},
doi = {10.1021/acsomega.6c07655},
pmid = {43066164},
issn = {2470-1343},
abstract = {To enhance the resource utilization value of Pouteria caimito leaves, this study employed ultrasound-assisted enzymatic extraction (UAE) to extract flavonoids from Pouteria caimito leaves (PCL). The UAE process was optimized using single-factor experiments combined with response surface methodology. Scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), and X-ray diffraction (XRD) were used to investigate structural changes in leaf tissues and the synergistic extraction effects of ultrasound and enzymatic hydrolysis. UHPLC-HRMS/MS was used to characterize extracts obtained by different extraction methods, and seasonal variations in flavonoid content and biological activity were also evaluated. The optimal extraction conditions were as follows: solid-liquid ratio of 1:50, ethanol concentration of 50%, pH 3.6, enzyme addition of 1.6%, enzymatic hydrolysis temperature of 50 °C, enzymatic hydrolysis time of 51 min, ultrasonic temperature of 50 °C, and ultrasonic time of 39 min. Under these conditions, the flavonoid extraction yield by UAE was higher than that achieved by ultrasonic extraction (UE) or enzymatic extraction (EE) alone. SEM, FT-IR, and XRD results demonstrated more extensive cell wall disruption and higher extraction efficiency with UAE. After purification using AB-8 macroporous resin, flavonoid purity increased from 32.84% to 73.15%. Activity evaluation showed that the purified product (MRP) exhibited strong antioxidant and multienzyme inhibitory activities: DPPH IC50 = (0.0197 ± 0.0014) mg/mL, ABTS[+]• IC50 = (0.0560 ± 0.0016) mg/mL, tyrosinase IC50 = (0.2911 ± 0.0022) mg/mL, acetylcholinesterase IC50 = (0.5303 ± 0.0101) mg/mL, and α-amylase IC50 = (0.3328 ± 0.0100) mg/mL. Network pharmacology further identified catechin, dihydrotricetin, and kaempferol 3,5,7-trimethyl ether as key candidate compounds and suggested that their potential effects against Alzheimer's disease may involve AChE-related regulation within the "Neuroactive ligand signaling" pathway. January was identified as the optimal harvest period. This study demonstrates the potential of UAE for the high-value utilization of PCL flavonoids.},
}
RevDate: 2026-11-21
CmpDate: 2026-11-21
Transcranial pulse stimulation in the treatment of cognitive disorders of aging: a systematic review.
Frontiers in psychiatry, 17:1958477.
INTRODUCTION: Non-invasive brain stimulation techniques, specifically transcranial pulse stimulation (TPS) are of increasing interest due to their potential to fill in gaps left by current pharmacological treatments in cognitive disorders of aging. The current review's aims were to systematically determine what cognitive disorders of aging have been studied with TPS as a treatment and to narratively summarize what is known about the effectiveness of TPS treatment in the aging subpopulation through neurocognitive performance metrics and neuroimaging metrics.
METHODS: This review is PRISMA 2020 compliant. Searches were conducted in PubMed, PsycINFO (through PsycNET to include all APA Databases), Embase, and Scopus. Title/Abstract screening, full text screening, and extraction were completed by two independent reviewers with discrepancies worked out through discussion. Outcomes were systematically chosen for formal analysis where dual reviewers completed risk of bias and certainty of evidence assessments, and remaining outcomes were synthesized narratively.
RESULTS: 11 studies were included, consisting of 10 nonrandomized studies and 1 randomized controlled trial (RCT). Due to follow ups and suspected cohort overlap, the 11 studies are not representative of 11 independent patient cohorts. Included studies examined Alzheimer's Disease and related dementias, mild neurocognitive disorder, mild cognitive impairment and Parkinson's Disease through a variety of neurocognitive performance metrics and neuroimaging metrics. Formal synthesis showed a preliminary trend for positive change from before to after stimulation, particularly in neuropsychological batteries measuring global cognition, however number of contributing results and overall certainty of evidence were both very low. Neuroimaging results varied with trends of statistically significant functional changes, though also limited by limited literature and low certainty.
DISCUSSION: Though there is a continued need for high quality research and randomized controlled trials using TPS in the treatment of neurocognitive disorders of aging, the current evidence indicates potential for promising changes in neurocognitive performance metric outcomes and functional neuroimaging measures from before to after stimulation pending additional controlled trials. Though there is currently not enough high quality evidence to support clinical recommendations, what is known could support the use of TPS in the treatment of neurocognitive disorders of aging should RCTs continue to support positive improvements associated with this non-invasive intervention.
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251246424.
Additional Links: PMID-43066253
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066253,
year = {2026},
author = {Wiechens, K and Engesser, A and Ryan, G and Gullett, JM},
title = {Transcranial pulse stimulation in the treatment of cognitive disorders of aging: a systematic review.},
journal = {Frontiers in psychiatry},
volume = {17},
number = {},
pages = {1958477},
doi = {10.3389/fpsyt.2026.1958477},
pmid = {43066253},
issn = {1664-0640},
abstract = {INTRODUCTION: Non-invasive brain stimulation techniques, specifically transcranial pulse stimulation (TPS) are of increasing interest due to their potential to fill in gaps left by current pharmacological treatments in cognitive disorders of aging. The current review's aims were to systematically determine what cognitive disorders of aging have been studied with TPS as a treatment and to narratively summarize what is known about the effectiveness of TPS treatment in the aging subpopulation through neurocognitive performance metrics and neuroimaging metrics.
METHODS: This review is PRISMA 2020 compliant. Searches were conducted in PubMed, PsycINFO (through PsycNET to include all APA Databases), Embase, and Scopus. Title/Abstract screening, full text screening, and extraction were completed by two independent reviewers with discrepancies worked out through discussion. Outcomes were systematically chosen for formal analysis where dual reviewers completed risk of bias and certainty of evidence assessments, and remaining outcomes were synthesized narratively.
RESULTS: 11 studies were included, consisting of 10 nonrandomized studies and 1 randomized controlled trial (RCT). Due to follow ups and suspected cohort overlap, the 11 studies are not representative of 11 independent patient cohorts. Included studies examined Alzheimer's Disease and related dementias, mild neurocognitive disorder, mild cognitive impairment and Parkinson's Disease through a variety of neurocognitive performance metrics and neuroimaging metrics. Formal synthesis showed a preliminary trend for positive change from before to after stimulation, particularly in neuropsychological batteries measuring global cognition, however number of contributing results and overall certainty of evidence were both very low. Neuroimaging results varied with trends of statistically significant functional changes, though also limited by limited literature and low certainty.
DISCUSSION: Though there is a continued need for high quality research and randomized controlled trials using TPS in the treatment of neurocognitive disorders of aging, the current evidence indicates potential for promising changes in neurocognitive performance metric outcomes and functional neuroimaging measures from before to after stimulation pending additional controlled trials. Though there is currently not enough high quality evidence to support clinical recommendations, what is known could support the use of TPS in the treatment of neurocognitive disorders of aging should RCTs continue to support positive improvements associated with this non-invasive intervention.
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251246424.},
}
RevDate: 2026-11-21
Targeted cholinesterase inhibition by novel oxoisoindoline derivatives with potential activity against BACE1 and serotonin receptor.
RSC medicinal chemistry pii:d6md00482b [Epub ahead of print].
In the ongoing search to target Alzheimer's disease, the inhibitory potential of novel oxoisoindoline derivatives against two key enzymes, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), was investigated. The structures of all synthesized derivatives were confirmed through [1]H-NMR, [13]C-NMR, IR spectroscopy, and CHN analysis. Among the derivatives, compound 7e exhibited remarkable inhibitory activities, with IC50 values of 1.22 ± 0.26 and 0.40 ± 0.13 against AChE and BChE, respectively. Further kinetic studies revealed that compound 7e exhibited mixed-type inhibition for both AChE and BChE. Molecular dynamics simulations demonstrated the stability of compound 7e within the active sites of AChE, reinforcing its inhibitory potency. Toxicity assessments on SH-SY5Y cells indicated no significant cytotoxic effects at concentrations up to 50 μM over 72 hours. Additionally, at a concentration of 25 μM, compound 7e was shown to reduce mRNA expression levels of BACE1 and HTR6 in cell-based assays, with minimal effects observed on GSK-3α and GSK-3β levels. The in vivo evaluation of compound 7e using an Alzheimer's disease animal model demonstrated significant improvements in cognitive and behavioral parameters, further substantiating its therapeutic potential. These findings provide valuable insights into the potential of oxoisoindoline derivatives as promising leads for Alzheimer's disease therapy and warrant further investigation.
Additional Links: PMID-43066429
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066429,
year = {2026},
author = {Dastyafteh, N and Noori, M and Hashempur, MH and Safapoor, S and Dekamin, MG and Mohammadi, H and Irajie, C and Ghomi, MK and Iraji, A and Mahdavi, M},
title = {Targeted cholinesterase inhibition by novel oxoisoindoline derivatives with potential activity against BACE1 and serotonin receptor.},
journal = {RSC medicinal chemistry},
volume = {},
number = {},
pages = {},
doi = {10.1039/d6md00482b},
pmid = {43066429},
issn = {2632-8682},
abstract = {In the ongoing search to target Alzheimer's disease, the inhibitory potential of novel oxoisoindoline derivatives against two key enzymes, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), was investigated. The structures of all synthesized derivatives were confirmed through [1]H-NMR, [13]C-NMR, IR spectroscopy, and CHN analysis. Among the derivatives, compound 7e exhibited remarkable inhibitory activities, with IC50 values of 1.22 ± 0.26 and 0.40 ± 0.13 against AChE and BChE, respectively. Further kinetic studies revealed that compound 7e exhibited mixed-type inhibition for both AChE and BChE. Molecular dynamics simulations demonstrated the stability of compound 7e within the active sites of AChE, reinforcing its inhibitory potency. Toxicity assessments on SH-SY5Y cells indicated no significant cytotoxic effects at concentrations up to 50 μM over 72 hours. Additionally, at a concentration of 25 μM, compound 7e was shown to reduce mRNA expression levels of BACE1 and HTR6 in cell-based assays, with minimal effects observed on GSK-3α and GSK-3β levels. The in vivo evaluation of compound 7e using an Alzheimer's disease animal model demonstrated significant improvements in cognitive and behavioral parameters, further substantiating its therapeutic potential. These findings provide valuable insights into the potential of oxoisoindoline derivatives as promising leads for Alzheimer's disease therapy and warrant further investigation.},
}
RevDate: 2026-11-21
CmpDate: 2026-11-21
Evaluating the Role of Visceral Adiposity in Neurological Disorders: A Systematic Review and Meta-Analysis.
Neurosciences (Riyadh, Saudi Arabia), 31(4):336-358.
BACKGROUND: Neurological disorders represent a major global health challenge. According to recent Global Burden of Disease (GBD) estimates, Alzheimer's disease and other dementias, Parkinson's disease, multiple sclerosis, epilepsy, and headache disorders together account for nearly 3% of the worldwide disease burden. While visceral adipose tissue has traditionally been viewed as a metabolic concern, emerging evidence highlights visceral adiposity as an independent risk factor and potential contributor to the pathogenesis and progression of several neurological disorders.
MATERIALS AND METHODS: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines to evaluate the association between visceral adiposity and neurological disorders. The protocol was registered in PROSPERO (CRD420251083846). A comprehensive search of PubMed, the Cochrane Library, and Web of Science was performed in June 2025. Eligibility criteria were defined using the PICOS framework. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS), adapted for cross-sectional designs where applicable. Adjusted effect estimates were pooled using a random-effects model.
RESULTS: A total of 26 studies involving 1, 059, 075 participants were included; approximately 96% of participants were female, largely because of one nationwide female-only cohort, and mean ages ranged from 44.5 to 78.3 years. Twenty-three studies (88.5%) reported at least one adverse association between greater visceral or central adiposity and poorer neurological or cognitive outcomes.The meta-analysis of 12 studies showed that elevated visceral adiposity was associated with a 48% higher likelihood of adverse neurological outcomes (pooled effect estimate [OR/HR] = 1.48, 95% CI: 1.27-1.72, p < 0.001; I[2] = 83%). Significant associations were observed for stroke-related outcomes (OR = 1.41, 95% CI: 1.15-1.74), young-onset dementia (HR = 1.55, 95% CI: 1.34-1.79), and migraine (OR = 1.41, 95% CI: 1.05-1.88), whereas the pooled estimate for subclinical cerebrovascular imaging findings was elevated but imprecise (OR = 3.49, 95% CI: 0.64-19.10).
CONCLUSION: Elevated visceral adiposity is associated with a higher risk of stroke-related outcomes, dementia, migraine, and adverse brain imaging findings. Given the substantial heterogeneity and the predominance of cross-sectional data, these findings should be confirmed in prospective studies using standardized measures of visceral fat; nevertheless, they support the incorporation of visceral fat assessment into neurological disease prevention strategies.
Additional Links: PMID-43066480
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066480,
year = {2026},
author = {Aldeaiji, LA and Almutairi, AG and Alharbi, LM and Alsulaim, KM and AlShalahi, EE and Alghamdi, YK and Alhamdan, NA},
title = {Evaluating the Role of Visceral Adiposity in Neurological Disorders: A Systematic Review and Meta-Analysis.},
journal = {Neurosciences (Riyadh, Saudi Arabia)},
volume = {31},
number = {4},
pages = {336-358},
doi = {10.17712/1658-3183.2814},
pmid = {43066480},
issn = {1319-6138},
mesh = {Humans ; *Nervous System Diseases/epidemiology ; *Intra-Abdominal Fat ; *Obesity, Abdominal/complications ; *Adiposity ; Female ; },
abstract = {BACKGROUND: Neurological disorders represent a major global health challenge. According to recent Global Burden of Disease (GBD) estimates, Alzheimer's disease and other dementias, Parkinson's disease, multiple sclerosis, epilepsy, and headache disorders together account for nearly 3% of the worldwide disease burden. While visceral adipose tissue has traditionally been viewed as a metabolic concern, emerging evidence highlights visceral adiposity as an independent risk factor and potential contributor to the pathogenesis and progression of several neurological disorders.
MATERIALS AND METHODS: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines to evaluate the association between visceral adiposity and neurological disorders. The protocol was registered in PROSPERO (CRD420251083846). A comprehensive search of PubMed, the Cochrane Library, and Web of Science was performed in June 2025. Eligibility criteria were defined using the PICOS framework. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS), adapted for cross-sectional designs where applicable. Adjusted effect estimates were pooled using a random-effects model.
RESULTS: A total of 26 studies involving 1, 059, 075 participants were included; approximately 96% of participants were female, largely because of one nationwide female-only cohort, and mean ages ranged from 44.5 to 78.3 years. Twenty-three studies (88.5%) reported at least one adverse association between greater visceral or central adiposity and poorer neurological or cognitive outcomes.The meta-analysis of 12 studies showed that elevated visceral adiposity was associated with a 48% higher likelihood of adverse neurological outcomes (pooled effect estimate [OR/HR] = 1.48, 95% CI: 1.27-1.72, p < 0.001; I[2] = 83%). Significant associations were observed for stroke-related outcomes (OR = 1.41, 95% CI: 1.15-1.74), young-onset dementia (HR = 1.55, 95% CI: 1.34-1.79), and migraine (OR = 1.41, 95% CI: 1.05-1.88), whereas the pooled estimate for subclinical cerebrovascular imaging findings was elevated but imprecise (OR = 3.49, 95% CI: 0.64-19.10).
CONCLUSION: Elevated visceral adiposity is associated with a higher risk of stroke-related outcomes, dementia, migraine, and adverse brain imaging findings. Given the substantial heterogeneity and the predominance of cross-sectional data, these findings should be confirmed in prospective studies using standardized measures of visceral fat; nevertheless, they support the incorporation of visceral fat assessment into neurological disease prevention strategies.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Nervous System Diseases/epidemiology
*Intra-Abdominal Fat
*Obesity, Abdominal/complications
*Adiposity
Female
RevDate: 2026-11-21
External validation of a mathematical model of brain health.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundUnderstanding the mechanisms underlying brain aging and age-related pathological changes is essential for advancing brain health research. Our group previously developed a mechanistic mathematical model of healthy brain that integrates key biological processes involved in normal aging, from which Alzheimer's disease (AD)-related changes may emerge naturally.ObjectiveTo characterize and validate this brain model by evaluating its sensitivity, calibrating its parameters, and assessing generalizability in independent populations.MethodsThe model represents the evolution of key biological processes associated with brain aging, including amyloid-β (Aβ), tau pathologies, neuroinflammation, and neuronal death. After identifying the 30 most influential parameters, we calibrated the model using cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (n = 211) by minimizing a loss function composed of three outcomes (Aβ plaques, tau tangles, and neuronal density). The calibrated model was then applied to the UK Biobank cohort (n = 35,899) of normal controls (aged 44-82 years). The effects of sex and APOE were evaluated using stratified simulations.ResultsParameter calibration significantly reduced the prediction errors for Aβ and tau. Neuronal density predictions showed strong agreement in the UK Biobank cohort. The variance decomposition identified APOE status as a major contributor to variability in Aβ.ConclusionsOur validated brain health model links mechanistic pathways with population data and reproduces neuronal density patterns in an independent cohort. These findings support its use as a framework for studying brain aging and investigating how AD-related pathological changes may emerge with aging.
Additional Links: PMID-43066571
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066571,
year = {2026},
author = {Sadia, H and Doyon, N and Duchesne, S and , },
title = {External validation of a mathematical model of brain health.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261507101},
doi = {10.1177/13872877261507101},
pmid = {43066571},
issn = {1875-8908},
abstract = {BackgroundUnderstanding the mechanisms underlying brain aging and age-related pathological changes is essential for advancing brain health research. Our group previously developed a mechanistic mathematical model of healthy brain that integrates key biological processes involved in normal aging, from which Alzheimer's disease (AD)-related changes may emerge naturally.ObjectiveTo characterize and validate this brain model by evaluating its sensitivity, calibrating its parameters, and assessing generalizability in independent populations.MethodsThe model represents the evolution of key biological processes associated with brain aging, including amyloid-β (Aβ), tau pathologies, neuroinflammation, and neuronal death. After identifying the 30 most influential parameters, we calibrated the model using cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (n = 211) by minimizing a loss function composed of three outcomes (Aβ plaques, tau tangles, and neuronal density). The calibrated model was then applied to the UK Biobank cohort (n = 35,899) of normal controls (aged 44-82 years). The effects of sex and APOE were evaluated using stratified simulations.ResultsParameter calibration significantly reduced the prediction errors for Aβ and tau. Neuronal density predictions showed strong agreement in the UK Biobank cohort. The variance decomposition identified APOE status as a major contributor to variability in Aβ.ConclusionsOur validated brain health model links mechanistic pathways with population data and reproduces neuronal density patterns in an independent cohort. These findings support its use as a framework for studying brain aging and investigating how AD-related pathological changes may emerge with aging.},
}
RevDate: 2026-11-21
Shifting landscapes of disease definition and language use in the Alzheimer's disease clinic: A study of specialist clinicians.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundAccompanying paradigm shifts in our biological understanding and treatment of Alzheimer's disease (AD) has been a parallel evolution in conceptualizations of the disease and the culture of clinical care. Diagnostic criteria offer biological and clinical-biological constructs which shape clinicians' mental models of AD, their language use in the clinic, and their patients' experience in society.ObjectiveTo examine how specialist clinicians navigate evolving biological advances in AD, how their perspectives may affect who gets diagnosed and treated, and how patients' lives are impacted outside of the clinic.MethodsOnline survey exploring beliefs and practices of AD specialty clinicians (ASCs) regarding conceptualizations of AD within evolving clinical and biological frameworks. Rapid qualitative analysis was utilized to thematically analyze open-ended responses.ResultsTwenty ASCs completed the survey. Most view AD as a disease or pathology, while less than half view it as an illness. All in this sample actively consider a clinical continuum model of AD when communicating with patients. All cite the opportunity for forthcoming therapeutics, enrolling in clinical trials, future planning, lifestyle changes, and clarified prognosis as advantages of diagnosing early AD in asymptomatic individuals. Disadvantages include emotional distress, potential misunderstandings accompanying the diagnosis, implications for insurance coverage, and stigma.ConclusionsIt is imperative to understand the views and enacted behaviors of all stakeholders in AD care to optimize its many goals. Among ASCs, a deeper fluency with philosophical foundations and assumptions surrounding AD concepts may improve desired outcomes, enable ethically attuned communication, and strengthen therapeutic alliance.
Additional Links: PMID-43066572
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066572,
year = {2026},
author = {Bhardwaj, T and Gale, SA},
title = {Shifting landscapes of disease definition and language use in the Alzheimer's disease clinic: A study of specialist clinicians.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261509203},
doi = {10.1177/13872877261509203},
pmid = {43066572},
issn = {1875-8908},
abstract = {BackgroundAccompanying paradigm shifts in our biological understanding and treatment of Alzheimer's disease (AD) has been a parallel evolution in conceptualizations of the disease and the culture of clinical care. Diagnostic criteria offer biological and clinical-biological constructs which shape clinicians' mental models of AD, their language use in the clinic, and their patients' experience in society.ObjectiveTo examine how specialist clinicians navigate evolving biological advances in AD, how their perspectives may affect who gets diagnosed and treated, and how patients' lives are impacted outside of the clinic.MethodsOnline survey exploring beliefs and practices of AD specialty clinicians (ASCs) regarding conceptualizations of AD within evolving clinical and biological frameworks. Rapid qualitative analysis was utilized to thematically analyze open-ended responses.ResultsTwenty ASCs completed the survey. Most view AD as a disease or pathology, while less than half view it as an illness. All in this sample actively consider a clinical continuum model of AD when communicating with patients. All cite the opportunity for forthcoming therapeutics, enrolling in clinical trials, future planning, lifestyle changes, and clarified prognosis as advantages of diagnosing early AD in asymptomatic individuals. Disadvantages include emotional distress, potential misunderstandings accompanying the diagnosis, implications for insurance coverage, and stigma.ConclusionsIt is imperative to understand the views and enacted behaviors of all stakeholders in AD care to optimize its many goals. Among ASCs, a deeper fluency with philosophical foundations and assumptions surrounding AD concepts may improve desired outcomes, enable ethically attuned communication, and strengthen therapeutic alliance.},
}
RevDate: 2026-11-21
Pharmacological and non-pharmacological management of sleep disturbances in Alzheimer's disease: A systematic review and meta-analysis.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundSleep disturbances affect half of Alzheimer's disease patients, accelerating cognitive decline and increasing caregiver burden. The comparative effectiveness of available interventions remains unclear.ObjectiveTo compare pharmacological and non-pharmacological interventions on sleep outcomes in Alzheimer's disease using network meta-analysis of randomized controlled trials (RCTs).MethodsFollowing PRISMA and a registered PROSPERO protocol (CRD420250653178), four databases (PubMed/MEDLINE, EMBASE, Scopus, Web of Science) were searched through July 2026 for RCTs. Pairwise and frequentist random-effects network meta-analyses using Hedges' g were performed for six sleep outcomes: total sleep time (TST), wake after sleep onset (WASO), nocturnal awakenings (NoA), sleep efficiency, daytime sleep, and daytime naps. A Bayesian network meta-analysis served as a sensitivity analysis.ResultsTwelve RCTs (N = 936, 32 study arms) were included. Zolpidem and zopiclone reduced sleep fragmentation, with improvements in NoA (SMD -1.09) and WASO (SMD -0.86), although these findings were based on a single short-term trial. Suvorexant increased TST (SMD 0.376) and increased TST (SMD 0.376), while lemborexant 2.5 mg reduced NoA (SMD -0.98), with favorable short-term tolerability. Walking (SMD -0.48), bright light therapy (SMD -0.37), and NITE-AD (SMD -0.52) reduced NoA, while combined light therapy and melatonin reduced daytime sleep (SMD -0.858). Melatonin monotherapy, trazodone, and mirtazapine showed limited or inconsistent effects.ConclusionsNon-pharmacological interventions may be considered before pharmacological treatment. When pharmacotherapy is required, dual orexin receptor antagonists may be useful for selected sleep outcomes, whereas Z-drugs should be used cautiously given their established safety concerns. Larger, longer-duration head-to-head trials using standardized sleep outcomes are needed.
Additional Links: PMID-43066573
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066573,
year = {2026},
author = {Sharma, A and Raj, R and Azmi, MO and Puchakayala, N and Kaur, A and S, P and Suresh, V and Datta, A and Deka, AR and Panchawagh, S and Nithyanandam, A and Singh Malhotra, H and Kumar Garg, R and Uwishema, O},
title = {Pharmacological and non-pharmacological management of sleep disturbances in Alzheimer's disease: A systematic review and meta-analysis.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261504983},
doi = {10.1177/13872877261504983},
pmid = {43066573},
issn = {1875-8908},
abstract = {BackgroundSleep disturbances affect half of Alzheimer's disease patients, accelerating cognitive decline and increasing caregiver burden. The comparative effectiveness of available interventions remains unclear.ObjectiveTo compare pharmacological and non-pharmacological interventions on sleep outcomes in Alzheimer's disease using network meta-analysis of randomized controlled trials (RCTs).MethodsFollowing PRISMA and a registered PROSPERO protocol (CRD420250653178), four databases (PubMed/MEDLINE, EMBASE, Scopus, Web of Science) were searched through July 2026 for RCTs. Pairwise and frequentist random-effects network meta-analyses using Hedges' g were performed for six sleep outcomes: total sleep time (TST), wake after sleep onset (WASO), nocturnal awakenings (NoA), sleep efficiency, daytime sleep, and daytime naps. A Bayesian network meta-analysis served as a sensitivity analysis.ResultsTwelve RCTs (N = 936, 32 study arms) were included. Zolpidem and zopiclone reduced sleep fragmentation, with improvements in NoA (SMD -1.09) and WASO (SMD -0.86), although these findings were based on a single short-term trial. Suvorexant increased TST (SMD 0.376) and increased TST (SMD 0.376), while lemborexant 2.5 mg reduced NoA (SMD -0.98), with favorable short-term tolerability. Walking (SMD -0.48), bright light therapy (SMD -0.37), and NITE-AD (SMD -0.52) reduced NoA, while combined light therapy and melatonin reduced daytime sleep (SMD -0.858). Melatonin monotherapy, trazodone, and mirtazapine showed limited or inconsistent effects.ConclusionsNon-pharmacological interventions may be considered before pharmacological treatment. When pharmacotherapy is required, dual orexin receptor antagonists may be useful for selected sleep outcomes, whereas Z-drugs should be used cautiously given their established safety concerns. Larger, longer-duration head-to-head trials using standardized sleep outcomes are needed.},
}
RevDate: 2026-11-21
TToTP model: An automated detection of Alzheimer's disease and frontotemporal dementia using Tesla Tree of Thought Pattern with EEG signals.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundAlzheimer's disease (AD) and frontotemporal dementia (FTD) are common neurological disorders.Objective:To facilitate the early detection of these conditions, we aimed to propose a new self-organized explainable feature engineering (SOXFE) model. Additionally, we sought to investigate the feature extraction capabilities.MethodsWe used a publicly available electroencephalography (EEG) dementia detection dataset. This dataset was created to collect EEG signals from participants in three categories: (i) AD, (ii) FTD, and (iii) healthy control (HC). To automatically detect these groups, we proposed a new SOXFE model. This model includes a novel feature extraction function inspired by Tesla's 369 vortex and the Tree of Thought (ToT), termed the Tesla Tree of Thought Pattern (TToTP). In the feature selection phase, we applied cumulative weighted iterative neighborhood component analysis (CWINCA), to select the most informative features. In the classification phase, we employed the t algorithm-based k-nearest neighbors (tkNN). The fourth phase involves information fusion, where the results from each channel are voted on using iterative majority voting (IMV), and the best outcome is selected. The final phase is explainable results generation, in which a cortical channel map (CCMap) is created based on the findings from the information fusion phase.ResultsWe applied the TToTP-based SOXFE model to the EEG dementia dataset, achieving over 99% classification accuracy. Additionally, a cortical channel map was generated using the classification results.ConclusionsThe proposed TToTP-based SOXFE model achieved high classification performance and successfully generated a cortical channel map. The model contributes to both feature engineering and neuroscience.
Additional Links: PMID-43066578
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066578,
year = {2026},
author = {Tasci, I and Tuncer, T and Barua, PD and Dogan, S and Taşcı, B and Hafeez-Baig, A and Tan, RS and Acharya, UR},
title = {TToTP model: An automated detection of Alzheimer's disease and frontotemporal dementia using Tesla Tree of Thought Pattern with EEG signals.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261509096},
doi = {10.1177/13872877261509096},
pmid = {43066578},
issn = {1875-8908},
abstract = {BackgroundAlzheimer's disease (AD) and frontotemporal dementia (FTD) are common neurological disorders.Objective:To facilitate the early detection of these conditions, we aimed to propose a new self-organized explainable feature engineering (SOXFE) model. Additionally, we sought to investigate the feature extraction capabilities.MethodsWe used a publicly available electroencephalography (EEG) dementia detection dataset. This dataset was created to collect EEG signals from participants in three categories: (i) AD, (ii) FTD, and (iii) healthy control (HC). To automatically detect these groups, we proposed a new SOXFE model. This model includes a novel feature extraction function inspired by Tesla's 369 vortex and the Tree of Thought (ToT), termed the Tesla Tree of Thought Pattern (TToTP). In the feature selection phase, we applied cumulative weighted iterative neighborhood component analysis (CWINCA), to select the most informative features. In the classification phase, we employed the t algorithm-based k-nearest neighbors (tkNN). The fourth phase involves information fusion, where the results from each channel are voted on using iterative majority voting (IMV), and the best outcome is selected. The final phase is explainable results generation, in which a cortical channel map (CCMap) is created based on the findings from the information fusion phase.ResultsWe applied the TToTP-based SOXFE model to the EEG dementia dataset, achieving over 99% classification accuracy. Additionally, a cortical channel map was generated using the classification results.ConclusionsThe proposed TToTP-based SOXFE model achieved high classification performance and successfully generated a cortical channel map. The model contributes to both feature engineering and neuroscience.},
}
RevDate: 2026-11-21
Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundElevated concentrations of fibroblast growth factor 23 (FGF23), a hormone involved in bone mineral and vitamin D metabolism, may be associated with risk of stroke and dementia through inflammation, endothelial dysfunction, vessel calcification and stiffness, and axonal degeneration.ObjectiveWe tested the hypothesis that elevated FGF23 is associated with increased risk of dementia and stroke.MethodsFGF23 was measured in serum samples collected in 1990-1992 from 12,391 participants of the Atherosclerosis Risk in Communities study. Participants were followed through 2019 for incident stroke and dementia. Cox regression was used to examine the associations of FGF23 (in quintiles) with risk of stroke and dementia, with adjustment for demographics, cardiovascular and dementia risk factors, and kidney function.ResultsParticipants (mean 56.9 years; 57% female) were followed a median of 24 years; 1183 developed stroke and 2402 developed dementia. Participants in the highest versus lowest quintile of serum FGF23 were at elevated risk of stroke [HR (95% CI): 1.27 (1.06-1.51)] and dementia [HR: 1.21 (1.06-1.38)] independent of baseline demographics. Associations attenuated with additional adjustment for traditional cardiovascular risk factors [HRstroke: 1.20 (1.00-1.45); HRdementia: 1.17 (1.03-1.35)], and became even weaker after accounting for eGFR [HRstroke: 1.13 (0.94-1.37); HRdementia: 1.14 (1.00-1.31)]. The associations of FGF23 with incident stroke and dementia were not modified by categories of age, sex, race, or eGFR.ConclusionsHigher FGF23 was associated with modestly greater risk of stroke and dementia in this population-based sample, though the association was largely attenuated after adjustment for traditional cardiovascular risk factors and kidney function.
Additional Links: PMID-43066583
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066583,
year = {2026},
author = {Lutsey, PL and Sauerer, DM and Michos, ED and Selvin, E and Rebholz, CM and Gottesman, RF and Alonso, A and Matsushita, K and Sedaghat, S},
title = {Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261507035},
doi = {10.1177/13872877261507035},
pmid = {43066583},
issn = {1875-8908},
abstract = {BackgroundElevated concentrations of fibroblast growth factor 23 (FGF23), a hormone involved in bone mineral and vitamin D metabolism, may be associated with risk of stroke and dementia through inflammation, endothelial dysfunction, vessel calcification and stiffness, and axonal degeneration.ObjectiveWe tested the hypothesis that elevated FGF23 is associated with increased risk of dementia and stroke.MethodsFGF23 was measured in serum samples collected in 1990-1992 from 12,391 participants of the Atherosclerosis Risk in Communities study. Participants were followed through 2019 for incident stroke and dementia. Cox regression was used to examine the associations of FGF23 (in quintiles) with risk of stroke and dementia, with adjustment for demographics, cardiovascular and dementia risk factors, and kidney function.ResultsParticipants (mean 56.9 years; 57% female) were followed a median of 24 years; 1183 developed stroke and 2402 developed dementia. Participants in the highest versus lowest quintile of serum FGF23 were at elevated risk of stroke [HR (95% CI): 1.27 (1.06-1.51)] and dementia [HR: 1.21 (1.06-1.38)] independent of baseline demographics. Associations attenuated with additional adjustment for traditional cardiovascular risk factors [HRstroke: 1.20 (1.00-1.45); HRdementia: 1.17 (1.03-1.35)], and became even weaker after accounting for eGFR [HRstroke: 1.13 (0.94-1.37); HRdementia: 1.14 (1.00-1.31)]. The associations of FGF23 with incident stroke and dementia were not modified by categories of age, sex, race, or eGFR.ConclusionsHigher FGF23 was associated with modestly greater risk of stroke and dementia in this population-based sample, though the association was largely attenuated after adjustment for traditional cardiovascular risk factors and kidney function.},
}
RevDate: 2026-11-21
A comparison of data reduction approaches for the identification of non-cognitive symptom subsyndromes in Alzheimer's disease, based on Neuropsychiatric Inventory scores.
Journal of Alzheimer's disease : JAD [Epub ahead of print].
BackgroundWithin Alzheimer's disease, attempts to perform data reduction on the non-cognitive symptoms comprising the Neuropsychiatric Inventory (NPI) have been inconsistent. Here, most studies used principal component analysis (PCA), despite reports that exploratory factor analysis (EFA) estimates loadings more accurately.ObjectiveWe compared how well different data reduction approaches derived NPI models in a discovery dataset (Alzheimer's Disease Neuroimaging Initiative, n = 460), based on confirmatory factor analysis (CFA) in two independent datasets (Brains for Dementia Research, n = 337 and Memento, n = 211). Specifically, we assessed PCA, maximum likelihood (ML) EFA, principal axis (PA) EFA, and a PCA extension that adjusts for zero inflation. For each method, we additionally compared how different approaches to determine the number of factors/components affected CFA fit indices.MethodsEFA and standard PCA were performed using PSYCH, the zero-inflation adjusted PCA using zibppca, and CFA was performed in Lavaan (all R packages).ResultsIn both confirmatory datasets, PA EFA yielded the closest fitting model (Tucker Lewis Index > 0.95). This model comprised [agitation and irritability], [depression and anxiety], [delusions and hallucinations], and [elation and disinhibition]. We also demonstrated that selecting the number of latent constructs to retain using parallel analysis based on null factors, as opposed to component eigenvalues, was necessary to identify this best fitting model.ConclusionsPA EFA allowed the identification of an acceptable CFA verified NPI subsyndrome structure. Our findings also indicate that previous attempts to identify NPI subsyndrome structure might have been hindered by extracting too few factors/components.
Additional Links: PMID-43066584
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066584,
year = {2026},
author = {Henley, PP and Holmans, P and Kehoe, PG and Sims, R and Sinclair, L and , },
title = {A comparison of data reduction approaches for the identification of non-cognitive symptom subsyndromes in Alzheimer's disease, based on Neuropsychiatric Inventory scores.},
journal = {Journal of Alzheimer's disease : JAD},
volume = {},
number = {},
pages = {13872877261507355},
doi = {10.1177/13872877261507355},
pmid = {43066584},
issn = {1875-8908},
abstract = {BackgroundWithin Alzheimer's disease, attempts to perform data reduction on the non-cognitive symptoms comprising the Neuropsychiatric Inventory (NPI) have been inconsistent. Here, most studies used principal component analysis (PCA), despite reports that exploratory factor analysis (EFA) estimates loadings more accurately.ObjectiveWe compared how well different data reduction approaches derived NPI models in a discovery dataset (Alzheimer's Disease Neuroimaging Initiative, n = 460), based on confirmatory factor analysis (CFA) in two independent datasets (Brains for Dementia Research, n = 337 and Memento, n = 211). Specifically, we assessed PCA, maximum likelihood (ML) EFA, principal axis (PA) EFA, and a PCA extension that adjusts for zero inflation. For each method, we additionally compared how different approaches to determine the number of factors/components affected CFA fit indices.MethodsEFA and standard PCA were performed using PSYCH, the zero-inflation adjusted PCA using zibppca, and CFA was performed in Lavaan (all R packages).ResultsIn both confirmatory datasets, PA EFA yielded the closest fitting model (Tucker Lewis Index > 0.95). This model comprised [agitation and irritability], [depression and anxiety], [delusions and hallucinations], and [elation and disinhibition]. We also demonstrated that selecting the number of latent constructs to retain using parallel analysis based on null factors, as opposed to component eigenvalues, was necessary to identify this best fitting model.ConclusionsPA EFA allowed the identification of an acceptable CFA verified NPI subsyndrome structure. Our findings also indicate that previous attempts to identify NPI subsyndrome structure might have been hindered by extracting too few factors/components.},
}
RevDate: 2026-11-21
The burden of Alzheimer's disease and other dementias in adults aged =60 years in Latin America and the Caribbean, 1990-2023: A systematic analysis of the Global Burden of Disease Study 2023.
Neuroepidemiology pii:9108624 [Epub ahead of print].
Introduction Alzheimer's disease and other dementias (ADOD) represent a growing public health challenge in Latin America and the Caribbean (LAC). Understanding the temporal trends and drivers of the disease burden is essential for health planning. Methods This study analyzed the burden of ADOD, measured by disability-adjusted life years (DALYs), among adults aged ≥60 years across 20 LAC countries from 1990 to 2023. Using estimates from the Global Burden of Disease (GBD) study 2023, we assessed crude and age-standardized DALY rates by sex, age, country and LAC subregions. We also examined the ADOD burden attributable to six modifiable risk factors and applied the Das Gupta decomposition method to estimate the contributions of population growth, aging, and other factors to changes in ADOD DALYs. Results In 2023, ADOD accounted for 2,843,700 (95% UI: 1,300,775-5,858,229) DALYs in LAC, with a higher burden observed in females than males. From 1990 to 2023, crude DALY rates increased sharply with age and across subregions, with Southern Latin America showing the highest relative growth (+32.1% in females; +27.5% in males). ADOD ranked among the top three causes of DALYs for females in Chile, Argentina, Colombia and Uruguay. Modifiable risks accounted for 47.6% of the ADOD burden in the region. Population growth was the primary driver of increased absolute DALYs. Conclusion The burden of ADOD in LAC increased substantially since 1990, driven by demographic shifts. Regional disparities and sex differences underscore the need for tailored public health strategies to prevent and mitigate the ADOD burden in the region.
Additional Links: PMID-43066606
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066606,
year = {2026},
author = {Morales-Juarez, L and Rios-Blancas, MJ and Razo, C and Sosa-Ortiz, AL and Acosta, I and Lozano, R},
title = {The burden of Alzheimer's disease and other dementias in adults aged =60 years in Latin America and the Caribbean, 1990-2023: A systematic analysis of the Global Burden of Disease Study 2023.},
journal = {Neuroepidemiology},
volume = {},
number = {},
pages = {},
doi = {10.1159/ned/adwag084},
pmid = {43066606},
issn = {1423-0208},
abstract = {Introduction Alzheimer's disease and other dementias (ADOD) represent a growing public health challenge in Latin America and the Caribbean (LAC). Understanding the temporal trends and drivers of the disease burden is essential for health planning. Methods This study analyzed the burden of ADOD, measured by disability-adjusted life years (DALYs), among adults aged ≥60 years across 20 LAC countries from 1990 to 2023. Using estimates from the Global Burden of Disease (GBD) study 2023, we assessed crude and age-standardized DALY rates by sex, age, country and LAC subregions. We also examined the ADOD burden attributable to six modifiable risk factors and applied the Das Gupta decomposition method to estimate the contributions of population growth, aging, and other factors to changes in ADOD DALYs. Results In 2023, ADOD accounted for 2,843,700 (95% UI: 1,300,775-5,858,229) DALYs in LAC, with a higher burden observed in females than males. From 1990 to 2023, crude DALY rates increased sharply with age and across subregions, with Southern Latin America showing the highest relative growth (+32.1% in females; +27.5% in males). ADOD ranked among the top three causes of DALYs for females in Chile, Argentina, Colombia and Uruguay. Modifiable risks accounted for 47.6% of the ADOD burden in the region. Population growth was the primary driver of increased absolute DALYs. Conclusion The burden of ADOD in LAC increased substantially since 1990, driven by demographic shifts. Regional disparities and sex differences underscore the need for tailored public health strategies to prevent and mitigate the ADOD burden in the region.},
}
RevDate: 2026-11-21
Predictors of Fear of Dementia: A 2-Year Longitudinal Analysis.
International journal of aging & human development [Epub ahead of print].
In this 2-year longitudinal study, we explored predictors of fear of dementia (FOD) among community-residing middle-aged and older persons. Hierarchical regression analyses suggested that with the exception of age, sociodemographic characteristics failed to covary with or predict fear of Alzheimer's disease (AD) dementia. Notable here was that (1) For FOD total scores and FOD Burden and Loss scores, greater knowledge about AD sensitized persons to their fears about receiving a diagnosis of AD, (2) For FOD total scores and FOD Social and Consequences scores, greater anxiety about aging was weakly, but consistently related to greater fears about AD dementia and more strongly predicted Social and Cognitive Consequences scores 2 years later, (3) greater self-reported memory difficulties were related to and predicted 2 years later greater fears for Loss of Quality of Life and Social and Cognitive Consequences scores, (4) more depression symptoms were weakly but consistently associated with Time 1 higher FOD total scores as well as Burden and Loss and Social and Cognitive Consequences scores, and more strongly predicted FOD total scores 2 years later, and (5) importantly, fewer efforts to prevent AD weakly predicted fear of AD total scores and FOD Social and Cognitive Consequences scores 2 years later; they also more strongly predicted FOD Loss of Quality of Life scores 2 years later. In contrast to previous work, a variety of AD-related experiential variables failed to correlate with or predict FOD scores. A reported family history of a diagnosis of AD or a death due to AD also related to greater FOD scores. While some findings are limited in that they accounted for little variance in FOD scores, others were more substantial. These findings do paint an overall complex picture of variables predicting AD dementia and have practical implications for among middle-aged and older persons who are fearful of AD.
Additional Links: PMID-43066613
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066613,
year = {2026},
author = {Hayslip, B and Page, KS and Wadsworth, D},
title = {Predictors of Fear of Dementia: A 2-Year Longitudinal Analysis.},
journal = {International journal of aging & human development},
volume = {},
number = {},
pages = {914150261467660},
doi = {10.1177/00914150261467660},
pmid = {43066613},
issn = {1541-3535},
abstract = {In this 2-year longitudinal study, we explored predictors of fear of dementia (FOD) among community-residing middle-aged and older persons. Hierarchical regression analyses suggested that with the exception of age, sociodemographic characteristics failed to covary with or predict fear of Alzheimer's disease (AD) dementia. Notable here was that (1) For FOD total scores and FOD Burden and Loss scores, greater knowledge about AD sensitized persons to their fears about receiving a diagnosis of AD, (2) For FOD total scores and FOD Social and Consequences scores, greater anxiety about aging was weakly, but consistently related to greater fears about AD dementia and more strongly predicted Social and Cognitive Consequences scores 2 years later, (3) greater self-reported memory difficulties were related to and predicted 2 years later greater fears for Loss of Quality of Life and Social and Cognitive Consequences scores, (4) more depression symptoms were weakly but consistently associated with Time 1 higher FOD total scores as well as Burden and Loss and Social and Cognitive Consequences scores, and more strongly predicted FOD total scores 2 years later, and (5) importantly, fewer efforts to prevent AD weakly predicted fear of AD total scores and FOD Social and Cognitive Consequences scores 2 years later; they also more strongly predicted FOD Loss of Quality of Life scores 2 years later. In contrast to previous work, a variety of AD-related experiential variables failed to correlate with or predict FOD scores. A reported family history of a diagnosis of AD or a death due to AD also related to greater FOD scores. While some findings are limited in that they accounted for little variance in FOD scores, others were more substantial. These findings do paint an overall complex picture of variables predicting AD dementia and have practical implications for among middle-aged and older persons who are fearful of AD.},
}
RevDate: 2026-11-21
CmpDate: 2026-11-21
Effects of Palmitoylethanolamide on the Retinal Endocannabinoid System in Amyloidosis Mice.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(22):.
Recently, we demonstrated the dysregulation of the endocannabinoid (eCB) system (ECS) in the retinas of Alzheimer's disease (AD)-like mice. Here, we explored the impact of the eCB-like lipid palmitoylethanolamide (PEA) on the retinal ECS of the Tg2576 (TG) mouse model of amyloidosis. Chronic subcutaneous administration of PEA via implanted micro-pellets was associated with the up-regulation of cannabinoid receptor 2 (CB2) and the modulation of the two eCB metabolic enzymes Diacylglycerol-lipase β (DAGL-β) and monoacylglycerol lipase (MAGL). Intriguingly, these effects were restricted to TG mice and were absent in wild-type animals, pointing to a condition-dependent modulation of the retinal ECS by PEA. Additionally, a distinctive nuclear CB2 signal consistent with nuclear localization was observed in the ganglion cell layer of TG retinas, a finding independent of PEA treatment. Taken together, our data provide novel insights into the PEA-associated biochemical modulation of the retinal ECS in a model of amyloidosis.
Additional Links: PMID-43066655
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066655,
year = {2026},
author = {Tisi, A and Di Meo, C and Fletcher, L and Cimino, G and Carnicelli, V and Giacovazzo, G and Coccurello, R and Oddi, S and Maccarrone, M},
title = {Effects of Palmitoylethanolamide on the Retinal Endocannabinoid System in Amyloidosis Mice.},
journal = {FASEB journal : official publication of the Federation of American Societies for Experimental Biology},
volume = {40},
number = {22},
pages = {},
doi = {10.1096/fj.202602185RRR},
pmid = {43066655},
issn = {1530-6860},
support = {T5-AN-11; CUP: F63C22000460008//Piano Sviluppo e Coesione Salute Traiettoria 5 Nutraceutica, nutrigenomica e alimenti funzionali Linea di azione 5.1/ ; },
mesh = {Animals ; *Palmitic Acids/pharmacology ; Amides ; *Ethanolamines/pharmacology ; *Endocannabinoids/metabolism ; Mice ; *Retina/metabolism/drug effects ; Mice, Transgenic ; *Amyloidosis/metabolism/drug therapy ; Receptor, Cannabinoid, CB2/metabolism/genetics ; Lipoprotein Lipase/metabolism/genetics ; Monoacylglycerol Lipases/metabolism/genetics ; Disease Models, Animal ; Male ; Mice, Inbred C57BL ; },
abstract = {Recently, we demonstrated the dysregulation of the endocannabinoid (eCB) system (ECS) in the retinas of Alzheimer's disease (AD)-like mice. Here, we explored the impact of the eCB-like lipid palmitoylethanolamide (PEA) on the retinal ECS of the Tg2576 (TG) mouse model of amyloidosis. Chronic subcutaneous administration of PEA via implanted micro-pellets was associated with the up-regulation of cannabinoid receptor 2 (CB2) and the modulation of the two eCB metabolic enzymes Diacylglycerol-lipase β (DAGL-β) and monoacylglycerol lipase (MAGL). Intriguingly, these effects were restricted to TG mice and were absent in wild-type animals, pointing to a condition-dependent modulation of the retinal ECS by PEA. Additionally, a distinctive nuclear CB2 signal consistent with nuclear localization was observed in the ganglion cell layer of TG retinas, a finding independent of PEA treatment. Taken together, our data provide novel insights into the PEA-associated biochemical modulation of the retinal ECS in a model of amyloidosis.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Palmitic Acids/pharmacology
Amides
*Ethanolamines/pharmacology
*Endocannabinoids/metabolism
Mice
*Retina/metabolism/drug effects
Mice, Transgenic
*Amyloidosis/metabolism/drug therapy
Receptor, Cannabinoid, CB2/metabolism/genetics
Lipoprotein Lipase/metabolism/genetics
Monoacylglycerol Lipases/metabolism/genetics
Disease Models, Animal
Male
Mice, Inbred C57BL
RevDate: 2026-11-21
Greater DTI-ALPS reduction in normal pressure hydrocephalus compared with Alzheimer's and Parkinson's diseases: a systematic review and meta-analysis.
European radiology [Epub ahead of print].
OBJECTIVES: To compare the magnitude of diffusion tensor image analysis along the perivascular space (DTI-ALPS) reduction across normal pressure hydrocephalus (NPH), Alzheimer's disease (AD), and Parkinson's disease (PD), and to refine its interpretation across the fluid-dynamic spectrum.
MATERIALS AND METHODS: PubMed, Embase, Scopus, and Web of Science were searched on 2 March 2026. Studies reporting baseline ALPS indices in AD, PD, or NPH with healthy controls were included. Standardized mean differences were calculated using Hedges' g with random-effects models. Cross-disease differences were evaluated using independent Z-tests.
RESULTS: Forty-nine studies contributing 50 datasets and involving 5318 participants were included. ALPS indices were reduced in all three disorders compared with controls. The pooled standardized mean difference was -0.95 (95% CI -1.16 to -0.75; k = 16; I² = 59.5%) in AD and -0.70 (95% CI -0.86 to -0.54; k = 28; I² = 78.8%) in PD. In contrast, NPH demonstrated a markedly larger reduction of -2.20 (95% CI -2.84 to -1.56; k = 6; I² = 82.0%). The distribution of study-level ALPS values showed NPH clustered at markedly lower values with minimal overlap with AD or PD. Consistent with this, summary-level (unadjusted) Z-tests indicated a larger reduction in NPH than in AD (Z = 3.63, p < 0.001) and PD (Z = 4.44, p < 0.001), whereas AD and PD did not differ significantly (p = 0.061).
CONCLUSION: DTI-ALPS reductions were observed across AD, PD, and NPH, with a substantially greater though heterogeneous reduction in NPH. This pattern may reflect CSF fluid-dynamic disturbance, structural distortion of the ALPS measurement environment, or both, although its physiological basis and diagnostic utility require prospective validation.
KEY POINTS: Question Do diffusion tensor image analysis along the perivascular space (DTI-ALPS) alterations demonstrate distinct magnitudes and patterns across normal pressure hydrocephalus and major neurodegenerative disorders? Findings ALPS indices were reduced across all three disorders, with a substantially larger reduction in normal pressure hydrocephalus (Hedges' g = -2.20) than in Alzheimer's disease (-0.95) or Parkinson's disease (-0.70). Clinical relevance Beyond the diagnosis of normal pressure hydrocephalus, which is radiologically apparent, the magnitude of DTI-ALPS reduction may hold value as a marker of fluid-dynamic or structural severity and treatment response, warranting prospective evaluation.
Additional Links: PMID-43066744
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066744,
year = {2026},
author = {Lee, SJ and Cho, SR and Kwon, OK and Cho, M},
title = {Greater DTI-ALPS reduction in normal pressure hydrocephalus compared with Alzheimer's and Parkinson's diseases: a systematic review and meta-analysis.},
journal = {European radiology},
volume = {},
number = {},
pages = {},
pmid = {43066744},
issn = {1432-1084},
abstract = {OBJECTIVES: To compare the magnitude of diffusion tensor image analysis along the perivascular space (DTI-ALPS) reduction across normal pressure hydrocephalus (NPH), Alzheimer's disease (AD), and Parkinson's disease (PD), and to refine its interpretation across the fluid-dynamic spectrum.
MATERIALS AND METHODS: PubMed, Embase, Scopus, and Web of Science were searched on 2 March 2026. Studies reporting baseline ALPS indices in AD, PD, or NPH with healthy controls were included. Standardized mean differences were calculated using Hedges' g with random-effects models. Cross-disease differences were evaluated using independent Z-tests.
RESULTS: Forty-nine studies contributing 50 datasets and involving 5318 participants were included. ALPS indices were reduced in all three disorders compared with controls. The pooled standardized mean difference was -0.95 (95% CI -1.16 to -0.75; k = 16; I² = 59.5%) in AD and -0.70 (95% CI -0.86 to -0.54; k = 28; I² = 78.8%) in PD. In contrast, NPH demonstrated a markedly larger reduction of -2.20 (95% CI -2.84 to -1.56; k = 6; I² = 82.0%). The distribution of study-level ALPS values showed NPH clustered at markedly lower values with minimal overlap with AD or PD. Consistent with this, summary-level (unadjusted) Z-tests indicated a larger reduction in NPH than in AD (Z = 3.63, p < 0.001) and PD (Z = 4.44, p < 0.001), whereas AD and PD did not differ significantly (p = 0.061).
CONCLUSION: DTI-ALPS reductions were observed across AD, PD, and NPH, with a substantially greater though heterogeneous reduction in NPH. This pattern may reflect CSF fluid-dynamic disturbance, structural distortion of the ALPS measurement environment, or both, although its physiological basis and diagnostic utility require prospective validation.
KEY POINTS: Question Do diffusion tensor image analysis along the perivascular space (DTI-ALPS) alterations demonstrate distinct magnitudes and patterns across normal pressure hydrocephalus and major neurodegenerative disorders? Findings ALPS indices were reduced across all three disorders, with a substantially larger reduction in normal pressure hydrocephalus (Hedges' g = -2.20) than in Alzheimer's disease (-0.95) or Parkinson's disease (-0.70). Clinical relevance Beyond the diagnosis of normal pressure hydrocephalus, which is radiologically apparent, the magnitude of DTI-ALPS reduction may hold value as a marker of fluid-dynamic or structural severity and treatment response, warranting prospective evaluation.},
}
RevDate: 2026-11-21
CmpDate: 2026-11-21
Hesperetin Modulates the PINK1/Parkin-Mediated Mitophagy Pathway to Alleviate Cognitive Deficits and Mitochondrial Dysfunction in a Rat Model of Alzheimer's Disease.
Molecular neurobiology, 63(1):.
Recent research has underscored the potential of hesperetin, a flavonoid compound, in mitigating mitochondrial dysfunction associated with Alzheimer's disease (AD). This study explored the impact of hesperetin on mitophagy-the selective degradation of mitochondria-within the framework of AD pathology. An experimental model was developed by administering amyloid-beta into the hippocampus of rats, which was subsequently followed by comprehensive behavioral assessments. The investigation employed a multifaceted analytical approach, incorporating metabonomics, transcriptomics, molecular biology techniques, and mitochondrial function assays, to assess the effects of hesperetin treatment. In addition, molecular docking simulations, dynamic analyses, and fluorescence spectroscopy were utilized to investigate the interaction between hesperetin and PTEN-induced kinase 1 (PINK1) protein. The results demonstrated that hesperetin administration significantly improved cognitive deficits, decreased amyloid-beta accumulation, and restored mitochondrial function in the animal model. Multivariate analysis suggested that these improvements were associated with the activation of the PINK1/Parkin signaling pathway, a crucial regulator of mitophagy. Moreover, hesperetin exhibited a strong binding affinity to PINK1, which facilitated the autophagic clearance of damaged mitochondria and reduced oxidative stress. These findings suggest that hesperetin directly binds to PINK1 and is linked to the activation of the PINK1/Parkin mitophagy pathway. Although direct binding may influence this effect, it is not definitively required. However, hesperetin's ability to improve mitochondrial quality control makes it a promising candidate for Alzheimer's disease treatment research. The compound's potential to enhance mitochondrial quality control mechanisms positions it as a promising therapeutic candidate for further exploration in Alzheimer's disease treatment strategies.
Additional Links: PMID-43066855
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43066855,
year = {2026},
author = {Wen, H and Sun, Y and Xu, W and Dong, Y and Wang, R},
title = {Hesperetin Modulates the PINK1/Parkin-Mediated Mitophagy Pathway to Alleviate Cognitive Deficits and Mitochondrial Dysfunction in a Rat Model of Alzheimer's Disease.},
journal = {Molecular neurobiology},
volume = {63},
number = {1},
pages = {},
pmid = {43066855},
issn = {1559-1182},
mesh = {Animals ; *Hesperidin/pharmacology/therapeutic use ; PTEN-Induced Putative Kinase ; *Alzheimer Disease/drug therapy/metabolism/pathology/complications ; *Mitophagy/drug effects ; *Protein Kinases/metabolism ; *Mitochondria/drug effects/metabolism/pathology ; Disease Models, Animal ; *Ubiquitin-Protein Ligases/metabolism ; *Signal Transduction/drug effects ; Male ; Rats, Sprague-Dawley ; Amyloid beta-Peptides/metabolism ; Molecular Docking Simulation ; Hippocampus/drug effects/metabolism/pathology ; *Cognition Disorders/drug therapy ; Rats ; },
abstract = {Recent research has underscored the potential of hesperetin, a flavonoid compound, in mitigating mitochondrial dysfunction associated with Alzheimer's disease (AD). This study explored the impact of hesperetin on mitophagy-the selective degradation of mitochondria-within the framework of AD pathology. An experimental model was developed by administering amyloid-beta into the hippocampus of rats, which was subsequently followed by comprehensive behavioral assessments. The investigation employed a multifaceted analytical approach, incorporating metabonomics, transcriptomics, molecular biology techniques, and mitochondrial function assays, to assess the effects of hesperetin treatment. In addition, molecular docking simulations, dynamic analyses, and fluorescence spectroscopy were utilized to investigate the interaction between hesperetin and PTEN-induced kinase 1 (PINK1) protein. The results demonstrated that hesperetin administration significantly improved cognitive deficits, decreased amyloid-beta accumulation, and restored mitochondrial function in the animal model. Multivariate analysis suggested that these improvements were associated with the activation of the PINK1/Parkin signaling pathway, a crucial regulator of mitophagy. Moreover, hesperetin exhibited a strong binding affinity to PINK1, which facilitated the autophagic clearance of damaged mitochondria and reduced oxidative stress. These findings suggest that hesperetin directly binds to PINK1 and is linked to the activation of the PINK1/Parkin mitophagy pathway. Although direct binding may influence this effect, it is not definitively required. However, hesperetin's ability to improve mitochondrial quality control makes it a promising candidate for Alzheimer's disease treatment research. The compound's potential to enhance mitochondrial quality control mechanisms positions it as a promising therapeutic candidate for further exploration in Alzheimer's disease treatment strategies.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Hesperidin/pharmacology/therapeutic use
PTEN-Induced Putative Kinase
*Alzheimer Disease/drug therapy/metabolism/pathology/complications
*Mitophagy/drug effects
*Protein Kinases/metabolism
*Mitochondria/drug effects/metabolism/pathology
Disease Models, Animal
*Ubiquitin-Protein Ligases/metabolism
*Signal Transduction/drug effects
Male
Rats, Sprague-Dawley
Amyloid beta-Peptides/metabolism
Molecular Docking Simulation
Hippocampus/drug effects/metabolism/pathology
*Cognition Disorders/drug therapy
Rats
RevDate: 2026-11-19
Protective relation between influenza vaccination and subjective cognitive decline in older US adults.
Annals of geriatric medicine and research pii:agmr.26.0054 [Epub ahead of print].
BACKGROUND: Subjective cognitive decline (SCD) has been shown to be associated with increased risk of dementia and Alzheimer's disease. Some studies have reported an inverse association between influenza vaccination and dementia; however, the relationship between vaccination and SCD is not known. In this context, we examined the association between influenza vaccination and SCD in a large, multiethnic sample of older US adults.
METHODS: Cross-sectional study of n=5,729 older adults (aged ≥65 years) who participated in the 2021-2022 Behavioral Risk Factor Surveillance System (BRFSS) and completed the BRFSS Cognitive Decline Module questions. Influenza vaccination status during the past 12 months was ascertained from the questionnaire, and the main outcome of interest was SCD.
RESULTS: SCD was present among 43.4% of older US adults aged ≥65 years. The weighted prevalence of SCD was 51.7% among those without influenza vaccination vs. 39.3% among those with influenza vaccination (P<0.001). Compared to those without influenza vaccination (reference category), the multivariable-adjusted odds ratio (95% confidence interval) of SCD was 0.67 (0.53-0.86; P=0.001) among those with influenza vaccination. The inverse association was present consistently in subgroup analyses by sex, age, education, and body mass index, and persisted after adjusting for potential confounders.
CONCLUSION: In this nationally representative sample of older US adults, we found that influenza vaccination showed a significant inverse association with SCD, though a causal effect cannot be inferred due to the cross-sectional design.
Additional Links: PMID-43057894
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43057894,
year = {2026},
author = {Syamala, S and Joseph, P},
title = {Protective relation between influenza vaccination and subjective cognitive decline in older US adults.},
journal = {Annals of geriatric medicine and research},
volume = {},
number = {},
pages = {},
doi = {10.4235/agmr.26.0054},
pmid = {43057894},
issn = {2508-4909},
abstract = {BACKGROUND: Subjective cognitive decline (SCD) has been shown to be associated with increased risk of dementia and Alzheimer's disease. Some studies have reported an inverse association between influenza vaccination and dementia; however, the relationship between vaccination and SCD is not known. In this context, we examined the association between influenza vaccination and SCD in a large, multiethnic sample of older US adults.
METHODS: Cross-sectional study of n=5,729 older adults (aged ≥65 years) who participated in the 2021-2022 Behavioral Risk Factor Surveillance System (BRFSS) and completed the BRFSS Cognitive Decline Module questions. Influenza vaccination status during the past 12 months was ascertained from the questionnaire, and the main outcome of interest was SCD.
RESULTS: SCD was present among 43.4% of older US adults aged ≥65 years. The weighted prevalence of SCD was 51.7% among those without influenza vaccination vs. 39.3% among those with influenza vaccination (P<0.001). Compared to those without influenza vaccination (reference category), the multivariable-adjusted odds ratio (95% confidence interval) of SCD was 0.67 (0.53-0.86; P=0.001) among those with influenza vaccination. The inverse association was present consistently in subgroup analyses by sex, age, education, and body mass index, and persisted after adjusting for potential confounders.
CONCLUSION: In this nationally representative sample of older US adults, we found that influenza vaccination showed a significant inverse association with SCD, though a causal effect cannot be inferred due to the cross-sectional design.},
}
RevDate: 2026-11-19
Preparing geriatric nurses for a new era in Alzheimer's care.
Geriatric nursing (New York, N.Y.) pii:S0197-4572(26)00642-7 [Epub ahead of print].
Recent advances in Alzheimer's diagnosis and treatment are changing the care needs of older adults and creating new responsibilities for geriatric nurses. Blood-based biomarkers and disease-modifying therapies offer new opportunities for earlier diagnosis and treatment, while increasing demands for patient education, care coordination, and monitoring. This NICHE column examines the evolving role of geriatric nurses across the Alzheimer's care journey and highlights the importance of workforce support, empowerment, and capacity building to translate scientific advances into person-centered care.
Additional Links: PMID-43057911
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43057911,
year = {2026},
author = {Marcal, T and Sohmer, D},
title = {Preparing geriatric nurses for a new era in Alzheimer's care.},
journal = {Geriatric nursing (New York, N.Y.)},
volume = {},
number = {},
pages = {104437},
doi = {10.1016/j.gerinurse.2026.104437},
pmid = {43057911},
issn = {1528-3984},
abstract = {Recent advances in Alzheimer's diagnosis and treatment are changing the care needs of older adults and creating new responsibilities for geriatric nurses. Blood-based biomarkers and disease-modifying therapies offer new opportunities for earlier diagnosis and treatment, while increasing demands for patient education, care coordination, and monitoring. This NICHE column examines the evolving role of geriatric nurses across the Alzheimer's care journey and highlights the importance of workforce support, empowerment, and capacity building to translate scientific advances into person-centered care.},
}
RevDate: 2026-11-19
Measuring cognition in Nepal: Factor structure of the Nepal Harmonized Cognitive Assessment Protocol (N-HCAP).
International psychogeriatrics pii:S1041-6102(26)00150-X [Epub ahead of print].
Reliable and valid cognitive assessment instruments are needed to study cognitive aging and dementia in Nepal. To address this need, the Harmonized Cognitive Assessment Protocol was adapted for Nepal (N-HCAP). We aimed to evaluate the factor structure, measurement precision, and criterion validity of the N-HCAP. We analyzed N-HCAP data from 3051 participants aged ≥ 50 in the Chitwan Valley Family Study-Study on Cognition and Aging in Nepal. Using confirmatory factor analysis, we evaluated five theoretically driven domains: orientation, memory, executive functioning, language, and visuospatial. We also evaluated a hierarchical measurement model in which the five domains loaded on a higher-order factor. We examined factor score distributions, reliability, and evaluated criterion validity through associations with age and years of school. Participants had a mean age of 64.0 years, 51.6% were female, and 48.1% had no formal schooling. Domain-specific models showed adequate to good fit (comparative fit index [CFI] = 0.95-1.00, root mean square error of approximation [RMSEA] = 0.02-0.06, standardized root mean square residual [SRMR] = 0.01-0.08). The hierarchical model also showed good fit (CFI = 0.96, RMSEA = 0.03, SRMR = 0.052). Measurement precision was generally adequate (≥0.70) but varied across domains and performance levels. All factor scores were negatively correlated with age (r = -0.47 to -0.31) and positively correlated with years of school (r = 0.36-0.62). Findings support the measurement structure and preliminary criterion validity of the N-HCAP, consistent with findings from other HCAP studies. Future research should evaluate clinical validity.
Additional Links: PMID-43057949
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43057949,
year = {2026},
author = {Yang, G and Ghimire, DJ and Jones, RN and Sapkota, H and Dhakal, U and Pradhan, MS and Rai, J and Jalan, P and Shrestha, L and Bogati, U and Gurung, A and Chaudhary, I and Pandit, P and Mendes de Leon, C and Briceño, EM},
title = {Measuring cognition in Nepal: Factor structure of the Nepal Harmonized Cognitive Assessment Protocol (N-HCAP).},
journal = {International psychogeriatrics},
volume = {},
number = {},
pages = {100323},
doi = {10.1016/j.inpsyc.2026.100323},
pmid = {43057949},
issn = {1741-203X},
abstract = {Reliable and valid cognitive assessment instruments are needed to study cognitive aging and dementia in Nepal. To address this need, the Harmonized Cognitive Assessment Protocol was adapted for Nepal (N-HCAP). We aimed to evaluate the factor structure, measurement precision, and criterion validity of the N-HCAP. We analyzed N-HCAP data from 3051 participants aged ≥ 50 in the Chitwan Valley Family Study-Study on Cognition and Aging in Nepal. Using confirmatory factor analysis, we evaluated five theoretically driven domains: orientation, memory, executive functioning, language, and visuospatial. We also evaluated a hierarchical measurement model in which the five domains loaded on a higher-order factor. We examined factor score distributions, reliability, and evaluated criterion validity through associations with age and years of school. Participants had a mean age of 64.0 years, 51.6% were female, and 48.1% had no formal schooling. Domain-specific models showed adequate to good fit (comparative fit index [CFI] = 0.95-1.00, root mean square error of approximation [RMSEA] = 0.02-0.06, standardized root mean square residual [SRMR] = 0.01-0.08). The hierarchical model also showed good fit (CFI = 0.96, RMSEA = 0.03, SRMR = 0.052). Measurement precision was generally adequate (≥0.70) but varied across domains and performance levels. All factor scores were negatively correlated with age (r = -0.47 to -0.31) and positively correlated with years of school (r = 0.36-0.62). Findings support the measurement structure and preliminary criterion validity of the N-HCAP, consistent with findings from other HCAP studies. Future research should evaluate clinical validity.},
}
RevDate: 2026-11-19
Ins and Outs of Lysosomal Ca[2+]: Recent Advances.
Cold Spring Harbor perspectives in biology pii:cshperspect.a041785 [Epub ahead of print].
Lysosomes are multifunctional organelles that store and release calcium ions (Ca[2+]), a key second messenger. Two-pore channels (TPCs) and members of the transient receptor potential (TRP) mucolipin (TRPML) subfamily are the principal lysosomal Ca[2+] release channels, but how Ca[2+] is taken up by lysosomes is less clear. TPCs have emerged as unusual ion channels that are able to dramatically switch their ion selectivity from a Ca[2+]-permeable state to a more Na[+]-selective state to differentially control cell-wide Ca[2+] signals and lysosomal function in an agonist-selective manner. Long-sought accessory proteins that confer sensitivity of these channels to the Ca[2+] mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) have been identified as JPT2 and Lsm12. Functional roles for TPCs in trafficking both inwardly (phagocytosis) as well as outwardly (hormone/inflammatory mediator secretion and adhesion molecule presentation) have been resolved-roles likely linked to the actions of TPCs at membrane contact sites between the endolysosomal system and the endoplasmic reticulum (ER). Gain-of-function in TPC2 by mutation, or by loss of a negative channel regulation (through TMEM63A), causes pigmentation and pancreatic dysfunction, respectively. Inhibiting TPCs by molecular or chemical means, in particular with tetrandrine (for which analog-bound structures exist), is proving beneficial in models of Alzheimer disease, Parkinson's disease, stroke, and melanoma. Select activation of TPC2 by new "mode-switching" agonists appears to be equally beneficial in correcting lysosomal storage disorders and Parkinson's disease. Like TPCs, TRP mucolipins are activated by the phosphoinositide PI(3,5)P2 More recently discovered endogenous TRP mucolipin activators include pressure and PI(3)P. Also, like TPCs, TRP mucolipins appear functionally coupled to Ca[2+] channels on the sarcoplasmic reticulum with a surprising role for TRPML1 in generating ryanodine receptor-dependent subcellular Ca[2+] signals underpinning smooth muscle contractility. Insight into regulation of autophagy by TRP mucolipins accrues; we also now know that activation of TRPML1 results in direct Ca[2+] transfer from lysosomes to mitochondria at contact sites between the two organelles, and that this communication is disrupted in Mucolipidosis type IV, as well as in models of other neurogenerative diseases. TRP mucolipins are implicated in lung dysfunction and cancer, with the first identification of cancer-causing mutations in TRPML3. TRP mucolipin agonists have now been used successfully to correct phenotypes in a number of disease models, and agonist, as well as antagonist-bound structures, are providing new atomic insight into channel workings. The molecular basis for lysosomal Ca[2+] uptake continues to be actively investigated. Candidates include the Ca[2+] transporter TMEM165, the mutation of which is known to cause congenital disorders of glycosylation, and pumps such as ATP13A2 and those found typically on the ER.
Additional Links: PMID-43058011
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058011,
year = {2026},
author = {Patel, S},
title = {Ins and Outs of Lysosomal Ca[2+]: Recent Advances.},
journal = {Cold Spring Harbor perspectives in biology},
volume = {},
number = {},
pages = {},
doi = {10.1101/cshperspect.a041785},
pmid = {43058011},
issn = {1943-0264},
abstract = {Lysosomes are multifunctional organelles that store and release calcium ions (Ca[2+]), a key second messenger. Two-pore channels (TPCs) and members of the transient receptor potential (TRP) mucolipin (TRPML) subfamily are the principal lysosomal Ca[2+] release channels, but how Ca[2+] is taken up by lysosomes is less clear. TPCs have emerged as unusual ion channels that are able to dramatically switch their ion selectivity from a Ca[2+]-permeable state to a more Na[+]-selective state to differentially control cell-wide Ca[2+] signals and lysosomal function in an agonist-selective manner. Long-sought accessory proteins that confer sensitivity of these channels to the Ca[2+] mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) have been identified as JPT2 and Lsm12. Functional roles for TPCs in trafficking both inwardly (phagocytosis) as well as outwardly (hormone/inflammatory mediator secretion and adhesion molecule presentation) have been resolved-roles likely linked to the actions of TPCs at membrane contact sites between the endolysosomal system and the endoplasmic reticulum (ER). Gain-of-function in TPC2 by mutation, or by loss of a negative channel regulation (through TMEM63A), causes pigmentation and pancreatic dysfunction, respectively. Inhibiting TPCs by molecular or chemical means, in particular with tetrandrine (for which analog-bound structures exist), is proving beneficial in models of Alzheimer disease, Parkinson's disease, stroke, and melanoma. Select activation of TPC2 by new "mode-switching" agonists appears to be equally beneficial in correcting lysosomal storage disorders and Parkinson's disease. Like TPCs, TRP mucolipins are activated by the phosphoinositide PI(3,5)P2 More recently discovered endogenous TRP mucolipin activators include pressure and PI(3)P. Also, like TPCs, TRP mucolipins appear functionally coupled to Ca[2+] channels on the sarcoplasmic reticulum with a surprising role for TRPML1 in generating ryanodine receptor-dependent subcellular Ca[2+] signals underpinning smooth muscle contractility. Insight into regulation of autophagy by TRP mucolipins accrues; we also now know that activation of TRPML1 results in direct Ca[2+] transfer from lysosomes to mitochondria at contact sites between the two organelles, and that this communication is disrupted in Mucolipidosis type IV, as well as in models of other neurogenerative diseases. TRP mucolipins are implicated in lung dysfunction and cancer, with the first identification of cancer-causing mutations in TRPML3. TRP mucolipin agonists have now been used successfully to correct phenotypes in a number of disease models, and agonist, as well as antagonist-bound structures, are providing new atomic insight into channel workings. The molecular basis for lysosomal Ca[2+] uptake continues to be actively investigated. Candidates include the Ca[2+] transporter TMEM165, the mutation of which is known to cause congenital disorders of glycosylation, and pumps such as ATP13A2 and those found typically on the ER.},
}
RevDate: 2026-11-19
CmpDate: 2026-11-19
Psychobiotics and the Microbiota-Gut-Brain Axis: Mechanistic Insights, Multi-Omics Advances, and Therapeutic Potential in Mental and Systemic Disorders.
Journal of food science, 91(11):.
Common mental illnesses, such as anxiety, depression, and neurodegenerative diseases, are increasing worldwide, and there is increasing evidence that their pathogenesis is associated with gut microbiota dysbiosis and disruption of the microbiota-gut-brain axis (MGBA). Nevertheless, there is a lack of mechanistic understanding and clinical translation of psychobiotics. This review consolidates the results of preclinical, clinical, and multi-omics research to assess the role of psychobiotics, such as prebiotics, probiotics, synbiotics, and postbiotics, in regulating MGBA pathways, including endocrine, immune, neural, and metabolic pathways, along with developments in metabolite detection and microbial profiling. Psychobiotics normalize the intestinal microbial composition, increase the intestinal barrier integrity, and balance neuroinflammation. They modulate the levels of major neurotransmitters (dopamine, serotonin, γ-aminobutyric acid) and suppress hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis. There is growing evidence showing their therapeutic efficacy in gastrointestinal, metabolic, autoimmune, and neuropsychiatric diseases, including anxiety, depression, and Alzheimer's and Parkinson's diseases. Synergistic effects with neuro-nutrition and physical activity further enhance cognitive function and neuroplasticity. Psychobiotics provide a mechanism-based approach to address interconnected pathways of the MGBA, which is an exciting addition to traditional treatments with an excellent safety profile. Precision psychobiotic intervention and translation of multi-omics approaches into clinical practice require standardized and large-scale clinical trials as well as integration of these methods.
Additional Links: PMID-43058025
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058025,
year = {2026},
author = {Mohiuddin, M},
title = {Psychobiotics and the Microbiota-Gut-Brain Axis: Mechanistic Insights, Multi-Omics Advances, and Therapeutic Potential in Mental and Systemic Disorders.},
journal = {Journal of food science},
volume = {91},
number = {11},
pages = {},
doi = {10.1111/1750-3841.71650},
pmid = {43058025},
issn = {1750-3841},
mesh = {Humans ; *Gastrointestinal Microbiome/drug effects/physiology ; Multiomics ; *Mental Disorders/microbiology/therapy ; Animals ; Probiotics ; Prebiotics/administration & dosage ; *Brain/metabolism ; Dysbiosis ; *Brain-Gut Axis ; },
abstract = {Common mental illnesses, such as anxiety, depression, and neurodegenerative diseases, are increasing worldwide, and there is increasing evidence that their pathogenesis is associated with gut microbiota dysbiosis and disruption of the microbiota-gut-brain axis (MGBA). Nevertheless, there is a lack of mechanistic understanding and clinical translation of psychobiotics. This review consolidates the results of preclinical, clinical, and multi-omics research to assess the role of psychobiotics, such as prebiotics, probiotics, synbiotics, and postbiotics, in regulating MGBA pathways, including endocrine, immune, neural, and metabolic pathways, along with developments in metabolite detection and microbial profiling. Psychobiotics normalize the intestinal microbial composition, increase the intestinal barrier integrity, and balance neuroinflammation. They modulate the levels of major neurotransmitters (dopamine, serotonin, γ-aminobutyric acid) and suppress hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis. There is growing evidence showing their therapeutic efficacy in gastrointestinal, metabolic, autoimmune, and neuropsychiatric diseases, including anxiety, depression, and Alzheimer's and Parkinson's diseases. Synergistic effects with neuro-nutrition and physical activity further enhance cognitive function and neuroplasticity. Psychobiotics provide a mechanism-based approach to address interconnected pathways of the MGBA, which is an exciting addition to traditional treatments with an excellent safety profile. Precision psychobiotic intervention and translation of multi-omics approaches into clinical practice require standardized and large-scale clinical trials as well as integration of these methods.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Gastrointestinal Microbiome/drug effects/physiology
Multiomics
*Mental Disorders/microbiology/therapy
Animals
Probiotics
Prebiotics/administration & dosage
*Brain/metabolism
Dysbiosis
*Brain-Gut Axis
RevDate: 2026-11-19
CmpDate: 2026-11-19
Sex differences in polygenic risk for sex-biased brain disorders: Associations with diagnostic status and brain age gap.
Translational psychiatry, 16(1):.
Biological sex influences the prevalence and progression of several brain disorders, yet it remains unclear whether genetic risk interacts with sex in relation to case-control status or brain health. Using data from up to 220 836 females and 187 651 males in the UK Biobank (aged 39-81), we assessed how sex and polygenic risk scores (PRSs) for major depressive disorder (PRSMDD), Alzheimer's disease (PRSAD), schizophrenia (PRSSCZ), and Parkinson's disease (PRSPD) relate to case-control status and MRI-derived brain age gap (BAG) as a proxy of brain health. We tested for sex differences in PRSs and performed regression analyses examining associations between sex, PRSs, and both outcomes. We then compared models with sex-pooled or sex-specific PRSs to explore whether sex-specific PRSs improve predictive accuracy. PRSSCZ was higher in females, while no other PRSs differed by sex. A significant PRSAD-by-sex interaction revealed weaker associations with AD case-control status in males than females. Sex-pooled models outperformed sex-specific models for case-control status, apart from PRSAD, where the female-only PRSAD model outperformed the sex-pooled model. No sex-by-PRS interactions were significantly associated with BAG. However, male sex, higher PRSMDD, higher PRSAD, and lower PRSPD were associated with higher BAG, indicative of an older brain age. BAG model performance did not differ between sex-pooled and sex-specific PRS models. In summary, while sex-specific PRSs currently offer limited value over sex-pooled scores, the superior performance of the female-specific PRSAD model suggests that the value of sex-specific PRSs will likely grow with increased statistical power. Link to preregistration and preprint: https://osf.io/a8pt2/ .
Additional Links: PMID-43058114
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058114,
year = {2026},
author = {Crestol, A and van der Meer, D and Parker, N and de Lange, AG and Hagen, E and Oppenheimer, H and Nerland, S and Breton, É and Tamnes, CK and Andreassen, OA and Agartz, I and Barth, C},
title = {Sex differences in polygenic risk for sex-biased brain disorders: Associations with diagnostic status and brain age gap.},
journal = {Translational psychiatry},
volume = {16},
number = {1},
pages = {},
pmid = {43058114},
issn = {2158-3188},
support = {351751//Norges Forskningsråd (Research Council of Norway)/ ; 323951//Norges Forskningsråd (Research Council of Norway)/ ; 288083//Norges Forskningsråd (Research Council of Norway)/ ; 324252//Norges Forskningsråd (Research Council of Norway)/ ; 324499//Norges Forskningsråd (Research Council of Norway)/ ; 300767//Norges Forskningsråd (Research Council of Norway)/ ; 213700//Norges Forskningsråd (Research Council of Norway)/ ; 223273//Norges Forskningsråd (Research Council of Norway)/ ; 250358//Norges Forskningsråd (Research Council of Norway)/ ; 334326//Norges Forskningsråd (Research Council of Norway)/ ; 2021070//Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority)/ ; 2023012//Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority)/ ; 500189//Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority)/ ; 2017097//Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority)/ ; 2019104//Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority)/ ; 2020020//Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority)/ ; 2023037//Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority)/ ; 2022103//Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority)/ ; 847776//EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)/ ; 964874//EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)/ ; },
mesh = {Humans ; Male ; Female ; Genetic Risk Score ; Aged ; Sex Factors ; Middle Aged ; *Schizophrenia/genetics ; Aged, 80 and over ; Adult ; *Brain/diagnostic imaging ; Magnetic Resonance Imaging ; Case-Control Studies ; *Alzheimer Disease/genetics ; UK Biobank ; Multifactorial Inheritance ; *Major Depressive Disorder/genetics ; *Brain Diseases/genetics/diagnosis ; *Parkinson Disease/genetics ; United Kingdom ; *Sex Characteristics ; Genetic Predisposition to Disease ; },
abstract = {Biological sex influences the prevalence and progression of several brain disorders, yet it remains unclear whether genetic risk interacts with sex in relation to case-control status or brain health. Using data from up to 220 836 females and 187 651 males in the UK Biobank (aged 39-81), we assessed how sex and polygenic risk scores (PRSs) for major depressive disorder (PRSMDD), Alzheimer's disease (PRSAD), schizophrenia (PRSSCZ), and Parkinson's disease (PRSPD) relate to case-control status and MRI-derived brain age gap (BAG) as a proxy of brain health. We tested for sex differences in PRSs and performed regression analyses examining associations between sex, PRSs, and both outcomes. We then compared models with sex-pooled or sex-specific PRSs to explore whether sex-specific PRSs improve predictive accuracy. PRSSCZ was higher in females, while no other PRSs differed by sex. A significant PRSAD-by-sex interaction revealed weaker associations with AD case-control status in males than females. Sex-pooled models outperformed sex-specific models for case-control status, apart from PRSAD, where the female-only PRSAD model outperformed the sex-pooled model. No sex-by-PRS interactions were significantly associated with BAG. However, male sex, higher PRSMDD, higher PRSAD, and lower PRSPD were associated with higher BAG, indicative of an older brain age. BAG model performance did not differ between sex-pooled and sex-specific PRS models. In summary, while sex-specific PRSs currently offer limited value over sex-pooled scores, the superior performance of the female-specific PRSAD model suggests that the value of sex-specific PRSs will likely grow with increased statistical power. Link to preregistration and preprint: https://osf.io/a8pt2/ .},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Male
Female
Genetic Risk Score
Aged
Sex Factors
Middle Aged
*Schizophrenia/genetics
Aged, 80 and over
Adult
*Brain/diagnostic imaging
Magnetic Resonance Imaging
Case-Control Studies
*Alzheimer Disease/genetics
UK Biobank
Multifactorial Inheritance
*Major Depressive Disorder/genetics
*Brain Diseases/genetics/diagnosis
*Parkinson Disease/genetics
United Kingdom
*Sex Characteristics
Genetic Predisposition to Disease
RevDate: 2026-11-19
CmpDate: 2026-11-19
AMYPAD-PNHS: A Pan-European, Multi-Site & Multimodal MRI Dataset of Older Adults Without Dementia.
Scientific data, 13(1):.
The Amyloid Imaging to Prevent Alzheimer's Disease Prognostic and Natural History Study (AMYPAD-PNHS) multimodal magnetic resonance imaging (MRI) dataset provides open-access longitudinal MRI data of 2759 cognitively normal or mild cognitive impairment individuals, encompassing (micro-)structural, physiological, and functional MRI sequences from 10 European parent cohorts. Processed and raw images, and image-derived (endo-)phenotypes, are organized in Brain Imaging Data Structure (BIDS) standards and accessible upon request, to enhance generalizability and comparability between future neuroimaging studies. This dataset supports preclinical Alzheimer's disease (AD) and aging-related research by enabling robust multimodal analyses of neurodegeneration, microvascular pathology, and structural and functional connectivity changes, facilitating advanced investigations into preclinical AD mechanisms, informing early intervention strategies and allowing reproducible and centralized neuroimaging (endo-)phenotyping.
Additional Links: PMID-43058145
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058145,
year = {2026},
author = {Pieperhoff, L and Tranfa, M and Arunachalam, P and Sudre, CH and Dijsselhof, MBJ and Padrela, BE and Masserini, F and Caneva, S and Pontillo, G and Cash, DM and Luckett, ES and Ritchie, C and Boada, M and Marquié, M and van der Flier, WM and Vandenberghe, R and Quenon, L and Hanseeuw, BJ and Martinez-Lage, P and Payoux, P and den Braber, A and Visser, PJ and Schöll, M and Frisoni, GB and Stephens, AW and Jessen, F and Gispert, JD and Mutsaerts, HMM and Wink, AM and Collij, LE and Lorenzini, L and Barkhof, F},
title = {AMYPAD-PNHS: A Pan-European, Multi-Site & Multimodal MRI Dataset of Older Adults Without Dementia.},
journal = {Scientific data},
volume = {13},
number = {1},
pages = {},
pmid = {43058145},
issn = {2052-4463},
support = {115952//European Federation of Pharmaceutical Industries and Associations (EFPIA)/ ; },
mesh = {Humans ; *Magnetic Resonance Imaging ; *Alzheimer Disease/diagnostic imaging ; Brain/diagnostic imaging ; Aged ; Multimodal Imaging ; Cognitive Dysfunction/diagnostic imaging ; Neuroimaging ; Europe ; },
abstract = {The Amyloid Imaging to Prevent Alzheimer's Disease Prognostic and Natural History Study (AMYPAD-PNHS) multimodal magnetic resonance imaging (MRI) dataset provides open-access longitudinal MRI data of 2759 cognitively normal or mild cognitive impairment individuals, encompassing (micro-)structural, physiological, and functional MRI sequences from 10 European parent cohorts. Processed and raw images, and image-derived (endo-)phenotypes, are organized in Brain Imaging Data Structure (BIDS) standards and accessible upon request, to enhance generalizability and comparability between future neuroimaging studies. This dataset supports preclinical Alzheimer's disease (AD) and aging-related research by enabling robust multimodal analyses of neurodegeneration, microvascular pathology, and structural and functional connectivity changes, facilitating advanced investigations into preclinical AD mechanisms, informing early intervention strategies and allowing reproducible and centralized neuroimaging (endo-)phenotyping.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Magnetic Resonance Imaging
*Alzheimer Disease/diagnostic imaging
Brain/diagnostic imaging
Aged
Multimodal Imaging
Cognitive Dysfunction/diagnostic imaging
Neuroimaging
Europe
RevDate: 2026-11-19
CmpDate: 2026-11-19
Predicting Alzheimer progression using EEG-based digital twins.
NPJ digital medicine, 9(1):.
Early and accurate prognosis of Alzheimer's disease (AD) remains limited by current biomarkers, which are often invasive, require expensive equipment, or fail to predict individual trajectories of cognitive decline. In this study, we evaluated the Digital Alzheimer's Disease Diagnosis (DADD) model, a digital twin framework that extracts neurodegeneration-related digital biomarkers from non-invasive recordings such as electroencephalography (EEG), mapping early functional neural alterations to latent parameters linked to structural AD mechanisms. DADD was applied to a cohort of 459 participants with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), evaluating its performance against established AD biomarkers like APOE genotype, magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) markers in predicting prognostic outcomes over a 10-year follow-up. Digital biomarkers demonstrated strong prognostic value, predicting participants who converted at follow-up, significantly outperforming standard EEG metrics. They also robustly forecast both risk and timing of clinical conversion, matching the performance of established AD biomarkers and even outperforming them in SCD participants. Moreover, combining established AD biomarkers with digital biomarkers led to a significant increase in prognostic accuracy. DADD represents a robust clinical tool, enabling scalable, affordable, non-invasive AD detection and prognostic stratification across diverse clinical settings.
Additional Links: PMID-43058167
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058167,
year = {2026},
author = {Amato, LG and Scheijbeler, E and van Nifterick, A and Lassi, M and de Haan, W and Gouw, A and Mazzoni, A},
title = {Predicting Alzheimer progression using EEG-based digital twins.},
journal = {NPJ digital medicine},
volume = {9},
number = {1},
pages = {},
pmid = {43058167},
issn = {2398-6352},
abstract = {Early and accurate prognosis of Alzheimer's disease (AD) remains limited by current biomarkers, which are often invasive, require expensive equipment, or fail to predict individual trajectories of cognitive decline. In this study, we evaluated the Digital Alzheimer's Disease Diagnosis (DADD) model, a digital twin framework that extracts neurodegeneration-related digital biomarkers from non-invasive recordings such as electroencephalography (EEG), mapping early functional neural alterations to latent parameters linked to structural AD mechanisms. DADD was applied to a cohort of 459 participants with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), evaluating its performance against established AD biomarkers like APOE genotype, magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) markers in predicting prognostic outcomes over a 10-year follow-up. Digital biomarkers demonstrated strong prognostic value, predicting participants who converted at follow-up, significantly outperforming standard EEG metrics. They also robustly forecast both risk and timing of clinical conversion, matching the performance of established AD biomarkers and even outperforming them in SCD participants. Moreover, combining established AD biomarkers with digital biomarkers led to a significant increase in prognostic accuracy. DADD represents a robust clinical tool, enabling scalable, affordable, non-invasive AD detection and prognostic stratification across diverse clinical settings.},
}
RevDate: 2026-11-19
Real world evidence of second-generation antipsychotics for the management of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis.
Psychopharmacology [Epub ahead of print].
PURPOSE: This is the first systematic review synthesizing exclusively real-world evidence about the efficacy, acceptability, and tolerability of the most used Second-generation antipsychotics (SGAs) for the management of Behavioral and psychological symptoms of dementia (BPSD).
METHODS: Observational or quasi-experimental real-world studies were included involving participants with a mean age of > 50 years and an Alzheimer Disease, vascular dementia or mixed dementia diagnosis with BPSD. Interventions were SGAs. Suitable comparators were placebo, other SGAs or no-treatment. Studies with or without a control group were eligible. The primary outcomes were efficacy, acceptability and tolerability of SGAs for the management of BPSD. Certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. PROSPERO (CRD420251143630).
RESULTS: 17 studies were included, encompassing 7,748 participants. Of the evaluated SGAs, only risperidone (k = 5 studies, n = 1469) and quetiapine (k = 4 studies, n = 89) had sufficient real-world evidence for pre-post analyses. Two studies provided direct comparisons between risperidone and olanzapine. The pooled analysis showed no significant difference between risperidone and olanzapine on efficacy (SMD = - 0.19; 95% CI [ - 1.72, 1.34], I[2] = 0%). BPSD appear to improve in pre-post studies with risperidone (SMD = - 1.36; 95% CI [ - 1.67, - 1.06], I[2] = 82.1%), but not with quetiapine (MD: - 15.17; 95% CI [-32.18 to 1.84]; I[2] = 89.7%). Quality of evidence was evaluated as very low on all outcomes.
CONCLUSION: While evidence suggests that risperidone is associated with significant management of BPSD in routine clinical practice, quetiapine appears to show limited efficacy and lower acceptability; although apparent inefficacy may probably depend on small sample size. Despite lower discontinuation rates than those reported in clinical trials, the risks of EPS, falls, and mortality support the need for careful monitoring and individualized risk-benefit assessment. The very low quality of the evidence demands careful interpretation of findings.
Additional Links: PMID-43058262
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058262,
year = {2026},
author = {Morales-Delgado, R and Álvarez-Villalobos, NA and Merino-Varela, C and Castillo-Herrera, LR and Robledo-Atilano, PM and Limón-Castillo, RD and Peraza-Muñiz, MA and Sandoval-Nandín, GA and Ramírez-Delgado, MV and Saucedo-Uribe, E},
title = {Real world evidence of second-generation antipsychotics for the management of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis.},
journal = {Psychopharmacology},
volume = {},
number = {},
pages = {},
pmid = {43058262},
issn = {1432-2072},
abstract = {PURPOSE: This is the first systematic review synthesizing exclusively real-world evidence about the efficacy, acceptability, and tolerability of the most used Second-generation antipsychotics (SGAs) for the management of Behavioral and psychological symptoms of dementia (BPSD).
METHODS: Observational or quasi-experimental real-world studies were included involving participants with a mean age of > 50 years and an Alzheimer Disease, vascular dementia or mixed dementia diagnosis with BPSD. Interventions were SGAs. Suitable comparators were placebo, other SGAs or no-treatment. Studies with or without a control group were eligible. The primary outcomes were efficacy, acceptability and tolerability of SGAs for the management of BPSD. Certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. PROSPERO (CRD420251143630).
RESULTS: 17 studies were included, encompassing 7,748 participants. Of the evaluated SGAs, only risperidone (k = 5 studies, n = 1469) and quetiapine (k = 4 studies, n = 89) had sufficient real-world evidence for pre-post analyses. Two studies provided direct comparisons between risperidone and olanzapine. The pooled analysis showed no significant difference between risperidone and olanzapine on efficacy (SMD = - 0.19; 95% CI [ - 1.72, 1.34], I[2] = 0%). BPSD appear to improve in pre-post studies with risperidone (SMD = - 1.36; 95% CI [ - 1.67, - 1.06], I[2] = 82.1%), but not with quetiapine (MD: - 15.17; 95% CI [-32.18 to 1.84]; I[2] = 89.7%). Quality of evidence was evaluated as very low on all outcomes.
CONCLUSION: While evidence suggests that risperidone is associated with significant management of BPSD in routine clinical practice, quetiapine appears to show limited efficacy and lower acceptability; although apparent inefficacy may probably depend on small sample size. Despite lower discontinuation rates than those reported in clinical trials, the risks of EPS, falls, and mortality support the need for careful monitoring and individualized risk-benefit assessment. The very low quality of the evidence demands careful interpretation of findings.},
}
RevDate: 2026-11-19
CmpDate: 2026-11-20
Anacyclus pyrethrum extract improves spatial memory and cognition in a rat model of Alzheimer's disease.
BMC complementary medicine and therapies, 26(1):.
BACKGROUND: Alzheimer's disease (AD) is the most prevalent dementia disorder, causing significant disability in the affected patients. This disorder is currently considered incurable. In this study, we aim to use the hydroalcoholic extract of Anacyclus Pyrethrum (AP) as a potential treatment for cognitive dysfunction in a rat model of AD induced with intracerebroventricular injection of Amyloid-beta 1-42.
METHODS: Forty-eight rats were randomly assigned to six groups (n = 8): control, sham, Aβ-injected (5 µg, ICV), and treatment groups receiving AP extract (500 mg/kg/day), donepezil (0.3 mg/kg/day), or their combination for 14 days following AD induction. Spatial memory was assessed using the Morris Water Maze (MWM), and brain metabolic changes were evaluated using positron emission tomography (PET). Histopathological analyses were also performed.
RESULTS: Positron emission tomography (PET) scan results supported the successful induction of Aβ‑related metabolic changes. MWM results showed that treatment groups significantly decreased swim distance to the platform, increased time spent in the target quadrant, and reduced mean distance from the former platform location. AP-treated, donepezil, and combination therapies demonstrated significantly better performance over time.
CONCLUSION: Oral administration of the hydroalcoholic extract of AP was associated with improved memory performance in a rat model of AD. These results call for more research to assess the AP extract's ability to reduce cognitive impairments in AD.
Additional Links: PMID-43058684
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058684,
year = {2026},
author = {Valibeygi, A and Zareian, F and Tavassoli, A and Ebrahimbabaei, A and Shojaeifard, M},
title = {Anacyclus pyrethrum extract improves spatial memory and cognition in a rat model of Alzheimer's disease.},
journal = {BMC complementary medicine and therapies},
volume = {26},
number = {1},
pages = {},
pmid = {43058684},
issn = {2662-7671},
mesh = {Animals ; *Alzheimer Disease/drug therapy ; *Plant Extracts/pharmacology ; Rats ; Disease Models, Animal ; *Spatial Memory/drug effects ; Male ; *Asteraceae/chemistry ; *Cognition/drug effects ; Donepezil ; Amyloid beta-Peptides ; Rats, Sprague-Dawley ; Maze Learning/drug effects ; Rats, Wistar ; Cognitive Enhancement ; },
abstract = {BACKGROUND: Alzheimer's disease (AD) is the most prevalent dementia disorder, causing significant disability in the affected patients. This disorder is currently considered incurable. In this study, we aim to use the hydroalcoholic extract of Anacyclus Pyrethrum (AP) as a potential treatment for cognitive dysfunction in a rat model of AD induced with intracerebroventricular injection of Amyloid-beta 1-42.
METHODS: Forty-eight rats were randomly assigned to six groups (n = 8): control, sham, Aβ-injected (5 µg, ICV), and treatment groups receiving AP extract (500 mg/kg/day), donepezil (0.3 mg/kg/day), or their combination for 14 days following AD induction. Spatial memory was assessed using the Morris Water Maze (MWM), and brain metabolic changes were evaluated using positron emission tomography (PET). Histopathological analyses were also performed.
RESULTS: Positron emission tomography (PET) scan results supported the successful induction of Aβ‑related metabolic changes. MWM results showed that treatment groups significantly decreased swim distance to the platform, increased time spent in the target quadrant, and reduced mean distance from the former platform location. AP-treated, donepezil, and combination therapies demonstrated significantly better performance over time.
CONCLUSION: Oral administration of the hydroalcoholic extract of AP was associated with improved memory performance in a rat model of AD. These results call for more research to assess the AP extract's ability to reduce cognitive impairments in AD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Alzheimer Disease/drug therapy
*Plant Extracts/pharmacology
Rats
Disease Models, Animal
*Spatial Memory/drug effects
Male
*Asteraceae/chemistry
*Cognition/drug effects
Donepezil
Amyloid beta-Peptides
Rats, Sprague-Dawley
Maze Learning/drug effects
Rats, Wistar
Cognitive Enhancement
RevDate: 2026-11-20
CmpDate: 2026-11-20
GFAP upregulation by astrocytes attenuates tau neurofibrillary tangle pathology in a mouse model of tauopathy.
Molecular neurodegeneration, 21(1):.
BACKGROUND: The upregulation of the intermediate filament glial fibrillary acidic protein (GFAP) by reactive astrocytes has been traditionally assigned structural functions such as the shaping of astrocyte morphology and the formation of the glial scar. However, in vitro studies have also implicated GFAP in chaperone-mediated autophagy and endolysosomal trafficking. Here we hypothesized a role of GFAP in proteostasis in neurodegenerative proteinopathies. Specifically, we tested whether GFAP upregulation by reactive astrocytes helps control phospho-tau (pTau) neurofibrillary tangle burden in vivo.
METHODS: We investigated the interactome of GFAP in human control and AD brains via co-immunoprecipitation (co-IP) followed by mass spectrometry. We also overexpressed GFAP in the astrocytes of THY-Tau22 mice using a viral transfer approach and characterized downstream effects on astrocyte phenotype, pTau burden, and neurodegenerative measures by combining immunohistochemistry, biochemistry, RNA-sequencing, and co-IP/mass spectrometry.
RESULTS: We show that the interactome of GFAP immunoprecipitated from human control and AD brains is unexpectedly enriched in proteostasis effectors. Overexpressing GFAP in astrocytes of THY-Tau22 mice reduced hippocampal pTau neurofibrillary tangle burden, increased presynaptic marker levels, and modulated neuronal c-Fos expression, with more pronounced effects in female mice. Mechanistically, transcriptomic analysis revealed an induction of genes involved in extracellular matrix and small GTPases mediating cytoskeleton dynamics, whereas co-IP/mass spectrometry revealed an extensive network of proteostasis-related interactors, including components of endocytosis/macropinocytosis, lysosomal autophagy, heat shock protein response, and the ubiquitin-proteasome system.
CONCLUSIONS: These findings challenge the conventional view of GFAP as a mere scaffold protein of the astrocyte cytoskeleton and suggest a novel role of GFAP in proteostasis with potential neuroprotective effects.
Additional Links: PMID-43058821
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058821,
year = {2026},
author = {Muñoz-Castro, C and Healey, MA and Noori, A and Jaisa-Aad, M and Gómez-Méndez, P and Jayakumar, R and Alla, S and Kashlan, ZD and Fan, Z and Zaniewski, EF and Animesh, S and Morris, RT and Calvo-Rodriguez, M and Hudry, E and Das, S and Haas, W and Hyman, BT and Serrano-Pozo, A},
title = {GFAP upregulation by astrocytes attenuates tau neurofibrillary tangle pathology in a mouse model of tauopathy.},
journal = {Molecular neurodegeneration},
volume = {21},
number = {1},
pages = {},
pmid = {43058821},
issn = {1750-1326},
mesh = {Animals ; *Astrocytes/metabolism/pathology ; *Glial Fibrillary Acidic Protein/metabolism ; Mice ; Humans ; Disease Models, Animal ; *Neurofibrillary Tangles/metabolism/pathology ; *Tauopathies/metabolism/pathology ; Up-Regulation ; Mice, Transgenic ; *tau Proteins/metabolism ; Female ; Brain/metabolism/pathology ; Male ; },
abstract = {BACKGROUND: The upregulation of the intermediate filament glial fibrillary acidic protein (GFAP) by reactive astrocytes has been traditionally assigned structural functions such as the shaping of astrocyte morphology and the formation of the glial scar. However, in vitro studies have also implicated GFAP in chaperone-mediated autophagy and endolysosomal trafficking. Here we hypothesized a role of GFAP in proteostasis in neurodegenerative proteinopathies. Specifically, we tested whether GFAP upregulation by reactive astrocytes helps control phospho-tau (pTau) neurofibrillary tangle burden in vivo.
METHODS: We investigated the interactome of GFAP in human control and AD brains via co-immunoprecipitation (co-IP) followed by mass spectrometry. We also overexpressed GFAP in the astrocytes of THY-Tau22 mice using a viral transfer approach and characterized downstream effects on astrocyte phenotype, pTau burden, and neurodegenerative measures by combining immunohistochemistry, biochemistry, RNA-sequencing, and co-IP/mass spectrometry.
RESULTS: We show that the interactome of GFAP immunoprecipitated from human control and AD brains is unexpectedly enriched in proteostasis effectors. Overexpressing GFAP in astrocytes of THY-Tau22 mice reduced hippocampal pTau neurofibrillary tangle burden, increased presynaptic marker levels, and modulated neuronal c-Fos expression, with more pronounced effects in female mice. Mechanistically, transcriptomic analysis revealed an induction of genes involved in extracellular matrix and small GTPases mediating cytoskeleton dynamics, whereas co-IP/mass spectrometry revealed an extensive network of proteostasis-related interactors, including components of endocytosis/macropinocytosis, lysosomal autophagy, heat shock protein response, and the ubiquitin-proteasome system.
CONCLUSIONS: These findings challenge the conventional view of GFAP as a mere scaffold protein of the astrocyte cytoskeleton and suggest a novel role of GFAP in proteostasis with potential neuroprotective effects.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Animals
*Astrocytes/metabolism/pathology
*Glial Fibrillary Acidic Protein/metabolism
Mice
Humans
Disease Models, Animal
*Neurofibrillary Tangles/metabolism/pathology
*Tauopathies/metabolism/pathology
Up-Regulation
Mice, Transgenic
*tau Proteins/metabolism
Female
Brain/metabolism/pathology
Male
RevDate: 2026-11-19
CmpDate: 2026-11-20
Do Interindividual Differences Matter? Testing Differences in Locus Coeruleus MRI Contrast as a Function of Age, Sex, and Body Mass Index.
Psychophysiology, 63(11):.
The locus coeruleus (LC) plays a key role in cognitive decline and Alzheimer's disease (AD). Investigating demographic differences in the LC is important because these differences may contribute to lifelong AD risk. Noninvasive MRI assessments of LC contrast are associated with cognitive performance and are hypothesized to reflect the nucleus's structural integrity. Age and sex differences in LC MRI contrast have been documented. Nonetheless, results are mixed, and most previous studies are hampered by small samples and a lack of standardization in the inspection of data quality and registration accuracy. In this cross-sectional study, we aim to investigate differences in LC MRI contrast as a function of demographic variables associated with increased AD prevalence: age, sex, and body mass index (BMI). We will pool fast spin echo (FSE) scans of young (age: 18-33) and older adults (age: 55-90) from eight datasets collected in three sites (N = 663). A semiautomatic pipeline will be adopted to register FSE scans to MNI space and segment the LC using a high-confidence LC mask. To maximize reproducibility, we will evaluate data quality using markers of in-scanner motion and nonphysiological noise, and we will rely on a standardized visual inspection to assess registration accuracy. We will run linear mixed models, including a nested random effect of acquisition batch (i.e., datasets grouped by study and site) to account for variability in LC MRI contrast driven by non-biological factors (e.g., hardware). We expect that LC contrast is positively associated with chronological age in young adults but negatively associated in older adults. On average, it is expected to be higher in older adults and in females. We will explore sex-by-age-group effects and BMI differences in LC MRI contrast. This study offers a reproducible foundation for understanding demographic variation in LC MRI contrast.
Additional Links: PMID-43058951
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058951,
year = {2026},
author = {D'Agostini, M and Zhao, W and Dahl, MJ and Wu, M and Ferguson, LA and Amin, S and Choi, P and Jaltare, K and Eich, T and Nation, DA and Mather, M},
title = {Do Interindividual Differences Matter? Testing Differences in Locus Coeruleus MRI Contrast as a Function of Age, Sex, and Body Mass Index.},
journal = {Psychophysiology},
volume = {63},
number = {11},
pages = {},
doi = {10.1111/psyp.70428},
pmid = {43058951},
issn = {1469-8986},
support = {R01AG082073/NH/NIH HHS/United States ; ADR A2024006F//BrightFocus Foundation/ ; 101150562//Marie Skłodowska-Curie Actions Postdoc Fellowship/ ; },
mesh = {Humans ; *Locus Coeruleus/diagnostic imaging ; *Magnetic Resonance Imaging ; Female ; Male ; Aged ; *Body Mass Index ; Middle Aged ; Adult ; Aged, 80 and over ; Young Adult ; Adolescent ; Cross-Sectional Studies ; Age Factors ; *Individuality ; Sex Characteristics ; Sex Factors ; *Aging/physiology ; },
abstract = {The locus coeruleus (LC) plays a key role in cognitive decline and Alzheimer's disease (AD). Investigating demographic differences in the LC is important because these differences may contribute to lifelong AD risk. Noninvasive MRI assessments of LC contrast are associated with cognitive performance and are hypothesized to reflect the nucleus's structural integrity. Age and sex differences in LC MRI contrast have been documented. Nonetheless, results are mixed, and most previous studies are hampered by small samples and a lack of standardization in the inspection of data quality and registration accuracy. In this cross-sectional study, we aim to investigate differences in LC MRI contrast as a function of demographic variables associated with increased AD prevalence: age, sex, and body mass index (BMI). We will pool fast spin echo (FSE) scans of young (age: 18-33) and older adults (age: 55-90) from eight datasets collected in three sites (N = 663). A semiautomatic pipeline will be adopted to register FSE scans to MNI space and segment the LC using a high-confidence LC mask. To maximize reproducibility, we will evaluate data quality using markers of in-scanner motion and nonphysiological noise, and we will rely on a standardized visual inspection to assess registration accuracy. We will run linear mixed models, including a nested random effect of acquisition batch (i.e., datasets grouped by study and site) to account for variability in LC MRI contrast driven by non-biological factors (e.g., hardware). We expect that LC contrast is positively associated with chronological age in young adults but negatively associated in older adults. On average, it is expected to be higher in older adults and in females. We will explore sex-by-age-group effects and BMI differences in LC MRI contrast. This study offers a reproducible foundation for understanding demographic variation in LC MRI contrast.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Locus Coeruleus/diagnostic imaging
*Magnetic Resonance Imaging
Female
Male
Aged
*Body Mass Index
Middle Aged
Adult
Aged, 80 and over
Young Adult
Adolescent
Cross-Sectional Studies
Age Factors
*Individuality
Sex Characteristics
Sex Factors
*Aging/physiology
RevDate: 2026-11-20
CmpDate: 2026-11-20
Ancestry-specific effects of apolipoprotein E on Alzheimer's disease endophenotypes.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.
INTRODUCTION: Apolipoprotein E (APOE) *ε4 is the strongest genetic risk factor for Alzheimer's disease (AD), yet its effect varies across ancestral populations. As plasma biomarkers increasingly inform AD diagnosis, failure to account for both APOE genotype and genetic ancestry could lead to diagnostic misclassification.
METHODS: In 2,733 participants from the Health and Aging Brain Study-Health Disparities (HABS-HD), we evaluated whether genetically-inferred ancestry modifies APOE associations with AD endophenotypes. Regression models were applied across three frameworks: ancestry-stratified analyses, compositional modeling of global ancestry, and local ancestry analyses at the APOE locus.
RESULTS: APOE ε4+ was associated with higher pTau217 and pTau181, lower Aβ42/Aβ40, and worse global cognition (Clinical Dementia Rating - Sum of Boxes [CDR-SB]), significant within ancestry groups after false discovery rate (FDR) correction. The ε4+ effect on pTau217 was ∼2.5-fold larger in EUR-like than AFR-like participants.
DISCUSSION: African ancestry attenuates APOE*ε4+ associations with pTau217, highlighting the need to consider both APOE genotype and ancestry in biomarker-based AD evaluations.
Additional Links: PMID-43058971
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43058971,
year = {2026},
author = {Boeriu, AI and Gu, T and Fulton-Howard, B and Lucero, EM and Garg, P and Sharp, AJ and Shortt, JA and Gignoux, CR and Rajabli, F and Griswold, AJ and Yaffe, K and Andrews, SJ and , },
title = {Ancestry-specific effects of apolipoprotein E on Alzheimer's disease endophenotypes.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
volume = {22},
number = {11},
pages = {},
pmid = {43058971},
issn = {1552-5279},
support = {ABA 969581//the Alzheimer's Association/ ; R01AG069453//NIH-NIA/ ; K00AG080847//NIH-NIA/ ; },
mesh = {Humans ; *Alzheimer Disease/genetics ; *Endophenotypes ; Female ; Male ; Aged ; *Apolipoproteins E/genetics ; Amyloid beta-Peptides/blood ; Genotype ; *Apolipoprotein E4/genetics ; Biomarkers/blood ; White People/genetics ; Black or African American/genetics ; Aged, 80 and over ; tau Proteins/blood ; Genetic Predisposition to Disease ; },
abstract = {INTRODUCTION: Apolipoprotein E (APOE) *ε4 is the strongest genetic risk factor for Alzheimer's disease (AD), yet its effect varies across ancestral populations. As plasma biomarkers increasingly inform AD diagnosis, failure to account for both APOE genotype and genetic ancestry could lead to diagnostic misclassification.
METHODS: In 2,733 participants from the Health and Aging Brain Study-Health Disparities (HABS-HD), we evaluated whether genetically-inferred ancestry modifies APOE associations with AD endophenotypes. Regression models were applied across three frameworks: ancestry-stratified analyses, compositional modeling of global ancestry, and local ancestry analyses at the APOE locus.
RESULTS: APOE ε4+ was associated with higher pTau217 and pTau181, lower Aβ42/Aβ40, and worse global cognition (Clinical Dementia Rating - Sum of Boxes [CDR-SB]), significant within ancestry groups after false discovery rate (FDR) correction. The ε4+ effect on pTau217 was ∼2.5-fold larger in EUR-like than AFR-like participants.
DISCUSSION: African ancestry attenuates APOE*ε4+ associations with pTau217, highlighting the need to consider both APOE genotype and ancestry in biomarker-based AD evaluations.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/genetics
*Endophenotypes
Female
Male
Aged
*Apolipoproteins E/genetics
Amyloid beta-Peptides/blood
Genotype
*Apolipoprotein E4/genetics
Biomarkers/blood
White People/genetics
Black or African American/genetics
Aged, 80 and over
tau Proteins/blood
Genetic Predisposition to Disease
RevDate: 2026-11-20
CmpDate: 2026-11-20
Exploring Predictive Genetic Testing Practices Across Adult-Onset Neurodegenerative Disorders.
Journal of genetic counseling, 35(6):.
A predictive genetic testing protocol for Huntington disease (HD) has been published and utilized since 1989. The current guideline recommends an intake call, pre-test genetic counseling, neurological examination, mental health assessment, results disclosure, and post-test follow up. Predictive testing is now available for other common adult-onset neurodegenerative disorders (AOND), including Alzheimer's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, frontotemporal dementia, Parkinson's disease, prion disease, and CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), yet similar protocols for most of these conditions have not been developed. It is hypothesized that the HD protocol is guiding predictive testing across AONDs, but this has not been formally evaluated. This exploratory, cross-sectional study surveyed genetic counselors (GCs) regarding their predictive testing practices. A total of 70 responses were received; 66 were included in demographic and other characteristic analysis, and 59 were included in practice descriptive analysis. GCs reported an average of 1.89 predictive cases per month and primarily operated within a neurology clinic (52/66, 79%). A total of 215 predictive testing practices were collected from the 59 respondents. Pre-test GC appointments (99%, n = 213) and a results disclosure session (100%, n = 215) were consistently incorporated in current practices. Over half of respondents utilized a mental health assessment (63%, n = 136) and structured follow-up after results are disclosed (58%, n = 124). Less than half of respondents utilized an intake call (48%, n = 104) and neurological examination (38%, n = 81). This study found that a vast majority of pre-test GC appointments were documented in the electronic medical record (207/213, 97%) and billed using insurance (164/213, 77%). GCs were reported as the most frequent healthcare professional involved in the assessment of mental health (118/136, 97%). Overall, these findings suggest that GCs are adapting the current HD predictive testing protocol similarly across AONDs. These findings provide insight into the current practices of predictive testing for AONDs in the absence of formal condition-specific guidelines.
Additional Links: PMID-43059034
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059034,
year = {2026},
author = {Burns, C and Bergner, AL and Mulhern, M and Harrington, E},
title = {Exploring Predictive Genetic Testing Practices Across Adult-Onset Neurodegenerative Disorders.},
journal = {Journal of genetic counseling},
volume = {35},
number = {6},
pages = {},
doi = {10.1002/jgc4.70305},
pmid = {43059034},
issn = {1573-3599},
mesh = {Humans ; *Genetic Testing ; *Neurodegenerative Diseases/genetics/diagnosis ; Cross-Sectional Studies ; Genetic Counseling ; Adult ; },
abstract = {A predictive genetic testing protocol for Huntington disease (HD) has been published and utilized since 1989. The current guideline recommends an intake call, pre-test genetic counseling, neurological examination, mental health assessment, results disclosure, and post-test follow up. Predictive testing is now available for other common adult-onset neurodegenerative disorders (AOND), including Alzheimer's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, frontotemporal dementia, Parkinson's disease, prion disease, and CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), yet similar protocols for most of these conditions have not been developed. It is hypothesized that the HD protocol is guiding predictive testing across AONDs, but this has not been formally evaluated. This exploratory, cross-sectional study surveyed genetic counselors (GCs) regarding their predictive testing practices. A total of 70 responses were received; 66 were included in demographic and other characteristic analysis, and 59 were included in practice descriptive analysis. GCs reported an average of 1.89 predictive cases per month and primarily operated within a neurology clinic (52/66, 79%). A total of 215 predictive testing practices were collected from the 59 respondents. Pre-test GC appointments (99%, n = 213) and a results disclosure session (100%, n = 215) were consistently incorporated in current practices. Over half of respondents utilized a mental health assessment (63%, n = 136) and structured follow-up after results are disclosed (58%, n = 124). Less than half of respondents utilized an intake call (48%, n = 104) and neurological examination (38%, n = 81). This study found that a vast majority of pre-test GC appointments were documented in the electronic medical record (207/213, 97%) and billed using insurance (164/213, 77%). GCs were reported as the most frequent healthcare professional involved in the assessment of mental health (118/136, 97%). Overall, these findings suggest that GCs are adapting the current HD predictive testing protocol similarly across AONDs. These findings provide insight into the current practices of predictive testing for AONDs in the absence of formal condition-specific guidelines.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Genetic Testing
*Neurodegenerative Diseases/genetics/diagnosis
Cross-Sectional Studies
Genetic Counseling
Adult
RevDate: 2026-11-20
Analytical validation of an in-house CSF neurogranin assay for clinical use.
Clinical chemistry and laboratory medicine [Epub ahead of print].
OBJECTIVES: Synaptic dysfunction is an early and central feature of Alzheimer's disease (AD), and cerebrospinal fluid (CSF) neurogranin (Ng) has emerged as a promising biomarker reflecting synaptic pathology. However, despite its increasing use in research, comprehensive analytical and clinical validation supporting its routine clinical use remains limited.
METHODS: We developed an updated version of an in-house CSF Ng enzyme-linked immunosorbent assay (UGOT-Ng) and performed a full analytical validation, including precision, selectivity, measurement range, dilution linearity, interference, and sample stability. Method comparison with a previous assay version and instrument comparability were also assessed. A distribution-derived upper threshold was established using a large set of prospectively measured routine clinical samples. Finally, the associations between CSF Ng concentrations and core AD biomarkers were examined in a large retrospective dataset.
RESULTS: The assay demonstrated acceptable analytical performance, with good repeatability and intermediate precision across the evaluated concentration levels. The measurement range was established at 38-1,200 ng/L, with satisfactory dilution linearity and minimal interference from blood contamination. CSF Ng showed high stability under various preanalytical conditions. Distribution-derived analysis in amyloid-negative clinical samples yielded an upper limit of 390 ng/L. In clinical samples, CSF Ng correlated strongly with total tau and phosphorylated tau, while associations with Aβ42/40 were weaker and largely driven by differences between amyloid-positive and -negative individuals.
CONCLUSIONS: This study provides a comprehensive analytical validation of an in-house CSF Ng assay, supporting its implementation in a routine clinical laboratory. CSF Ng was strongly associated with CSF total tau and phosphorylated tau, supporting its relationship with tau-associated neuronal and synaptic pathology in AD. However, the strength of these correlations also raises the possibility that CSF Ng provides information that overlaps with established tau biomarkers. Further studies should therefore determine whether Ng offers incremental diagnostic or prognostic value, identifies biologically distinct patient subgroups, or improves the monitoring of synaptic dysfunction beyond currently available biomarkers.
Additional Links: PMID-43059210
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059210,
year = {2026},
author = {Arslan, B and Simrén, J and Palm, K and Rasch, S and Andreasson, U and Kvartsberg, H},
title = {Analytical validation of an in-house CSF neurogranin assay for clinical use.},
journal = {Clinical chemistry and laboratory medicine},
volume = {},
number = {},
pages = {},
pmid = {43059210},
issn = {1437-4331},
abstract = {OBJECTIVES: Synaptic dysfunction is an early and central feature of Alzheimer's disease (AD), and cerebrospinal fluid (CSF) neurogranin (Ng) has emerged as a promising biomarker reflecting synaptic pathology. However, despite its increasing use in research, comprehensive analytical and clinical validation supporting its routine clinical use remains limited.
METHODS: We developed an updated version of an in-house CSF Ng enzyme-linked immunosorbent assay (UGOT-Ng) and performed a full analytical validation, including precision, selectivity, measurement range, dilution linearity, interference, and sample stability. Method comparison with a previous assay version and instrument comparability were also assessed. A distribution-derived upper threshold was established using a large set of prospectively measured routine clinical samples. Finally, the associations between CSF Ng concentrations and core AD biomarkers were examined in a large retrospective dataset.
RESULTS: The assay demonstrated acceptable analytical performance, with good repeatability and intermediate precision across the evaluated concentration levels. The measurement range was established at 38-1,200 ng/L, with satisfactory dilution linearity and minimal interference from blood contamination. CSF Ng showed high stability under various preanalytical conditions. Distribution-derived analysis in amyloid-negative clinical samples yielded an upper limit of 390 ng/L. In clinical samples, CSF Ng correlated strongly with total tau and phosphorylated tau, while associations with Aβ42/40 were weaker and largely driven by differences between amyloid-positive and -negative individuals.
CONCLUSIONS: This study provides a comprehensive analytical validation of an in-house CSF Ng assay, supporting its implementation in a routine clinical laboratory. CSF Ng was strongly associated with CSF total tau and phosphorylated tau, supporting its relationship with tau-associated neuronal and synaptic pathology in AD. However, the strength of these correlations also raises the possibility that CSF Ng provides information that overlaps with established tau biomarkers. Further studies should therefore determine whether Ng offers incremental diagnostic or prognostic value, identifies biologically distinct patient subgroups, or improves the monitoring of synaptic dysfunction beyond currently available biomarkers.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Biomarker-informed differences in treatment-associated cognitive decline in dementia with Lewy bodies.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.
INTRODUCTION: Alzheimer's disease (AD) co-pathology is common in dementia with Lewy bodies (DLB) and has been linked to worse clinical outcomes. Whether AD biomarker status influences cognitive trajectories and treatment-associated cognitive trajectories in DLB remains unclear.
METHODS: We conducted a retrospective cohort study by linking the Swedish Registry for Cognitive/Dementia Disorders (SveDem) with cerebrospinal fluid (CSF) biomarker data. Participants were individuals with incident DLB diagnosed between 2010 and 2020 who had CSF amyloid-β42/amyloid-β40 (Aβ42/40) or Aβ42/phosphorylated tau (p-tau) measurements and longitudinal Mini-Mental State Examination (MMSE) assessments during follow-up. Linear mixed-effects models incorporating inverse probability of treatment and censoring weighting estimated cognitive trajectories according to AD biomarker status and antidementia treatment.
RESULTS: Among 360 participants (mean age 73.3 years; 33.9% women), 196 (54.4%) were AD biomarker-positive. AD biomarker-positive participants exhibited faster cognitive decline than biomarker-negative participants, with an additional decline of 0.80 MMSE points per year (95% confidence interval [CI], -1.17 to -0.43). Overall, cholinesterase inhibitor (ChEI) use was associated with slower cognitive decline than no treatment, whereas associations for memantine were less consistent. In biomarker-stratified analyses, ChEI use was associated with slower decline among AD biomarker-positive participants but not among biomarker-negative participants. Formal interaction analyses indicated that treatment-associated differences in MMSE change varied according to AD biomarker status.
DISCUSSION: AD biomarker positivity identifies a subgroup of individuals with DLB at higher risk of accelerated cognitive decline. Treatment-associated cognitive trajectories also differed according to AD biomarker status; however, these observational treatment findings require cautious interpretation and confirmation in prospective biomarker-stratified studies.
Additional Links: PMID-43059509
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059509,
year = {2026},
author = {Chen, C and Xu, H and Rennie, A and Skillbäck, TB and Kern, S and Zetterberg, H and Jönsson, L and Ferreira, D and Eriksdotter, M},
title = {Biomarker-informed differences in treatment-associated cognitive decline in dementia with Lewy bodies.},
journal = {Alzheimer's & dementia : the journal of the Alzheimer's Association},
volume = {22},
number = {11},
pages = {},
pmid = {43059509},
issn = {1552-5279},
support = {2024-03599//Vetenskapsrådet/ ; },
mesh = {Humans ; Female ; *Lewy Body Disease/cerebrospinal fluid/drug therapy/complications ; Male ; Biomarkers/cerebrospinal fluid ; *Amyloid beta-Peptides/cerebrospinal fluid ; tau Proteins/cerebrospinal fluid ; Aged ; Retrospective Studies ; *Cognitive Dysfunction/cerebrospinal fluid ; Peptide Fragments/cerebrospinal fluid ; Sweden ; Aged, 80 and over ; Mental Status and Dementia Tests ; Registries ; },
abstract = {INTRODUCTION: Alzheimer's disease (AD) co-pathology is common in dementia with Lewy bodies (DLB) and has been linked to worse clinical outcomes. Whether AD biomarker status influences cognitive trajectories and treatment-associated cognitive trajectories in DLB remains unclear.
METHODS: We conducted a retrospective cohort study by linking the Swedish Registry for Cognitive/Dementia Disorders (SveDem) with cerebrospinal fluid (CSF) biomarker data. Participants were individuals with incident DLB diagnosed between 2010 and 2020 who had CSF amyloid-β42/amyloid-β40 (Aβ42/40) or Aβ42/phosphorylated tau (p-tau) measurements and longitudinal Mini-Mental State Examination (MMSE) assessments during follow-up. Linear mixed-effects models incorporating inverse probability of treatment and censoring weighting estimated cognitive trajectories according to AD biomarker status and antidementia treatment.
RESULTS: Among 360 participants (mean age 73.3 years; 33.9% women), 196 (54.4%) were AD biomarker-positive. AD biomarker-positive participants exhibited faster cognitive decline than biomarker-negative participants, with an additional decline of 0.80 MMSE points per year (95% confidence interval [CI], -1.17 to -0.43). Overall, cholinesterase inhibitor (ChEI) use was associated with slower cognitive decline than no treatment, whereas associations for memantine were less consistent. In biomarker-stratified analyses, ChEI use was associated with slower decline among AD biomarker-positive participants but not among biomarker-negative participants. Formal interaction analyses indicated that treatment-associated differences in MMSE change varied according to AD biomarker status.
DISCUSSION: AD biomarker positivity identifies a subgroup of individuals with DLB at higher risk of accelerated cognitive decline. Treatment-associated cognitive trajectories also differed according to AD biomarker status; however, these observational treatment findings require cautious interpretation and confirmation in prospective biomarker-stratified studies.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
Female
*Lewy Body Disease/cerebrospinal fluid/drug therapy/complications
Male
Biomarkers/cerebrospinal fluid
*Amyloid beta-Peptides/cerebrospinal fluid
tau Proteins/cerebrospinal fluid
Aged
Retrospective Studies
*Cognitive Dysfunction/cerebrospinal fluid
Peptide Fragments/cerebrospinal fluid
Sweden
Aged, 80 and over
Mental Status and Dementia Tests
Registries
RevDate: 2026-11-20
CmpDate: 2026-11-20
Contrasting within-donor gene covariation identifies disease-associated cells and genes in case-control single-cell studies.
bioRxiv : the preprint server for biology pii:2026.11.06.764894.
In case-control single-cell studies, disease often affects only a subset of cells of a given type within each patient. Comparing all cells from patients with all cells from control donors therefore dilutes disease signals, while donor variation and recorded or unrecorded batch effects can be confounded with disease status. We present IDC (Identification of Disease-associated Cells), which uses this cellular heterogeneity as signal. A mixture of affected and unaffected cells creates coordinated variation among disease-associated genes within each patient, whereas shifts shared by all cells of a donor leave this within-donor covariance unchanged. IDC therefore contrasts within-donor gene-gene covariance between patients and controls to learn disease-associated expression programs without batch labels, then applies positive-unlabeled learning to score each cell's disease-like state and estimate each donor's disease burden. IDC also computes, in closed form, gene contribution scores and leave-gene-out cell scores that exclude each tested gene, enabling within-donor differential expression testing and cross-donor meta-analysis without retraining. In simulations, IDC identified affected cells and estimated donor burden more accurately than deep generative and label-refinement methods, remained robust to strong unrecorded batch effects, and detected differentially expressed genes more sensitively than case-control pseudobulk methods while controlling false discoveries. In human pancreatic islets and prefrontal cortex, disease burden in held-out donors separated type 2 diabetes (T2D) from non-diabetic donors in beta cells, and late-stage Alzheimer's disease (AD) from non-AD donors in astrocytes and inhibitory neurons, while placing prediabetic and early-AD donors at intermediate levels. Genes with the highest IDC contribution scores were more strongly enriched for the KEGG T2D and AD pathways than case-control pseudobulk rankings, and within-donor testing revealed coordinated metabolic, cell-adhesion and synaptic changes along the inferred disease axis.
Additional Links: PMID-43059665
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059665,
year = {2026},
author = {Chang, F and Duren, Z},
title = {Contrasting within-donor gene covariation identifies disease-associated cells and genes in case-control single-cell studies.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.06.764894},
pmid = {43059665},
issn = {2692-8205},
abstract = {In case-control single-cell studies, disease often affects only a subset of cells of a given type within each patient. Comparing all cells from patients with all cells from control donors therefore dilutes disease signals, while donor variation and recorded or unrecorded batch effects can be confounded with disease status. We present IDC (Identification of Disease-associated Cells), which uses this cellular heterogeneity as signal. A mixture of affected and unaffected cells creates coordinated variation among disease-associated genes within each patient, whereas shifts shared by all cells of a donor leave this within-donor covariance unchanged. IDC therefore contrasts within-donor gene-gene covariance between patients and controls to learn disease-associated expression programs without batch labels, then applies positive-unlabeled learning to score each cell's disease-like state and estimate each donor's disease burden. IDC also computes, in closed form, gene contribution scores and leave-gene-out cell scores that exclude each tested gene, enabling within-donor differential expression testing and cross-donor meta-analysis without retraining. In simulations, IDC identified affected cells and estimated donor burden more accurately than deep generative and label-refinement methods, remained robust to strong unrecorded batch effects, and detected differentially expressed genes more sensitively than case-control pseudobulk methods while controlling false discoveries. In human pancreatic islets and prefrontal cortex, disease burden in held-out donors separated type 2 diabetes (T2D) from non-diabetic donors in beta cells, and late-stage Alzheimer's disease (AD) from non-AD donors in astrocytes and inhibitory neurons, while placing prediabetic and early-AD donors at intermediate levels. Genes with the highest IDC contribution scores were more strongly enriched for the KEGG T2D and AD pathways than case-control pseudobulk rankings, and within-donor testing revealed coordinated metabolic, cell-adhesion and synaptic changes along the inferred disease axis.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
First-in-class [ [18] F]-PET radiotracers for GPR39: A platform for noninvasive target engagement imaging in vivo.
bioRxiv : the preprint server for biology pii:2026.11.06.764940.
Disrupted zinc homeostasis is a hallmark of Alzheimer's disease. As a key zinc-sensing receptor, GPR39, a G-protein coupled receptor is implicated in neurodegeneration, vascular regulation, and neuropsychiatric disorders, represents an emerging target for molecular imaging. However, the lack of suitable positron emission tomography (PET) radiotracers has limited GPR39 in vivo characterization. Quantitative assessment of GPR39 levels in vivo helps in understanding its role in physiology and pathology. This will facilitate the development of targeted therapeutics and enable real-time monitoring of treatment response in clinical settings. This study introduces [ [18] F]GPR39-2.1 as a PET radiotracer specificity towards GPR39. [ [18] F]GPR39-2.1 exhibited excellent serum stability with negligible radio-metabolite formation. In vitro cell uptake studies showed reduced tracer uptake (55-70%) upon pharmacological blockade. PET imaging demonstrated rapid brain uptake and efficient with blood-brain barrier penetration, followed by gradual washout. Blockade studies in rats revealed significant reductions in brain uptake (up to ∼90%, **** p <0.0001), consistent across multiple brain regions. Receptor specificity was further validated in GPR39 knockout mice, which exhibited reduced brain uptake of 76% (** p <0.002) and 90% (*** p <0.0002) in both PET imaging and biodistribution studies, respectively. Moreover, significantly lower brain uptake observed in 5xFAD transgenic mice (PET imaging: 40%, *** p <0.0002 and biodistribution: 77%, ** p <0.002) indicates sensitivity of [ [18] F]GPR39-2.1 to disease-associated changes of GPR39. Biodistribution analysis revealed favorable pharmacokinetics. Autoradiography studies further confirmed the specificity of [ [18] F]GPR39-2.1 towards GPR39, corroborating PET imaging and biodistribution studies. These findings establish [ [18] F]GPR39-2.1 as a highly specific, stable, and brain-penetrant PET radiotracer for imaging GPR39 in vivo . This work supports the utility of [ [18] F]GPR39-2.1 as a noninvasive molecular imaging agent for neurological and systemic diseases associated with GPR39 dysregulation. Overall, this work establishes a translational framework for investigating GPR39 biology and facilitates its clinical translation as a diagnostic and therapeutic target through [ [18] F]GPR39-2.1.
Additional Links: PMID-43059711
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059711,
year = {2026},
author = {Bhoopal, B and Fitzgerald, RW and Gollapelli, KK and Miller, M and Damuka, N and Baity, CB and Roy, P and Myburgh, PJ and Zhu, D and Jadiya, P and Cervera-Juanes, R and Solingapuram Sai, KK},
title = {First-in-class [ [18] F]-PET radiotracers for GPR39: A platform for noninvasive target engagement imaging in vivo.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.06.764940},
pmid = {43059711},
issn = {2692-8205},
abstract = {Disrupted zinc homeostasis is a hallmark of Alzheimer's disease. As a key zinc-sensing receptor, GPR39, a G-protein coupled receptor is implicated in neurodegeneration, vascular regulation, and neuropsychiatric disorders, represents an emerging target for molecular imaging. However, the lack of suitable positron emission tomography (PET) radiotracers has limited GPR39 in vivo characterization. Quantitative assessment of GPR39 levels in vivo helps in understanding its role in physiology and pathology. This will facilitate the development of targeted therapeutics and enable real-time monitoring of treatment response in clinical settings. This study introduces [ [18] F]GPR39-2.1 as a PET radiotracer specificity towards GPR39. [ [18] F]GPR39-2.1 exhibited excellent serum stability with negligible radio-metabolite formation. In vitro cell uptake studies showed reduced tracer uptake (55-70%) upon pharmacological blockade. PET imaging demonstrated rapid brain uptake and efficient with blood-brain barrier penetration, followed by gradual washout. Blockade studies in rats revealed significant reductions in brain uptake (up to ∼90%, **** p <0.0001), consistent across multiple brain regions. Receptor specificity was further validated in GPR39 knockout mice, which exhibited reduced brain uptake of 76% (** p <0.002) and 90% (*** p <0.0002) in both PET imaging and biodistribution studies, respectively. Moreover, significantly lower brain uptake observed in 5xFAD transgenic mice (PET imaging: 40%, *** p <0.0002 and biodistribution: 77%, ** p <0.002) indicates sensitivity of [ [18] F]GPR39-2.1 to disease-associated changes of GPR39. Biodistribution analysis revealed favorable pharmacokinetics. Autoradiography studies further confirmed the specificity of [ [18] F]GPR39-2.1 towards GPR39, corroborating PET imaging and biodistribution studies. These findings establish [ [18] F]GPR39-2.1 as a highly specific, stable, and brain-penetrant PET radiotracer for imaging GPR39 in vivo . This work supports the utility of [ [18] F]GPR39-2.1 as a noninvasive molecular imaging agent for neurological and systemic diseases associated with GPR39 dysregulation. Overall, this work establishes a translational framework for investigating GPR39 biology and facilitates its clinical translation as a diagnostic and therapeutic target through [ [18] F]GPR39-2.1.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease.
bioRxiv : the preprint server for biology pii:2026.11.09.765491.
Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (Aβ), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: Aβ or tau. However, DMTs that concurrently target both tau and Aβ are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces Aβ and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual Aβ and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.
Additional Links: PMID-43059754
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059754,
year = {2026},
author = {Sgourdou, P and Vrettos, N and Hoxha, K and Baffic, T and Lee, EB and Xu, H and Lee, VM and Mourelatos, Z},
title = {SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.09.765491},
pmid = {43059754},
issn = {2692-8205},
abstract = {Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (Aβ), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: Aβ or tau. However, DMTs that concurrently target both tau and Aβ are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces Aβ and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual Aβ and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Histological characteristics of the quadriceps muscle and their associations with gait in older adults.
medRxiv : the preprint server for health sciences pii:2026.11.10.26367782.
BACKGROUND/OBJECTIVE: There is a paucity of data about muscle morphology in aging adults. We quantified histologic features of the quadriceps muscle and examined their associations with gait function and physical activity in community-dwelling older adults.
METHODS: Participants were from the Rush Memory and Aging Project. Postmortem sections of the quadriceps muscles were examined by immunohistochemistry using antibodies against myosin heavy chain, and histological characteristics of the quadriceps muscles were derived through images quantifications and segmentations. In addition, brain sections were assessed for collection of Alzheimer's disease and related dementias pathologies. Before death, participants' physical activity was objectively measured through wearing an accelerometer sensor for 10 days, and gait function was quantified by walking 8 feet and turning 360° twice. Linear regressions and compositional analyses were used for analyzing data.
RESULTS: Postmortem quadriceps was examined in 236 decedents (mean age at death was 91.7±6.0 years, and 71.6% (n=169) were females. On average, 44.7% (SD=19.5) of the muscle fibers were type I and 54.2% (SD=19.4) were type II, and 40.6% (SD=13.0) and 21.9% (12.9) of the quadriceps muscle area were composed of type I and II muscle fibers, respectively. In compositional analyses, male sex (estimate=0.303, SE=0.126, p=0.016) and more physical activity (estimate=0.118, SE=0.059, p=0.045) were associated with larger quadriceps muscle areas with type II muscle fibers, which were related to better gait (estimate=-0.049, SE=0.021, p=0.021). Quadriceps muscle composition explained an additional 3.2% of gait's variance beyond the 5.8% variance explained by Alzheimer's disease and related dementias brain pathologies.
CONCLUSION: Quadriceps muscles having larger areas with type II muscle fibers were associated with more physical activity and better gait function in aging adults. Elucidating the molecular mechanisms underlying these associations are critical for developing new therapies.
Additional Links: PMID-43059818
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059818,
year = {2026},
author = {Oveisgharan, S and Longo, S and Yang, J and Schneider, JA and Bennett, DA and Delbono, O and Buchman, AS},
title = {Histological characteristics of the quadriceps muscle and their associations with gait in older adults.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.10.26367782},
pmid = {43059818},
abstract = {BACKGROUND/OBJECTIVE: There is a paucity of data about muscle morphology in aging adults. We quantified histologic features of the quadriceps muscle and examined their associations with gait function and physical activity in community-dwelling older adults.
METHODS: Participants were from the Rush Memory and Aging Project. Postmortem sections of the quadriceps muscles were examined by immunohistochemistry using antibodies against myosin heavy chain, and histological characteristics of the quadriceps muscles were derived through images quantifications and segmentations. In addition, brain sections were assessed for collection of Alzheimer's disease and related dementias pathologies. Before death, participants' physical activity was objectively measured through wearing an accelerometer sensor for 10 days, and gait function was quantified by walking 8 feet and turning 360° twice. Linear regressions and compositional analyses were used for analyzing data.
RESULTS: Postmortem quadriceps was examined in 236 decedents (mean age at death was 91.7±6.0 years, and 71.6% (n=169) were females. On average, 44.7% (SD=19.5) of the muscle fibers were type I and 54.2% (SD=19.4) were type II, and 40.6% (SD=13.0) and 21.9% (12.9) of the quadriceps muscle area were composed of type I and II muscle fibers, respectively. In compositional analyses, male sex (estimate=0.303, SE=0.126, p=0.016) and more physical activity (estimate=0.118, SE=0.059, p=0.045) were associated with larger quadriceps muscle areas with type II muscle fibers, which were related to better gait (estimate=-0.049, SE=0.021, p=0.021). Quadriceps muscle composition explained an additional 3.2% of gait's variance beyond the 5.8% variance explained by Alzheimer's disease and related dementias brain pathologies.
CONCLUSION: Quadriceps muscles having larger areas with type II muscle fibers were associated with more physical activity and better gait function in aging adults. Elucidating the molecular mechanisms underlying these associations are critical for developing new therapies.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Beat-to-beat blood pressure variability and Alzheimer's disease pathophysiology.
medRxiv : the preprint server for health sciences pii:2026.11.10.26367476.
INTRODUCTION: Elevated blood pressure variability (BPV) is predictive of Alzheimer's disease neuropathologic change observed with AD biomarkers. However, prior studies have largely focused on visit-to-visit BPV, which may be influenced by antihypertensive medication adherence and other external factors. Few studies have investigated beat-to-beat BPV, a reliable and direct measure of cardiovascular and autonomic function relevant to AD.
METHODS: Independently living older adults (N=132) were recruited from the community. Participants underwent continuous blood pressure monitoring and venipuncture. Plasma p- Tau 217 , p-Tau 181 , GFAP, NfL, and amyloid-β 42/40 ratio were assessed. Linear regression examined the relationship between beat-to-beat systolic BPV and plasma AD biomarkers with and without adjustment for age, sex, systolic blood pressure, and apolipoprotein E4 (APOE4) carrier status.
RESULTS: Elevated beat-to-beat BPV was associated with elevated plasma p-Tau 217 (β=0.32, p=0.008), plasma p-Tau 181 (β=0.22, p=0.05), and plasma GFAP (β=0.41, p=0.00001). Elevated BPV was not associated with plasma amyloid-β 42/40 ratio or plasma NfL.
DISCUSSION: Increased beat-to-beat BPV is associated with increased Core 1 T 1 biomarkers of phosphorylated and secreted AD tau in blood plasma (i.e., pTau 217 , pTau 181), but not with amyloid-β 42/40 ratio, a biomarker more exclusively indexing cerebral amyloid retention alone. Elevated BPV was also associated with higher plasma GFAP, a marker of astrocyte reactivity. These findings are consistent with prior studies relating visit-to-visit BPV to AD biomarkers, suggesting that intrinsic cardiovascular and/or autonomic factors underlie links between BPV and AD.
Additional Links: PMID-43059842
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059842,
year = {2026},
author = {Lohman, T and Joyce, J and Quiring, M and Lashin, BI and Kapoor, A and Engstrom, AC and Law, KW and Ferrer, F and Contreras, L and Alitin, JPM and Gaubert, A and Rodgers, KE and Head, E and Malhas, R and Pahlevan, N and Nation, DA},
title = {Beat-to-beat blood pressure variability and Alzheimer's disease pathophysiology.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.10.26367476},
pmid = {43059842},
abstract = {INTRODUCTION: Elevated blood pressure variability (BPV) is predictive of Alzheimer's disease neuropathologic change observed with AD biomarkers. However, prior studies have largely focused on visit-to-visit BPV, which may be influenced by antihypertensive medication adherence and other external factors. Few studies have investigated beat-to-beat BPV, a reliable and direct measure of cardiovascular and autonomic function relevant to AD.
METHODS: Independently living older adults (N=132) were recruited from the community. Participants underwent continuous blood pressure monitoring and venipuncture. Plasma p- Tau 217 , p-Tau 181 , GFAP, NfL, and amyloid-β 42/40 ratio were assessed. Linear regression examined the relationship between beat-to-beat systolic BPV and plasma AD biomarkers with and without adjustment for age, sex, systolic blood pressure, and apolipoprotein E4 (APOE4) carrier status.
RESULTS: Elevated beat-to-beat BPV was associated with elevated plasma p-Tau 217 (β=0.32, p=0.008), plasma p-Tau 181 (β=0.22, p=0.05), and plasma GFAP (β=0.41, p=0.00001). Elevated BPV was not associated with plasma amyloid-β 42/40 ratio or plasma NfL.
DISCUSSION: Increased beat-to-beat BPV is associated with increased Core 1 T 1 biomarkers of phosphorylated and secreted AD tau in blood plasma (i.e., pTau 217 , pTau 181), but not with amyloid-β 42/40 ratio, a biomarker more exclusively indexing cerebral amyloid retention alone. Elevated BPV was also associated with higher plasma GFAP, a marker of astrocyte reactivity. These findings are consistent with prior studies relating visit-to-visit BPV to AD biomarkers, suggesting that intrinsic cardiovascular and/or autonomic factors underlie links between BPV and AD.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Peptide-centric proteomics reveals molecular subtypes of sporadic Alzheimer's disease.
bioRxiv : the preprint server for biology pii:2026.11.12.766321.
Alzheimer's disease (AD) is a complex, age-related disease that continues to increase in incidence worldwide. Although some cases are caused by known pathogenic mutations, the majority of cases are sporadic, with uncertain etiology and commonly complicated by comorbid diseases. To better understand the molecular landscape of AD we constructed a unique brain sample set free from neuropathologic comorbidities. This cohort consists of autosomal dominant AD dementia, sporadic AD dementia, cognitively normal individuals with high AD neuropathologic change - a condition called resilient to AD, and cognitively normal cases with no or minimal AD neuropathologic change. Through quantitative mass spectrometry proteomics we obtain measures of peptides mapping to Aβ and to tau, capturing differences in the histopathologic burden of disease. Correlations of these peptide abundance differences within sporadic AD dementia cases in the superior and medial temporal gyrus indicate the presence of two separate sporadic AD phenotypes. Additional differences are characterized at a peptide level between sporadic AD dementia and autosomal dominant AD dementia in the inferior parietal lobe and caudate nucleus. These findings indicate both shared and distinct molecular features in AD influenced by cause and age of onset of disease.
Additional Links: PMID-43059869
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059869,
year = {2026},
author = {Plubell, D and Merrihew, G and Park, J and Patterson, K and Smith, JD and Hsu, C and Wu, CC and Keene, CD and Montine, T and MacCoss, MJ},
title = {Peptide-centric proteomics reveals molecular subtypes of sporadic Alzheimer's disease.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.12.766321},
pmid = {43059869},
issn = {2692-8205},
abstract = {Alzheimer's disease (AD) is a complex, age-related disease that continues to increase in incidence worldwide. Although some cases are caused by known pathogenic mutations, the majority of cases are sporadic, with uncertain etiology and commonly complicated by comorbid diseases. To better understand the molecular landscape of AD we constructed a unique brain sample set free from neuropathologic comorbidities. This cohort consists of autosomal dominant AD dementia, sporadic AD dementia, cognitively normal individuals with high AD neuropathologic change - a condition called resilient to AD, and cognitively normal cases with no or minimal AD neuropathologic change. Through quantitative mass spectrometry proteomics we obtain measures of peptides mapping to Aβ and to tau, capturing differences in the histopathologic burden of disease. Correlations of these peptide abundance differences within sporadic AD dementia cases in the superior and medial temporal gyrus indicate the presence of two separate sporadic AD phenotypes. Additional differences are characterized at a peptide level between sporadic AD dementia and autosomal dominant AD dementia in the inferior parietal lobe and caudate nucleus. These findings indicate both shared and distinct molecular features in AD influenced by cause and age of onset of disease.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Genetic ancestry influences the relative expression of ancestral haplotypes within admixed individuals.
bioRxiv : the preprint server for biology pii:2026.11.11.765740.
Allele-specific expression (ASE) reflects differences between the two haplotypes a person carries, but most ASE studies have been done in European-descent samples. Admixed individuals carry haplotypes from different ancestral backgrounds within the same cell, which allows ancestry effects on regulation to be measured directly. We integrated phased whole-blood RNA-seq with local ancestry inference in 779 participants from the MAGENTA cohort, including non-Hispanic White, African American, Caribbean Hispanic, and Peruvian individuals. Higher West African (YRI) ancestry proportion was associated with more ASE-positive genes per person, and the association remained after adjusting for age, sex, Alzheimer's disease status, APOE genotype, and the number of heterozygous genes. Peruvian ancestry showed no significant association. A gene-level test of imbalance across population groups found 2,053 of 15,008 genes with significant differences, including the major histocompatibility complex in all four groups. A genome-wide scan of 2,213 1 Mb windows compared people carrying two haplotypes of different ancestries with those carrying two of the same ancestry. It identified 52 non-redundant loci that replicated across all four population groups, containing 201, 60, and 110 ancestry-associated genes under the CEU, YRI, and PEL reference baselines. A haplotype-resolved directional analysis showed no genome-wide advantage for either ancestry. It found locus-specific dominance at 11 loci, and only chr8:2-3 Mb (CSMD1) showed the same direction in more than one population group. Genetic ancestry therefore shapes allelic regulation at global, gene, and locus scales.
Additional Links: PMID-43059898
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059898,
year = {2026},
author = {Vazquez-Hidalgo, E and Mews, M and Gomez, L and Gu, T and Griswold, A and Bush, WS},
title = {Genetic ancestry influences the relative expression of ancestral haplotypes within admixed individuals.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.11.765740},
pmid = {43059898},
issn = {2692-8205},
abstract = {Allele-specific expression (ASE) reflects differences between the two haplotypes a person carries, but most ASE studies have been done in European-descent samples. Admixed individuals carry haplotypes from different ancestral backgrounds within the same cell, which allows ancestry effects on regulation to be measured directly. We integrated phased whole-blood RNA-seq with local ancestry inference in 779 participants from the MAGENTA cohort, including non-Hispanic White, African American, Caribbean Hispanic, and Peruvian individuals. Higher West African (YRI) ancestry proportion was associated with more ASE-positive genes per person, and the association remained after adjusting for age, sex, Alzheimer's disease status, APOE genotype, and the number of heterozygous genes. Peruvian ancestry showed no significant association. A gene-level test of imbalance across population groups found 2,053 of 15,008 genes with significant differences, including the major histocompatibility complex in all four groups. A genome-wide scan of 2,213 1 Mb windows compared people carrying two haplotypes of different ancestries with those carrying two of the same ancestry. It identified 52 non-redundant loci that replicated across all four population groups, containing 201, 60, and 110 ancestry-associated genes under the CEU, YRI, and PEL reference baselines. A haplotype-resolved directional analysis showed no genome-wide advantage for either ancestry. It found locus-specific dominance at 11 loci, and only chr8:2-3 Mb (CSMD1) showed the same direction in more than one population group. Genetic ancestry therefore shapes allelic regulation at global, gene, and locus scales.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Peripheral Immune Cell Shifts Associated With Alzheimer's Disease Vary in Multi-Ancestry Cohorts.
bioRxiv : the preprint server for biology pii:2026.11.11.765813.
BACKGROUND: Alzheimer's disease (AD) is heavily influenced by immune system dysregulation, yet the role of peripheral immune processes-and how these vary across ethnicities-remains understudied.
OBJECTIVE: To investigate ancestry-specific immune alterations in AD by profiling peripheral immune cell proportions using high-resolution deconvolution of whole blood RNA-sequencing data, characterizing disease associated cell types, and identifying enriched biological pathways.
METHODS: We analyzed whole blood RNA-seq data from non-Hispanic White (NHW), African American (AA), Caribbean Hispanic (CariHISP), and Peruvian (PERU) individuals, balanced between AD cases and cognitively normal controls. Immune cell proportions were estimated using CIBERSORTx and compared using linear models (propeller R package) adjusted for age, sex, and APOE genotypes in case-control models. Cell-type-specific differential expression was performed using CARseq, and pathway enrichment analyses performed using MSigDB gene sets.
RESULTS: Baseline immune composition differed substantially across cohorts for multiple innate and adaptive cell types. In a multi-ethnic AD versus control analysis, eight cell types reached FDR significance: AD was associated with decreased proportions naïve B cells, CD56dim NK cells, B cells, intermediate monocyte I, and double-negative T cells, alongside significant expansion in neutrophils and non-classical monocytes. Interaction analyses revealed heterogeneous group-specific effects, with the broadest shifts in AA and CariHISP. Pathway enrichment indicated shared heme metabolism, interferon, and oxidative phosphorylation programs across groups, with distinct emphases: broad, strong heme metabolism enrichment and the highest oxidative phosphorylation signal (in myeloid populations) in AA; MYC targets in naïve B cells and eosinophils in CariHISP; dendritic cell-and T follicular helper cell-centered interferon, inflammatory, and proliferative programs in NHW; and TGF-β and apoptosis signatures, unique to PERU, alongside the broadest cell-type coverage.
CONCLUSIONS: Peripheral immune dysregulation in AD is characterized by depletion of lymphoid and intermediate monocyte populations with concurrent neutrophil and non-classical monocyte expansion, and these patterns vary meaningfully by ancestry. These findings underscore the need for population-informed biomarkers and therapeutic strategies in AD.
Additional Links: PMID-43059900
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059900,
year = {2026},
author = {Mustafa, Y and Yang, Y and Mews, M and Gu, T and Gomez, L and Adams, LD and Starks, TD and Silva, C and McInerney, KF and Vance, JM and Cuccaro, ML and Illanes-Manrique, M and Cornejo-Olivas, MR and Feliciano-Astacio, BE and Byrd, GS and Pericak-Vance, MA and Haines, JL and Griswold, AJ and Bush, WS},
title = {Peripheral Immune Cell Shifts Associated With Alzheimer's Disease Vary in Multi-Ancestry Cohorts.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.11.765813},
pmid = {43059900},
issn = {2692-8205},
abstract = {BACKGROUND: Alzheimer's disease (AD) is heavily influenced by immune system dysregulation, yet the role of peripheral immune processes-and how these vary across ethnicities-remains understudied.
OBJECTIVE: To investigate ancestry-specific immune alterations in AD by profiling peripheral immune cell proportions using high-resolution deconvolution of whole blood RNA-sequencing data, characterizing disease associated cell types, and identifying enriched biological pathways.
METHODS: We analyzed whole blood RNA-seq data from non-Hispanic White (NHW), African American (AA), Caribbean Hispanic (CariHISP), and Peruvian (PERU) individuals, balanced between AD cases and cognitively normal controls. Immune cell proportions were estimated using CIBERSORTx and compared using linear models (propeller R package) adjusted for age, sex, and APOE genotypes in case-control models. Cell-type-specific differential expression was performed using CARseq, and pathway enrichment analyses performed using MSigDB gene sets.
RESULTS: Baseline immune composition differed substantially across cohorts for multiple innate and adaptive cell types. In a multi-ethnic AD versus control analysis, eight cell types reached FDR significance: AD was associated with decreased proportions naïve B cells, CD56dim NK cells, B cells, intermediate monocyte I, and double-negative T cells, alongside significant expansion in neutrophils and non-classical monocytes. Interaction analyses revealed heterogeneous group-specific effects, with the broadest shifts in AA and CariHISP. Pathway enrichment indicated shared heme metabolism, interferon, and oxidative phosphorylation programs across groups, with distinct emphases: broad, strong heme metabolism enrichment and the highest oxidative phosphorylation signal (in myeloid populations) in AA; MYC targets in naïve B cells and eosinophils in CariHISP; dendritic cell-and T follicular helper cell-centered interferon, inflammatory, and proliferative programs in NHW; and TGF-β and apoptosis signatures, unique to PERU, alongside the broadest cell-type coverage.
CONCLUSIONS: Peripheral immune dysregulation in AD is characterized by depletion of lymphoid and intermediate monocyte populations with concurrent neutrophil and non-classical monocyte expansion, and these patterns vary meaningfully by ancestry. These findings underscore the need for population-informed biomarkers and therapeutic strategies in AD.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
E2F4 gene therapy reverses established synaptic and cognitive deficits and remodels learning-associated signaling in Alzheimer's disease mice.
bioRxiv : the preprint server for biology pii:2026.11.13.766444.
Alzheimer's disease (AD) causes progressive synaptic dysfunction, neurodegeneration, and cognitive decline, yet strategies capable of reversing established deficits remain limited. Here, we show that neuronal expression of a p38MAPK phosphorylation-resistant human E2F4 variant (hE2F4DN), delivered by adeno-associated virus, restores hippocampal long-term potentiation and memory in homozygous 5xFAD mice after functional impairment is established. Treatment also reduces amyloid-β and phospho-tau pathology and prevents hippocampal neuronal loss. Integrated proteomic and phosphoproteomic analyses reveal remodeling of metabolic, redox, neuroimmune, synaptic-vesicle, and GSK3β-associated signaling pathways. Following contextual fear conditioning, hE2F4DN-treated mice exhibit broader learning-associated synaptic proteomic signatures and distinct phosphoregulatory responses involving synaptic machinery. These findings demonstrate that E2F4 gene therapy can reverse established synaptic and cognitive deficits while preserving neuronal integrity and reshaping molecular responses to learning, identifying E2F4 phosphorylation as a potential therapeutic target for advanced AD states.
Additional Links: PMID-43059911
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059911,
year = {2026},
author = {Sánchez-Puelles, C and Hernández-Vivanco, A and Grieco, A and Camacho-Olmos, I and Montero-Calle, A and López-Sánchez, N and Fraj-Cebrián, A and Garrido-García, A and Cano-Daganzo, V and Lozano-Ureña, A and Valdés-Lora, L and Barderas, R and Perea, G and Pascual-Leone, Á and Frade, JM},
title = {E2F4 gene therapy reverses established synaptic and cognitive deficits and remodels learning-associated signaling in Alzheimer's disease mice.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.13.766444},
pmid = {43059911},
issn = {2692-8205},
abstract = {Alzheimer's disease (AD) causes progressive synaptic dysfunction, neurodegeneration, and cognitive decline, yet strategies capable of reversing established deficits remain limited. Here, we show that neuronal expression of a p38MAPK phosphorylation-resistant human E2F4 variant (hE2F4DN), delivered by adeno-associated virus, restores hippocampal long-term potentiation and memory in homozygous 5xFAD mice after functional impairment is established. Treatment also reduces amyloid-β and phospho-tau pathology and prevents hippocampal neuronal loss. Integrated proteomic and phosphoproteomic analyses reveal remodeling of metabolic, redox, neuroimmune, synaptic-vesicle, and GSK3β-associated signaling pathways. Following contextual fear conditioning, hE2F4DN-treated mice exhibit broader learning-associated synaptic proteomic signatures and distinct phosphoregulatory responses involving synaptic machinery. These findings demonstrate that E2F4 gene therapy can reverse established synaptic and cognitive deficits while preserving neuronal integrity and reshaping molecular responses to learning, identifying E2F4 phosphorylation as a potential therapeutic target for advanced AD states.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
APOE4 Alters the Inflammatory and Metabolic Properties of Extracellular Vesicles of Induced Pluripotent Stem Cell-derived Astrocytes and Mesenchymal Stromal Cells.
Research square pii:rs.3.rs-11104163.
Background Apolipoprotein E (APOE) is a lipid transporter whose variant, APOE4 , is the strongest genetic predictor of Alzheimer's disease development. APOE's role as a lipid transporter is disrupted with E4 due to differences in its binding affinity, altering APOE's preferred lipid substrate. This alters the cholesterol homeostasis of neural cells such as astrocytes, leading to lipid droplet formation, a driver of neuroinflammation. In addition, APOE has been identified as a cargo protein carried within extracellular vesicles (EVs), including exosomes, suggesting EVs play a role in regulating neural lipid metabolism. However, the extent and further results of APOE disruption of EV excretion and cargo are not well-established. Methods This study seeks to identify differences in EV secretion and bioactivity between APOE3 and APOE4 genotypes in various cell types and the role they play in Alzheimer's disease pathogenesis. Human pluripotent potent stem cell-derived astrocytes (iASs) and mesenchymal stromal cells (iMSCs) with homozygous APOE3 and homozygous APOE44 cellswere derived and the secreted EVs were characterized. Results Our results indicate that EV secretion was comparable in APOE3 and APOE4 cells, although decreased expression of the endosomal sorting complex required for transport (ESCRT) dependent and independent genes in APOE4 cells was observed. When treating THP-1 cells, an innate inflammatory capability is observed across cell types in APOE4 EVs, increasing the levels of NF-κB activation significantly compared to untreated controls. Quantitative lipidomics revealed increased levels of total lipid and lipid classes involved in the mediation of lipid stress in APOE4 EVs. In addition, lipids involved in EV biogenesis are dysregulated. KEGG analysis showed upregulation of functional pathways of interest in Alzheimer's Disease progression, including efferocytosis, choline metabolism, and bile acid synthesis. Conclusions Our results suggest that APOE4 may affect the lipid cargo of the EVs, which is hypothesized to be a result of endosomal trafficking via interruptions in both ESCRT dependent and independent biogenesis pathways. Furthermore, disrupted lipid metabolism in APOE4 could affect ESCRT-independent EV formation. APOE4 derived EVs have innate inflammatory properties that are exacerbated in the presence of excess fatty acid. This study paves the way for understanding the role of EVs in mediating inflammation and lipid metabolism in APOE4 related Alzheimer's disease.
Additional Links: PMID-43059952
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059952,
year = {2026},
author = {Esmonde, C and Raulin, AC and Parsons, T and Sen, JB and Yun, Y and Kanekiyo, T and Li, Y},
title = {APOE4 Alters the Inflammatory and Metabolic Properties of Extracellular Vesicles of Induced Pluripotent Stem Cell-derived Astrocytes and Mesenchymal Stromal Cells.},
journal = {Research square},
volume = {},
number = {},
pages = {},
doi = {10.21203/rs.3.rs-11104163/v1},
pmid = {43059952},
issn = {2693-5015},
abstract = {Background Apolipoprotein E (APOE) is a lipid transporter whose variant, APOE4 , is the strongest genetic predictor of Alzheimer's disease development. APOE's role as a lipid transporter is disrupted with E4 due to differences in its binding affinity, altering APOE's preferred lipid substrate. This alters the cholesterol homeostasis of neural cells such as astrocytes, leading to lipid droplet formation, a driver of neuroinflammation. In addition, APOE has been identified as a cargo protein carried within extracellular vesicles (EVs), including exosomes, suggesting EVs play a role in regulating neural lipid metabolism. However, the extent and further results of APOE disruption of EV excretion and cargo are not well-established. Methods This study seeks to identify differences in EV secretion and bioactivity between APOE3 and APOE4 genotypes in various cell types and the role they play in Alzheimer's disease pathogenesis. Human pluripotent potent stem cell-derived astrocytes (iASs) and mesenchymal stromal cells (iMSCs) with homozygous APOE3 and homozygous APOE44 cellswere derived and the secreted EVs were characterized. Results Our results indicate that EV secretion was comparable in APOE3 and APOE4 cells, although decreased expression of the endosomal sorting complex required for transport (ESCRT) dependent and independent genes in APOE4 cells was observed. When treating THP-1 cells, an innate inflammatory capability is observed across cell types in APOE4 EVs, increasing the levels of NF-κB activation significantly compared to untreated controls. Quantitative lipidomics revealed increased levels of total lipid and lipid classes involved in the mediation of lipid stress in APOE4 EVs. In addition, lipids involved in EV biogenesis are dysregulated. KEGG analysis showed upregulation of functional pathways of interest in Alzheimer's Disease progression, including efferocytosis, choline metabolism, and bile acid synthesis. Conclusions Our results suggest that APOE4 may affect the lipid cargo of the EVs, which is hypothesized to be a result of endosomal trafficking via interruptions in both ESCRT dependent and independent biogenesis pathways. Furthermore, disrupted lipid metabolism in APOE4 could affect ESCRT-independent EV formation. APOE4 derived EVs have innate inflammatory properties that are exacerbated in the presence of excess fatty acid. This study paves the way for understanding the role of EVs in mediating inflammation and lipid metabolism in APOE4 related Alzheimer's disease.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
DECODE: DEcomposition of COupled and DEcoupled Brain States: Separating Structure-Coupled and Structure-Decoupled Functional Organization in Alzheimer's Disease.
bioRxiv : the preprint server for biology pii:2026.11.09.765343.
Brain functional activity emerges within an underlying structural scaffold. While structural network connectivity provides a relatively stable anatomical backbone for large-scale communication, functional interactions are high-dimensional and temporally dynamic, forming recurrent patterns that can be represented in a latent space of transient functional states. Yet, how these transient functional states are organized and the extent to which they remain constrained by structural network connectivity or become relatively decoupled from structural organization over time remain poorly understood. To address this gap, we introduce DECODE (DEcomposition of COupled and DEcoupled Brain States), a data-driven latent-space framework that uses independent component analysis (ICA) and multimodal data to decompose resting-state dynamic functional network connectivity into a lower-dimensional representation of transient functional states. These states capture temporally varying structure-coupled and structure-decoupled patterns using diffusion MRI-derived structural network connectivity priors. Structure-coupled states reflect functional configurations more strongly anchored to major structural motifs, whereas structure-decoupled states represent configurations less constrained by the identified structural organization, while potentially remaining within structurally defined dynamical bounds. DECODE identifies reproducible structure-coupled and structure-decoupled states, with mean squared error reconstruction of dynamic information < 0.1 and adjusted R [2] = 0.4. Applied to Alzheimer's disease (AD), DECODE revealed stronger group differences (FDR-corrected p-value 0.05) in both connectivity organization and temporal dynamics for decoupled states. These findings suggest that functional states less constrained by identified structural organization may be more vulnerable to AD-related disruption, whereas structure-coupled states may be relatively preserved. More broadly, DECODE provides a reproducible and generalizable framework for quantifying how functional dynamics are shaped by, or diverge from, structural organization by incorporating a latent representation of the structural connectome as an informative prior. Our findings established structural and functional alignment variation by distinguishing dynamic functional patterns closely coupled with structure from those that deviate from it.
Additional Links: PMID-43059953
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059953,
year = {2026},
author = {Fouladivanda, M and Iraji, A and Phadikar, S and Balm, R and Bimali, B and Adali, T and Calhoun, VD},
title = {DECODE: DEcomposition of COupled and DEcoupled Brain States: Separating Structure-Coupled and Structure-Decoupled Functional Organization in Alzheimer's Disease.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.09.765343},
pmid = {43059953},
issn = {2692-8205},
abstract = {Brain functional activity emerges within an underlying structural scaffold. While structural network connectivity provides a relatively stable anatomical backbone for large-scale communication, functional interactions are high-dimensional and temporally dynamic, forming recurrent patterns that can be represented in a latent space of transient functional states. Yet, how these transient functional states are organized and the extent to which they remain constrained by structural network connectivity or become relatively decoupled from structural organization over time remain poorly understood. To address this gap, we introduce DECODE (DEcomposition of COupled and DEcoupled Brain States), a data-driven latent-space framework that uses independent component analysis (ICA) and multimodal data to decompose resting-state dynamic functional network connectivity into a lower-dimensional representation of transient functional states. These states capture temporally varying structure-coupled and structure-decoupled patterns using diffusion MRI-derived structural network connectivity priors. Structure-coupled states reflect functional configurations more strongly anchored to major structural motifs, whereas structure-decoupled states represent configurations less constrained by the identified structural organization, while potentially remaining within structurally defined dynamical bounds. DECODE identifies reproducible structure-coupled and structure-decoupled states, with mean squared error reconstruction of dynamic information < 0.1 and adjusted R [2] = 0.4. Applied to Alzheimer's disease (AD), DECODE revealed stronger group differences (FDR-corrected p-value 0.05) in both connectivity organization and temporal dynamics for decoupled states. These findings suggest that functional states less constrained by identified structural organization may be more vulnerable to AD-related disruption, whereas structure-coupled states may be relatively preserved. More broadly, DECODE provides a reproducible and generalizable framework for quantifying how functional dynamics are shaped by, or diverge from, structural organization by incorporating a latent representation of the structural connectome as an informative prior. Our findings established structural and functional alignment variation by distinguishing dynamic functional patterns closely coupled with structure from those that deviate from it.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
LLM Representations Rival Traditional Predictors and Enhance Multimodal Prediction of APOE4 and Aβ-Burden.
medRxiv : the preprint server for health sciences pii:2026.11.09.26367620.
Spontaneous language offers a scalable, non-invasive approach for identifying biological indicators of preclinical Alzheimer's disease (AD). We examined prediction of APOE4 carrier status and cerebral amyloid-β (Aβ) burden using Cookie Theft picture-descriptions from two cohorts, including Hebrew- and English-speakers (IRAP, N=134; and WRAP, N=1,541). Aβ burden was classified across lowest-quartile, median, and highest-quartile cutoffs, capturing accumulation below conventional amyloid-positivity thresholds. We compared embeddings from pretrained large language models (LLMs) to standard cognitive test scores, reflecting current clinical assessment, and theory-driven linguistic features, reflecting traditional language analysis. Embedding-based models achieve the highest F1 among constituent models in five of eight tasks for APOE4 status and global Aβ. High prediction disagreement suggests complementary signals between approaches. An any-positive ensemble significantly outperforms every constituent model and a prior-informed random baseline across all eight tasks, and is also significantly superior to all constituent models in 21 of 24 regional Aβ tasks. These findings highlight the complementarity of LLM-based, theory-driven, and cognitive measures for predicting AD-related genetic risk and pathology, and supports development of early screening approaches.
Additional Links: PMID-43059980
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059980,
year = {2026},
author = {Zadok, M and Calderon, N and Wald, Y and Rein, N and Ganmore, I and Lesman Segev, O and Almog, G and Shamir, T and Ackler, R and Leviner, SY and Noimark, G and Levy, G and Mueller, KD and Ravona Springer, R and Schnaider Beeri, M and Reichart, R},
title = {LLM Representations Rival Traditional Predictors and Enhance Multimodal Prediction of APOE4 and Aβ-Burden.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.09.26367620},
pmid = {43059980},
abstract = {Spontaneous language offers a scalable, non-invasive approach for identifying biological indicators of preclinical Alzheimer's disease (AD). We examined prediction of APOE4 carrier status and cerebral amyloid-β (Aβ) burden using Cookie Theft picture-descriptions from two cohorts, including Hebrew- and English-speakers (IRAP, N=134; and WRAP, N=1,541). Aβ burden was classified across lowest-quartile, median, and highest-quartile cutoffs, capturing accumulation below conventional amyloid-positivity thresholds. We compared embeddings from pretrained large language models (LLMs) to standard cognitive test scores, reflecting current clinical assessment, and theory-driven linguistic features, reflecting traditional language analysis. Embedding-based models achieve the highest F1 among constituent models in five of eight tasks for APOE4 status and global Aβ. High prediction disagreement suggests complementary signals between approaches. An any-positive ensemble significantly outperforms every constituent model and a prior-informed random baseline across all eight tasks, and is also significantly superior to all constituent models in 21 of 24 regional Aβ tasks. These findings highlight the complementarity of LLM-based, theory-driven, and cognitive measures for predicting AD-related genetic risk and pathology, and supports development of early screening approaches.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Naturally Occurring Soluble Aβ Oligomers Induce State-Dependent Hippocampal Circuit Dysfunction in Nontransgenic Mice.
Research square pii:rs.3.rs-11234037.
Amyloid-beta (Aβ) plaques are a hallmark of Alzheimer's Disease (AD), but the modest cognitive benefit of anti-amyloid antibodies despite plaque clearance implicates plaque-independent mechanisms in disease progression. Aβ oligomers (AβOs), a toxic soluble species, disrupt synapses, but their effects on hippocampal circuit function in vivo remain unclear. We tested whether naturally occurring AβOs are sufficient to disrupt hippocampal circuit function independent of plaques in nontransgenic mice, infusing wild-type culture medium (WtCM), Tg2576-derived culture medium containing naturally occurring human AβOs (TgCM), or Aβ-immunodepleted TgCM into CA1. We recorded hippocampal calcium activity and local field potentials as mice explored a linear track and during post-learning quiet wakefulness. During exploratory behavior, TgCM impaired theta-gamma coupling versus WtCM, without affecting running, calcium activity, or place cells. During quiet wakefulness, TgCM reduced calcium activity versus WtCM, without a detectable effect on reactivation, delta oscillations, or sharp wave ripples. Aβ depletion prevented both effects. These results suggest that AβO-induced circuit disruption depends on behavioral state, implicating distinct vulnerabilities in encoding and offline processing. Because these effects occurred in nontransgenic hippocampus without amyloid plaques or chronic transgene expression, soluble AβOs are sufficient to disrupt memory-relevant circuit function and represent a therapeutic target upstream of plaque clearance.
Additional Links: PMID-43059986
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43059986,
year = {2026},
author = {Li, H and Fassini, A and Aygar, S and Vasilakos, Z and Hou, S and Yokomizo, M and Kastanenka, K and Gomperts, S},
title = {Naturally Occurring Soluble Aβ Oligomers Induce State-Dependent Hippocampal Circuit Dysfunction in Nontransgenic Mice.},
journal = {Research square},
volume = {},
number = {},
pages = {},
doi = {10.21203/rs.3.rs-11234037/v1},
pmid = {43059986},
issn = {2693-5015},
abstract = {Amyloid-beta (Aβ) plaques are a hallmark of Alzheimer's Disease (AD), but the modest cognitive benefit of anti-amyloid antibodies despite plaque clearance implicates plaque-independent mechanisms in disease progression. Aβ oligomers (AβOs), a toxic soluble species, disrupt synapses, but their effects on hippocampal circuit function in vivo remain unclear. We tested whether naturally occurring AβOs are sufficient to disrupt hippocampal circuit function independent of plaques in nontransgenic mice, infusing wild-type culture medium (WtCM), Tg2576-derived culture medium containing naturally occurring human AβOs (TgCM), or Aβ-immunodepleted TgCM into CA1. We recorded hippocampal calcium activity and local field potentials as mice explored a linear track and during post-learning quiet wakefulness. During exploratory behavior, TgCM impaired theta-gamma coupling versus WtCM, without affecting running, calcium activity, or place cells. During quiet wakefulness, TgCM reduced calcium activity versus WtCM, without a detectable effect on reactivation, delta oscillations, or sharp wave ripples. Aβ depletion prevented both effects. These results suggest that AβO-induced circuit disruption depends on behavioral state, implicating distinct vulnerabilities in encoding and offline processing. Because these effects occurred in nontransgenic hippocampus without amyloid plaques or chronic transgene expression, soluble AβOs are sufficient to disrupt memory-relevant circuit function and represent a therapeutic target upstream of plaque clearance.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
A shared slowing axis and phenotype-specific rhythms link clinical EEG to FDG-PET dementia phenotypes.
bioRxiv : the preprint server for biology pii:2026.11.09.764237.
Early and accurate identification of neurodegenerative disorders has notable implications for treatment and quality of life. Whereas neuroimaging-based biomarkers can accurately identify neurodegenerative subtypes, EEG represents a low-cost alternative that could expand access to dementia care. Here, we investigated whether six data-driven EEG latent factors, derived by nonnegative tensor decomposition of clinical EEGs, differ systematically across FDG-PET-defined neurodegenerative phenotypes. In 455 patients with EEG and FDG-PET acquired within one year of each other, factor expression was compared across 14 diagnostic classes assigned by StateViewer, a validated artificial intelligence framework for FDG-PET interpretation. To separate disease-general severity from phenotype-specific topography, each factor was also regressed on a subject-level slowing index. Finally, we related the factors to regional FDG uptake and to neuropsychological performance (n = 98) and assessed their potential utility for single-subject classification. Four factors reflecting neurophysiological oscillations (posterior alpha, Rolandic beta, frontotemporal delta-theta and posterior theta-slow alpha) varied significantly across phenotypes, with attenuation of faster and augmentation of slower rhythms most pronounced in dementia with Lewy bodies (DLB), dysexecutive Alzheimer disease (AD) and posterior cortical atrophy, whereas factors dominated by eye-movement and muscle artifact showed no robust phenotypic association. Alpha and beta effects were largely attributable to overall slowing, whereas posterior theta-slow alpha became more phenotype-specific after adjustment (eta-squared 0.082 to 0.147), dissociating the Alzheimer disease spectrum from frontotemporal syndromes. The slowing index tracked with an FDG-PET pattern highly associated with DLB across the cohort, irrespective of assigned phenotype (r = 0.51, P < 0.001). Consistent with a model in which dementia phenotypes reflect altered hippocampal-neocortical oscillatory coupling (stochastic latent oscillatory diffusion), frontotemporal delta-theta tracked a limbocortical axis of metabolic pattern expression, rising with neocortical and falling with limbic-predominant involvement, independent of overall slowing and phenotype. Each factor mapped onto a distinct metabolic topography, with frontotemporal delta-theta resembling Alzheimer-type hypometabolism and posterior theta-slow alpha the medial occipital hypometabolism of DLB. In terms of neuropsychological performance, Rolandic beta was associated with executive functions, and frontotemporal delta-theta with memory, visuospatial and global performance. Using these four factors alone, an exploratory logistic regression classifier separated cognitively unimpaired participants from DLB, posterior cortical atrophy, typical AD, and dysexecutive AD (area under the curve > 0.8) but poorly discriminated frontotemporal dementia phenotypes canonically associated with 4-repeat tau. Thus, data-driven decomposition of clinical EEG separates oscillatory activity from artifact into factors that track metabolic phenotype, regional metabolism and cognition, capturing both overall slowing and phenotype-specific patterns. This work informs the further development of scalable, biology-informed EEG-based phenotyping of neurodegenerative disease.
Additional Links: PMID-43060007
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060007,
year = {2026},
author = {Satyadev, N and Gogineni, V and Corriveau-Lecavalier, N and Zhang, G and Brinkmann, B and Varatharajah, Y and Day, GS and Whitwell, JL and Josephs, KA and Kantarci, K and Boeve, BF and Petersen, RC and Breakspear, M and Lowe, VJ and Jones, DT},
title = {A shared slowing axis and phenotype-specific rhythms link clinical EEG to FDG-PET dementia phenotypes.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.09.764237},
pmid = {43060007},
issn = {2692-8205},
abstract = {Early and accurate identification of neurodegenerative disorders has notable implications for treatment and quality of life. Whereas neuroimaging-based biomarkers can accurately identify neurodegenerative subtypes, EEG represents a low-cost alternative that could expand access to dementia care. Here, we investigated whether six data-driven EEG latent factors, derived by nonnegative tensor decomposition of clinical EEGs, differ systematically across FDG-PET-defined neurodegenerative phenotypes. In 455 patients with EEG and FDG-PET acquired within one year of each other, factor expression was compared across 14 diagnostic classes assigned by StateViewer, a validated artificial intelligence framework for FDG-PET interpretation. To separate disease-general severity from phenotype-specific topography, each factor was also regressed on a subject-level slowing index. Finally, we related the factors to regional FDG uptake and to neuropsychological performance (n = 98) and assessed their potential utility for single-subject classification. Four factors reflecting neurophysiological oscillations (posterior alpha, Rolandic beta, frontotemporal delta-theta and posterior theta-slow alpha) varied significantly across phenotypes, with attenuation of faster and augmentation of slower rhythms most pronounced in dementia with Lewy bodies (DLB), dysexecutive Alzheimer disease (AD) and posterior cortical atrophy, whereas factors dominated by eye-movement and muscle artifact showed no robust phenotypic association. Alpha and beta effects were largely attributable to overall slowing, whereas posterior theta-slow alpha became more phenotype-specific after adjustment (eta-squared 0.082 to 0.147), dissociating the Alzheimer disease spectrum from frontotemporal syndromes. The slowing index tracked with an FDG-PET pattern highly associated with DLB across the cohort, irrespective of assigned phenotype (r = 0.51, P < 0.001). Consistent with a model in which dementia phenotypes reflect altered hippocampal-neocortical oscillatory coupling (stochastic latent oscillatory diffusion), frontotemporal delta-theta tracked a limbocortical axis of metabolic pattern expression, rising with neocortical and falling with limbic-predominant involvement, independent of overall slowing and phenotype. Each factor mapped onto a distinct metabolic topography, with frontotemporal delta-theta resembling Alzheimer-type hypometabolism and posterior theta-slow alpha the medial occipital hypometabolism of DLB. In terms of neuropsychological performance, Rolandic beta was associated with executive functions, and frontotemporal delta-theta with memory, visuospatial and global performance. Using these four factors alone, an exploratory logistic regression classifier separated cognitively unimpaired participants from DLB, posterior cortical atrophy, typical AD, and dysexecutive AD (area under the curve > 0.8) but poorly discriminated frontotemporal dementia phenotypes canonically associated with 4-repeat tau. Thus, data-driven decomposition of clinical EEG separates oscillatory activity from artifact into factors that track metabolic phenotype, regional metabolism and cognition, capturing both overall slowing and phenotype-specific patterns. This work informs the further development of scalable, biology-informed EEG-based phenotyping of neurodegenerative disease.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Imipramine binds to amyloid-β and extends the survival of Alzheimer's disease patients.
bioRxiv : the preprint server for biology pii:2026.10.28.762584.
BACKGROUND: Apolipoprotein E (apoE) plays numerous roles in the pathogenic pathway to Alzheimer's disease (AD). We previously performed a high-throughput screen and identified the antidepressant imipramine as an inhibitor of the interaction between apoE and amyloid-β (Aβ). We also found that imipramine use to treat depression in AD patients was associated with better Mini-Mental State Exam (MMSE) scores. Here we studied the mechanisms by which imipramine inhibits the AD pathogenic pathway and investigated its effect on mortality in AD patients.
METHODS: Nuclear magnetic resonance spectroscopy was used to characterize the interaction between imipramine and Aβ monomers. Human induced pluripotent stem cell (hiPSC)-derived AD cerebral organoids (COs) and transgenic AD rats treated with imipramine underwent neuropathological evaluation, while rat learning and memory were assessed in the Morris Water Maze. AD patient mortality in the National Alzheimer's Coordinating Center's database was analyzed by Kaplan-Meier and Cox proportional hazards models.
RESULTS: Imipramine inhibits the apoE-Aβ interaction by binding directly to Aβ monomers. Imipramine reduces Aβ accumulation and neuronal cell loss in AD COs. Imipramine-treated female AD rats had enhanced reference memory and increased hippocampal cellularity and cholinergic neurotransmission. AD patients prescribed imipramine had reduced all-cause mortality over 10 years relative to those prescribed other tricyclic antidepressants (TCA), non-TCA antidepressants, or no antidepressants.
CONCLUSIONS: The findings support the conclusions that: a) the mechanism by which apoE confers risk for AD is by catalyzing the polymerization of Aβ into neurotoxic species, b) targeting apoE is a promising, underappreciated strategy for the prevention of AD, c) imipramine should be used more frequently to treat depression in AD clinical practice, and d) imipramine should be evaluated in prospective trials, particularly in APOE4 carriers, as a potential method to improve cognition and reduce mortality in AD.
Additional Links: PMID-43060016
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060016,
year = {2026},
author = {Johnson, NR and Beham, J and Sillau, S and Read, J and Wang, AC and Ahmed, MM and Quang, D and Stephenson, D and Henen, MA and Vögeli, B and Chial, HJ and Welty, R and Vugmeyster, L and Potter, H},
title = {Imipramine binds to amyloid-β and extends the survival of Alzheimer's disease patients.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.28.762584},
pmid = {43060016},
issn = {2692-8205},
abstract = {BACKGROUND: Apolipoprotein E (apoE) plays numerous roles in the pathogenic pathway to Alzheimer's disease (AD). We previously performed a high-throughput screen and identified the antidepressant imipramine as an inhibitor of the interaction between apoE and amyloid-β (Aβ). We also found that imipramine use to treat depression in AD patients was associated with better Mini-Mental State Exam (MMSE) scores. Here we studied the mechanisms by which imipramine inhibits the AD pathogenic pathway and investigated its effect on mortality in AD patients.
METHODS: Nuclear magnetic resonance spectroscopy was used to characterize the interaction between imipramine and Aβ monomers. Human induced pluripotent stem cell (hiPSC)-derived AD cerebral organoids (COs) and transgenic AD rats treated with imipramine underwent neuropathological evaluation, while rat learning and memory were assessed in the Morris Water Maze. AD patient mortality in the National Alzheimer's Coordinating Center's database was analyzed by Kaplan-Meier and Cox proportional hazards models.
RESULTS: Imipramine inhibits the apoE-Aβ interaction by binding directly to Aβ monomers. Imipramine reduces Aβ accumulation and neuronal cell loss in AD COs. Imipramine-treated female AD rats had enhanced reference memory and increased hippocampal cellularity and cholinergic neurotransmission. AD patients prescribed imipramine had reduced all-cause mortality over 10 years relative to those prescribed other tricyclic antidepressants (TCA), non-TCA antidepressants, or no antidepressants.
CONCLUSIONS: The findings support the conclusions that: a) the mechanism by which apoE confers risk for AD is by catalyzing the polymerization of Aβ into neurotoxic species, b) targeting apoE is a promising, underappreciated strategy for the prevention of AD, c) imipramine should be used more frequently to treat depression in AD clinical practice, and d) imipramine should be evaluated in prospective trials, particularly in APOE4 carriers, as a potential method to improve cognition and reduce mortality in AD.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
ApoE isoforms establish distinct antioxidant trajectories across the aging brain.
bioRxiv : the preprint server for biology pii:2026.11.06.765000.
APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer's disease, but how ApoE isoforms shape physiology before disease remains unclear. Across the ancestral-to-derived ApoE4→ApoE3→ApoE2 sequence, we examined antioxidant regulation during aging. Young humanized ApoE4 mice had lower antioxidant protein abundance and oxidized phospholipid reduction before detectable oxidative damage, yet accumulated lipid peroxidation products with age despite antioxidant remodeling. ApoE4 cells mounted the strongest antioxidant transcriptional response to sulforaphane but accumulated less protein from targets supporting proteostasis, glutathione synthesis and ferroptosis suppression, alongside altered eIF2α signaling and translation kinetics. Antioxidant transcription shifted from an ApoE4 bias in youth toward ApoE2 with age, and adult APOE4-to-APOE2 switching redirected expression in astrocytes and microglia. Cognitively normal human brains showed regional reductions in nuclear Nrf2 and antioxidant proteins, with transcriptomic analyses supporting context-dependent organization. ApoE isoforms differentially couple stress-responsive transcription to protein output, linking age-dependent antioxidant adaptation to neurodegenerative vulnerability.
Additional Links: PMID-43060026
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060026,
year = {2026},
author = {Shemtov, SJ and Cacciottolo, M and Christensen, A and Li, B and Haghani, A and Rice, MC and Anson, H and Chung, CS and Cohn, W and Zhang, H and Mack, WJ and Hiniker, A and Lee, CD and Morgan, TE and Head, E and Forman, HJ and Higuchi-Sanabria, R and Pike, CJ and Yassine, H and Vermulst, M and Finch, CE and Thorwald, MA},
title = {ApoE isoforms establish distinct antioxidant trajectories across the aging brain.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.06.765000},
pmid = {43060026},
issn = {2692-8205},
abstract = {APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer's disease, but how ApoE isoforms shape physiology before disease remains unclear. Across the ancestral-to-derived ApoE4→ApoE3→ApoE2 sequence, we examined antioxidant regulation during aging. Young humanized ApoE4 mice had lower antioxidant protein abundance and oxidized phospholipid reduction before detectable oxidative damage, yet accumulated lipid peroxidation products with age despite antioxidant remodeling. ApoE4 cells mounted the strongest antioxidant transcriptional response to sulforaphane but accumulated less protein from targets supporting proteostasis, glutathione synthesis and ferroptosis suppression, alongside altered eIF2α signaling and translation kinetics. Antioxidant transcription shifted from an ApoE4 bias in youth toward ApoE2 with age, and adult APOE4-to-APOE2 switching redirected expression in astrocytes and microglia. Cognitively normal human brains showed regional reductions in nuclear Nrf2 and antioxidant proteins, with transcriptomic analyses supporting context-dependent organization. ApoE isoforms differentially couple stress-responsive transcription to protein output, linking age-dependent antioxidant adaptation to neurodegenerative vulnerability.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Single-nucleus RNA-seq atlas of 5xFAD mouse brain maps cell-type-specific transcriptional disruption and preferential rolipram rescue in VIP interneurons.
bioRxiv : the preprint server for biology pii:2026.11.11.765944.
BACKGROUND: Alzheimer's disease is characterized by progressive synaptic dysfunction and inhibitory circuit disruption across multiple brain cell types. Rolipram, a selective phosphodiesterase 4 (PDE4) inhibitor that elevates intracellular cyclic AMP (cAMP), activates proteasome, and produces robust procognitive effects in AD mouse models. Still, the cell-type-specific transcriptional mechanisms underlying these effects remain uncharacterized.
METHODS: We profiled 29,664 nuclei from 5xFAD and wild-type (WT) mouse right hemisphere across four conditions: WT Vehicle, WT Rolipram, 5xFAD Vehicle, and 5xFAD Rolipram (0.03 mg/kg/day, 30-day subcutaneous osmotic pump) using the Parse Biosciences Evercode WT v3 combinatorial barcoding platform. Nuclei were clustered into 16 annotated cell type populations using Seurat v5. Disease and rescue effects were quantified as log fold changes (LFCs) across all clusters, with Gene Ontology enrichment assessed using clusterProfiler and transcription factor activity inferred using decoupleR.
RESULTS: Disease-associated transcriptional disruption was highly cell-type-specific in its magnitude. Among inhibitory subtypes, VIP/Reln disinhibitory interneurons (n = 149 nuclei) showed the most coherent transcriptional disruption: 289 candidate genes were lower in 5xFAD, with Gene Ontology enrichment concentrated in synapse organization programs, including regulation of synapse structure or activity (padj = 1.5x10^-14, 44 genes), regulation of synapse organization (padj = 1.9x10^-14, 43 genes), and postsynapse organization (padj = 1.1x10^-13, 38 genes). This pathway-level specificity was not reproduced in PVALB or SST interneurons. Astrocytes showed loss of cell-adhesion programs (cell-substrate adhesion padj = 2.4x10^-4, 10 genes). Rolipram rescue was preferential: VIP interneurons yielded 72 true rescue genes and astrocytes yielded 42, with the remaining 14 clusters showing substantially fewer. The cAMP-specific phosphodiesterase Pde7b was disease-context-specifically lower in 5xFAD VIP interneurons (LFC -0.53) and restored by rolipram (LFC +0.54), with WT expression unchanged. decoupleR CREB1 activity inference identified reduced CREB1 activity in 5xFAD VIP interneurons with partial restoration in 5xFAD Rolipram, supporting a stepwise transcriptional cascade in which amyloid pathology reduces cAMP, which suppresses PKA and CREB1 activity. This in turn reduces Pde7b transcription, and rolipram reverses this cascade by blocking cAMP hydrolysis upstream.
CONCLUSION: This single-nucleus atlas provides the first cell-type-resolved characterization of rolipram's transcriptional effects in the 5xFAD brain. VIP disinhibitory interneurons emerge as the most transcriptionally vulnerable inhibitory subtype and the preferential site of rolipram-associated rescue, with the Pde7b/CREB1 signaling axis nominating a tractable, disease-context-specific pharmacological substrate.
Additional Links: PMID-43060028
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060028,
year = {2026},
author = {Potokiri, A and Dwamena, AA and Wang, H},
title = {Single-nucleus RNA-seq atlas of 5xFAD mouse brain maps cell-type-specific transcriptional disruption and preferential rolipram rescue in VIP interneurons.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.11.765944},
pmid = {43060028},
issn = {2692-8205},
abstract = {BACKGROUND: Alzheimer's disease is characterized by progressive synaptic dysfunction and inhibitory circuit disruption across multiple brain cell types. Rolipram, a selective phosphodiesterase 4 (PDE4) inhibitor that elevates intracellular cyclic AMP (cAMP), activates proteasome, and produces robust procognitive effects in AD mouse models. Still, the cell-type-specific transcriptional mechanisms underlying these effects remain uncharacterized.
METHODS: We profiled 29,664 nuclei from 5xFAD and wild-type (WT) mouse right hemisphere across four conditions: WT Vehicle, WT Rolipram, 5xFAD Vehicle, and 5xFAD Rolipram (0.03 mg/kg/day, 30-day subcutaneous osmotic pump) using the Parse Biosciences Evercode WT v3 combinatorial barcoding platform. Nuclei were clustered into 16 annotated cell type populations using Seurat v5. Disease and rescue effects were quantified as log fold changes (LFCs) across all clusters, with Gene Ontology enrichment assessed using clusterProfiler and transcription factor activity inferred using decoupleR.
RESULTS: Disease-associated transcriptional disruption was highly cell-type-specific in its magnitude. Among inhibitory subtypes, VIP/Reln disinhibitory interneurons (n = 149 nuclei) showed the most coherent transcriptional disruption: 289 candidate genes were lower in 5xFAD, with Gene Ontology enrichment concentrated in synapse organization programs, including regulation of synapse structure or activity (padj = 1.5x10^-14, 44 genes), regulation of synapse organization (padj = 1.9x10^-14, 43 genes), and postsynapse organization (padj = 1.1x10^-13, 38 genes). This pathway-level specificity was not reproduced in PVALB or SST interneurons. Astrocytes showed loss of cell-adhesion programs (cell-substrate adhesion padj = 2.4x10^-4, 10 genes). Rolipram rescue was preferential: VIP interneurons yielded 72 true rescue genes and astrocytes yielded 42, with the remaining 14 clusters showing substantially fewer. The cAMP-specific phosphodiesterase Pde7b was disease-context-specifically lower in 5xFAD VIP interneurons (LFC -0.53) and restored by rolipram (LFC +0.54), with WT expression unchanged. decoupleR CREB1 activity inference identified reduced CREB1 activity in 5xFAD VIP interneurons with partial restoration in 5xFAD Rolipram, supporting a stepwise transcriptional cascade in which amyloid pathology reduces cAMP, which suppresses PKA and CREB1 activity. This in turn reduces Pde7b transcription, and rolipram reverses this cascade by blocking cAMP hydrolysis upstream.
CONCLUSION: This single-nucleus atlas provides the first cell-type-resolved characterization of rolipram's transcriptional effects in the 5xFAD brain. VIP disinhibitory interneurons emerge as the most transcriptionally vulnerable inhibitory subtype and the preferential site of rolipram-associated rescue, with the Pde7b/CREB1 signaling axis nominating a tractable, disease-context-specific pharmacological substrate.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Structure-Based Discovery of GTP-Enhanced Rab10 Modulators and Their Effects on Alzheimer's Disease-Relevant Cellular Phenotypes.
bioRxiv : the preprint server for biology pii:2026.10.30.763175.
Rab10-mediated membrane trafficking has been implicated in Alzheimer's disease (AD), but pharmacological tools for investigating its function remain limited. Here, we screened more than 80 million compounds using structure-based virtual screening and prioritized five candidate Rab10 modulators (R1-R5). These compounds exhibited favorable docking scores, stable modeled protein-ligand complexes in molecular dynamics (MD) simulations and predicted acceptable ADME/toxicity profiles. Comparative docking against Rab5, Rab8, and Rab11 predicted preferential interactions with GTP-associated Rab10. R1 and R2 yielded the most favorable Rab10 scores, whereas R3 showed the largest differences between GTP-associated, GDP-containing, and nucleotide-free Rab10 models. Surface plasmon resonance (SPR) revealed micromolar apparent affinities of R1-R4 without added GTP and nanomolar apparent affinities under GTP-containing conditions, generally favoring GTP-bound Rab10 over Rab5. In a cell-based GTP quantification assay, R1 , R2 , R3 , and R5 reduced GTP-bound Rab10, whereas R4 increased it. R3 produced dose- and time-dependent reductions in GTP-bound Rab10 and was selected for functional studies. R3 altered endosomal organization and reduced EEA1 and LAMP1 expressions. In amyloid precursor protein (APP)/presenilin-1-expressing CHO cells, R3 redistributed intracellular APP, reduced APP carboxyl-terminal fragments (APP-CTFs), and decreased enlarged endosome-like structures. In neuronal differentiated PC12 cells, R1 - R3 attenuated NGF withdrawal-induced cytoskeletal disruption and cell death, accompanied by reduced APP-CTF accumulation and tau phosphorylation. These studies highlight novel Rab10 modulators and support their further validation as candidate pharmacological probes for investigating Rab10-associated trafficking and AD-relevant cellular phenotypes.
Additional Links: PMID-43060043
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060043,
year = {2026},
author = {Malasala, S and Cox, N and Sellman, G and Chen, YH and Lu, Q},
title = {Structure-Based Discovery of GTP-Enhanced Rab10 Modulators and Their Effects on Alzheimer's Disease-Relevant Cellular Phenotypes.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.30.763175},
pmid = {43060043},
issn = {2692-8205},
abstract = {Rab10-mediated membrane trafficking has been implicated in Alzheimer's disease (AD), but pharmacological tools for investigating its function remain limited. Here, we screened more than 80 million compounds using structure-based virtual screening and prioritized five candidate Rab10 modulators (R1-R5). These compounds exhibited favorable docking scores, stable modeled protein-ligand complexes in molecular dynamics (MD) simulations and predicted acceptable ADME/toxicity profiles. Comparative docking against Rab5, Rab8, and Rab11 predicted preferential interactions with GTP-associated Rab10. R1 and R2 yielded the most favorable Rab10 scores, whereas R3 showed the largest differences between GTP-associated, GDP-containing, and nucleotide-free Rab10 models. Surface plasmon resonance (SPR) revealed micromolar apparent affinities of R1-R4 without added GTP and nanomolar apparent affinities under GTP-containing conditions, generally favoring GTP-bound Rab10 over Rab5. In a cell-based GTP quantification assay, R1 , R2 , R3 , and R5 reduced GTP-bound Rab10, whereas R4 increased it. R3 produced dose- and time-dependent reductions in GTP-bound Rab10 and was selected for functional studies. R3 altered endosomal organization and reduced EEA1 and LAMP1 expressions. In amyloid precursor protein (APP)/presenilin-1-expressing CHO cells, R3 redistributed intracellular APP, reduced APP carboxyl-terminal fragments (APP-CTFs), and decreased enlarged endosome-like structures. In neuronal differentiated PC12 cells, R1 - R3 attenuated NGF withdrawal-induced cytoskeletal disruption and cell death, accompanied by reduced APP-CTF accumulation and tau phosphorylation. These studies highlight novel Rab10 modulators and support their further validation as candidate pharmacological probes for investigating Rab10-associated trafficking and AD-relevant cellular phenotypes.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
A Multi-Cohort nnU-Net for White Matter Hyperintensity Segmentation Across 2D and 3D FLAIR Acquisitions.
medRxiv : the preprint server for health sciences pii:2026.11.11.26367656.
BACKGROUND: White matter hyperintensities (WMH) are increasingly pooled across aging, cerebral small vessel disease (CSVD), and dementia cohorts that differ in both disease composition and FLAIR acquisition. Most automated segmentation tools were developed within a narrower range of populations or protocols, and few have been tested for whether segmentation accuracy and error remain consistent across conventional 2D and isotropic 3D FLAIR, or whether the choice of algorithm alters downstream clinical associations.
METHODS: We developed a single nnU-Net model, taking FLAIR and T1-weighted images as inputs, using 460 2D and 3D FLAIR scans from a neurodegenerative cohort (Alzheimer's Disease Neuroimaging Initiative, ADNI), a CSVD-enriched cohort with same-visit paired 2D and 3D FLAIR (Washington University White Matter Ischemic-Hypoxia study, WWISH), and a population-based sample (UK Biobank), holding out 92 scans from 66 participants at the participant-level as an internal test set. We further evaluated the model in an independent ADNI3 3D FLAIR set (n = 25), benchmarking voxel-wise overlap (Dice), volumetric agreement, and lesion-level detection against SHIVA-WMH, segcsvdWMH, and FreeSurfer WMH-SynthSeg, and compared acquisition-specific volume bias in participants with paired 2D and 3D FLAIR. We then compared how WMH volumes from each method predicted incident dementia in cognitively unimpaired adults from ADNI and the Knight Alzheimer Disease Research Center (n = 1,174; 42 incident cases).
RESULTS: In the internal test set, the model achieved a mean Dice of 0.73 (SD 0.10), compared with 0.50, 0.57, and 0.29 for SHIVA-WMH, segcsvdWMH, and WMH-SynthSeg (all FDR-adjusted p < 0.001). Dice was similar on 2D and 3D FLAIR (0.75 vs. 0.71). In WWISH participants imaged with both acquisitions, mean volume bias differed between 2D and 3D scans by 1.8 mL for the model versus 4.7-9.9 mL for the comparators. Advantages were largest in low-burden scans (<5 mL; Dice 0.66 vs. 0.19-0.54) and for lesions of ≤100 voxels (detection 77-87% vs. 14-63%). In ADNI3, the model retained a mean Dice of 0.70 (SD 0.14) without retraining and exceeded all comparators (FDR-adjusted p ≤ 0.002). Model-derived WMH volume was associated with incident dementia beyond clinical covariates (OR per SD 1.40, 95% CI 1.11-1.77; likelihood-ratio p = 0.009; cross-validated AUC 0.71 vs. 0.68), whereas comparator-derived volumes did not significantly improve model fit.
CONCLUSIONS: Training a single model across disease contexts and FLAIR acquisitions yielded WMH segmentation that was similarly accurate on 2D and 3D FLAIR, sensitive to low-burden disease, transferable to an unseen protocol, and clinically informative, supporting its use in multi-cohort, mixed-etiology studies.
KEY POINTS: A single nnU-Net trained across neurodegenerative, cerebral small vessel disease, and population-based cohorts and across 2D and 3D FLAIR outperformed SHIVA-WMH, segcsvdWMH, and WMH-SynthSeg, with the largest gains in low-burden scans and small lesions.In same-visit paired 2D and 3D FLAIR scans, the model's volume bias relative to acquisition-specific reference masks varied less across acquisitions, whereas comparator biases varied with acquisition.Only WMH volume from the model significantly improved model fit for incident dementia beyond clinical covariates, highlighting the potential influence of segmentation algorithm choice on downstream clinical inference.
Additional Links: PMID-43060058
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060058,
year = {2026},
author = {Chen, Y and Khatri, U and Xu, B and Astafiev, SV and Ford, A and Lee, JM and An, H and Phuah, CL},
title = {A Multi-Cohort nnU-Net for White Matter Hyperintensity Segmentation Across 2D and 3D FLAIR Acquisitions.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.11.26367656},
pmid = {43060058},
abstract = {BACKGROUND: White matter hyperintensities (WMH) are increasingly pooled across aging, cerebral small vessel disease (CSVD), and dementia cohorts that differ in both disease composition and FLAIR acquisition. Most automated segmentation tools were developed within a narrower range of populations or protocols, and few have been tested for whether segmentation accuracy and error remain consistent across conventional 2D and isotropic 3D FLAIR, or whether the choice of algorithm alters downstream clinical associations.
METHODS: We developed a single nnU-Net model, taking FLAIR and T1-weighted images as inputs, using 460 2D and 3D FLAIR scans from a neurodegenerative cohort (Alzheimer's Disease Neuroimaging Initiative, ADNI), a CSVD-enriched cohort with same-visit paired 2D and 3D FLAIR (Washington University White Matter Ischemic-Hypoxia study, WWISH), and a population-based sample (UK Biobank), holding out 92 scans from 66 participants at the participant-level as an internal test set. We further evaluated the model in an independent ADNI3 3D FLAIR set (n = 25), benchmarking voxel-wise overlap (Dice), volumetric agreement, and lesion-level detection against SHIVA-WMH, segcsvdWMH, and FreeSurfer WMH-SynthSeg, and compared acquisition-specific volume bias in participants with paired 2D and 3D FLAIR. We then compared how WMH volumes from each method predicted incident dementia in cognitively unimpaired adults from ADNI and the Knight Alzheimer Disease Research Center (n = 1,174; 42 incident cases).
RESULTS: In the internal test set, the model achieved a mean Dice of 0.73 (SD 0.10), compared with 0.50, 0.57, and 0.29 for SHIVA-WMH, segcsvdWMH, and WMH-SynthSeg (all FDR-adjusted p < 0.001). Dice was similar on 2D and 3D FLAIR (0.75 vs. 0.71). In WWISH participants imaged with both acquisitions, mean volume bias differed between 2D and 3D scans by 1.8 mL for the model versus 4.7-9.9 mL for the comparators. Advantages were largest in low-burden scans (<5 mL; Dice 0.66 vs. 0.19-0.54) and for lesions of ≤100 voxels (detection 77-87% vs. 14-63%). In ADNI3, the model retained a mean Dice of 0.70 (SD 0.14) without retraining and exceeded all comparators (FDR-adjusted p ≤ 0.002). Model-derived WMH volume was associated with incident dementia beyond clinical covariates (OR per SD 1.40, 95% CI 1.11-1.77; likelihood-ratio p = 0.009; cross-validated AUC 0.71 vs. 0.68), whereas comparator-derived volumes did not significantly improve model fit.
CONCLUSIONS: Training a single model across disease contexts and FLAIR acquisitions yielded WMH segmentation that was similarly accurate on 2D and 3D FLAIR, sensitive to low-burden disease, transferable to an unseen protocol, and clinically informative, supporting its use in multi-cohort, mixed-etiology studies.
KEY POINTS: A single nnU-Net trained across neurodegenerative, cerebral small vessel disease, and population-based cohorts and across 2D and 3D FLAIR outperformed SHIVA-WMH, segcsvdWMH, and WMH-SynthSeg, with the largest gains in low-burden scans and small lesions.In same-visit paired 2D and 3D FLAIR scans, the model's volume bias relative to acquisition-specific reference masks varied less across acquisitions, whereas comparator biases varied with acquisition.Only WMH volume from the model significantly improved model fit for incident dementia beyond clinical covariates, highlighting the potential influence of segmentation algorithm choice on downstream clinical inference.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Joint Longitudinal Hazard Modeling Distinguishes Polygenic Effects on Dementia via Premorbid Cognitive Function and Aging-Related Decline.
medRxiv : the preprint server for health sciences pii:2026.11.06.26367441.
Alzheimer's disease and related dementias (AD/ADRD) are clinical disorders characterized by declines in cognitive function to levels at which everyday living is meaningfully impaired. Genetic variants may confer risk for AD/ADRD by way of steeper rates of aging-related cognitive declines or their association with lower premorbid levels of cognitive function that place individuals closer to a clinically severe threshold of cognitive function. We applied joint longitudinal-hazard models to 26-year data from an ancestrally diverse US sample of N = 11,518 adults to estimate effects of multi-ancestry polygenic indices (PGIs) for a range of established risk factors on dementia hazard and the degree they operate via premorbid cognitive function and longitudinal cognitive decline. APOE e4 and PGIs for ADRD, type 2 diabetes, stroke, LDL cholesterol, and hearing loss operated via rate of change, whereas PGIs for educational attainment, cognitive function, physical activity, BMI, smoking, loneliness, schizophrenia, and externalizing were associated with dementia hazard via premorbid differences in cognitive function. Some results varied by continental ancestry. Our implementation of joint longitudinal-hazard models allowed us to distinguish how different genetic risk factors for AD/ADRD operate via degenerative processes that might be therapeutically targeted during later life and via premorbid levels of cognitive function that would require intervention earlier in the life course.
Additional Links: PMID-43060060
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060060,
year = {2026},
author = {Clapp Sullivan, ML and de la Fuente, J and Corley, J and Harris, SE and Deary, IJ and Russ, TC and Cox, SR and Tucker-Drob, EM},
title = {Joint Longitudinal Hazard Modeling Distinguishes Polygenic Effects on Dementia via Premorbid Cognitive Function and Aging-Related Decline.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.06.26367441},
pmid = {43060060},
abstract = {Alzheimer's disease and related dementias (AD/ADRD) are clinical disorders characterized by declines in cognitive function to levels at which everyday living is meaningfully impaired. Genetic variants may confer risk for AD/ADRD by way of steeper rates of aging-related cognitive declines or their association with lower premorbid levels of cognitive function that place individuals closer to a clinically severe threshold of cognitive function. We applied joint longitudinal-hazard models to 26-year data from an ancestrally diverse US sample of N = 11,518 adults to estimate effects of multi-ancestry polygenic indices (PGIs) for a range of established risk factors on dementia hazard and the degree they operate via premorbid cognitive function and longitudinal cognitive decline. APOE e4 and PGIs for ADRD, type 2 diabetes, stroke, LDL cholesterol, and hearing loss operated via rate of change, whereas PGIs for educational attainment, cognitive function, physical activity, BMI, smoking, loneliness, schizophrenia, and externalizing were associated with dementia hazard via premorbid differences in cognitive function. Some results varied by continental ancestry. Our implementation of joint longitudinal-hazard models allowed us to distinguish how different genetic risk factors for AD/ADRD operate via degenerative processes that might be therapeutically targeted during later life and via premorbid levels of cognitive function that would require intervention earlier in the life course.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
ROCK inhibitor Ripasudil reduces Alzheimer's pathological proteins and enhances cellular bioenergetics.
bioRxiv : the preprint server for biology pii:2026.11.02.761117.
Rho-associated kinase (ROCK) inhibitors have been explored as an Alzheimer's Disease (AD) therapeutic agent. In this study, we aim to determine the efficacy of a potent ROCK inhibitor, ripasudil, in impacting AD pathological protein tau in mice. The time-course study showed that ripasudil rapidly penetrated mouse brains, reaching maximal concentration half an hour post-injection. To determine the efficacy of ripasudil, we injected App [NL-G-F] knock-in mice with ripasudil at 30 mg/kg and sacrificed them after three hours. We used Tandem Mass Tag labels and compared the proteomic profiles of mouse brains exposed to ripasudil to those exposed to saline. We also treated AD-patient-derived Neural Stem Cells (NSCs) with ripasudil and performed a Seahorse Mito Stress Test to evaluate their impact on mitochondrial activity. Bioinformatics analysis of the proteomic profiles revealed differentially enriched components of chromosome. The Mito Stress Test of NSCs revealed significant increases in basal oxygen consumption, ATP-linked respiration, maximal respiration, and reserve capacity oxygen consumption compared to untreated NSCs. Importantly, we found a significant reduction of Tau and pTau 396 in brains of mice treated with ripasudil. Overall, our findings highlight the feasibility and promise of ROCK inhibitor ripasudil as an AD therapeutic agent.
Additional Links: PMID-43060094
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060094,
year = {2026},
author = {Li, Y and Liu, Z and Cambi, XA and Paterson, J and Benavides, GA and Ouyang, X and Candib, A and Zaia, J and Darley-Usmar, V and Zheng, C and Zhang, J and Xia, W},
title = {ROCK inhibitor Ripasudil reduces Alzheimer's pathological proteins and enhances cellular bioenergetics.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.02.761117},
pmid = {43060094},
issn = {2692-8205},
abstract = {Rho-associated kinase (ROCK) inhibitors have been explored as an Alzheimer's Disease (AD) therapeutic agent. In this study, we aim to determine the efficacy of a potent ROCK inhibitor, ripasudil, in impacting AD pathological protein tau in mice. The time-course study showed that ripasudil rapidly penetrated mouse brains, reaching maximal concentration half an hour post-injection. To determine the efficacy of ripasudil, we injected App [NL-G-F] knock-in mice with ripasudil at 30 mg/kg and sacrificed them after three hours. We used Tandem Mass Tag labels and compared the proteomic profiles of mouse brains exposed to ripasudil to those exposed to saline. We also treated AD-patient-derived Neural Stem Cells (NSCs) with ripasudil and performed a Seahorse Mito Stress Test to evaluate their impact on mitochondrial activity. Bioinformatics analysis of the proteomic profiles revealed differentially enriched components of chromosome. The Mito Stress Test of NSCs revealed significant increases in basal oxygen consumption, ATP-linked respiration, maximal respiration, and reserve capacity oxygen consumption compared to untreated NSCs. Importantly, we found a significant reduction of Tau and pTau 396 in brains of mice treated with ripasudil. Overall, our findings highlight the feasibility and promise of ROCK inhibitor ripasudil as an AD therapeutic agent.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
In-vivo MRI of noradrenergic and dopaminergic nuclei predicts future cognition and Alzheimers disease progression.
bioRxiv : the preprint server for biology pii:2026.10.29.762942.
Noradrenergic and dopaminergic nuclei modulate cognition, and post-mortem data indicate they are affected early in the neurodegenerative cascade of Alzheimers disease. We derived in-vivo locus coeruleus (LC) and substantia nigra-ventral tegmental area (SN-VTA) MRI integrity measures from 739 ADNI participants, examined MRI-histology correspondence in individuals with both in-vivo imaging and post-mortem data, and tested whether these measures reflect early MRI-indexed degeneration predicting later cognitive decline. LC and SN-VTA contrast predicted cognitive and behavioral function 10 years later, despite only weak associations with current function. LC- and SN-VTA-associated brain-wide atrophy patterns aligned with PET-derived norepinephrine-transporter and dopamine-receptor maps, respectively. A one-standard-deviation decrease in baseline LC contrast was associated with 84% higher five-year odds of MCI-to-AD progression, and predictive effects of the catecholaminergic nuclei were mediated by their corresponding atrophy patterns. The SN-VTA pattern was associated with less amyloid PET-related memory decline. Together, these findings establish LC and SN-VTA MRI contrast as markers of early neurodegeneration that forecast cognitive decline years before clinical onset.
Additional Links: PMID-43060107
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060107,
year = {2026},
author = {Zhao, W and Guzman, SJ and Yoo, HJ and Ruiz, K and Chen, K and Moheban, A and Nation, DA and Dahl, MJ and Mather, M},
title = {In-vivo MRI of noradrenergic and dopaminergic nuclei predicts future cognition and Alzheimers disease progression.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.29.762942},
pmid = {43060107},
issn = {2692-8205},
abstract = {Noradrenergic and dopaminergic nuclei modulate cognition, and post-mortem data indicate they are affected early in the neurodegenerative cascade of Alzheimers disease. We derived in-vivo locus coeruleus (LC) and substantia nigra-ventral tegmental area (SN-VTA) MRI integrity measures from 739 ADNI participants, examined MRI-histology correspondence in individuals with both in-vivo imaging and post-mortem data, and tested whether these measures reflect early MRI-indexed degeneration predicting later cognitive decline. LC and SN-VTA contrast predicted cognitive and behavioral function 10 years later, despite only weak associations with current function. LC- and SN-VTA-associated brain-wide atrophy patterns aligned with PET-derived norepinephrine-transporter and dopamine-receptor maps, respectively. A one-standard-deviation decrease in baseline LC contrast was associated with 84% higher five-year odds of MCI-to-AD progression, and predictive effects of the catecholaminergic nuclei were mediated by their corresponding atrophy patterns. The SN-VTA pattern was associated with less amyloid PET-related memory decline. Together, these findings establish LC and SN-VTA MRI contrast as markers of early neurodegeneration that forecast cognitive decline years before clinical onset.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Interpretable Machine Learning Links Group-Specific Plasma Proteomics to Regional Structural Neuroimaging in Alzheimer's Disease.
bioRxiv : the preprint server for biology pii:2026.11.02.763368.
BACKGROUND: Alzheimer's disease (AD) pathology begins years before clinical symptoms, highlighting the need for scalable biomarkers that capture biological changes across the AD continuum. Broader plasma proteomics may capture systemic processes that vary with disease stage, yet their relationship to AD-related brain neurodegeneration remains unclear. We aimed to identify plasma proteomic signatures across cognitively normal (CN), mild cognitive impairment (MCI), and AD and evaluate their neuroanatomical associations.
METHODS: We analyzed 146 plasma analytes from 565 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants (58 CN, 396 MCI, 111 AD). Group-specific proteomic signatures were identified using pairwise classification models with nested 5×5 cross-validation. SHAP quantified feature importance, with the top 15 proteins per comparison being prioritized for MRI association analysis. We analyzed 103 regional structural MRI volumes harmonized across 57 acquisition sites using ComBat. Separate ordinary least squares regression tested protein-MRI associations, adjusting for age, sex, APOE ε4, diagnosis, and intracranial volume, followed by Benjamini-Hochberg false discovery rate (FDR) correction.
RESULTS: Classification models using proteomic data achieved AUC of 0.956 ± 0.017 for CN vs MCI, 0.963 ± 0.011 for MCI vs. AD, and 0.836 ± 0.085 for CN vs. AD. SHAP identified group-dependent proteomic signatures. No protein-MRI associations survived FDR correction for CN vs. MCI. In MCI vs. AD, higher cortisol was associated with lower left precuneus and superior parietal volumes, while higher osteopontin was associated with lower left paracentral and accumbens volumes. In CN vs. AD, higher vitronectin was associated with lower posterior corpus callosum volume.
CONCLUSION: These findings suggest that plasma proteomics capture group-specific systemic biological signals across the AD continuum. Linking ML-prioritized plasma proteins to regional brain structure provides neuroanatomical context for blood-based biomarker discovery.
Additional Links: PMID-43060131
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060131,
year = {2026},
author = {Laugi, H and Hosseinzadehketilateh, M and Lee, S and Weisberg, SM and Zhu, X and , },
title = {Interpretable Machine Learning Links Group-Specific Plasma Proteomics to Regional Structural Neuroimaging in Alzheimer's Disease.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.02.763368},
pmid = {43060131},
issn = {2692-8205},
abstract = {BACKGROUND: Alzheimer's disease (AD) pathology begins years before clinical symptoms, highlighting the need for scalable biomarkers that capture biological changes across the AD continuum. Broader plasma proteomics may capture systemic processes that vary with disease stage, yet their relationship to AD-related brain neurodegeneration remains unclear. We aimed to identify plasma proteomic signatures across cognitively normal (CN), mild cognitive impairment (MCI), and AD and evaluate their neuroanatomical associations.
METHODS: We analyzed 146 plasma analytes from 565 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants (58 CN, 396 MCI, 111 AD). Group-specific proteomic signatures were identified using pairwise classification models with nested 5×5 cross-validation. SHAP quantified feature importance, with the top 15 proteins per comparison being prioritized for MRI association analysis. We analyzed 103 regional structural MRI volumes harmonized across 57 acquisition sites using ComBat. Separate ordinary least squares regression tested protein-MRI associations, adjusting for age, sex, APOE ε4, diagnosis, and intracranial volume, followed by Benjamini-Hochberg false discovery rate (FDR) correction.
RESULTS: Classification models using proteomic data achieved AUC of 0.956 ± 0.017 for CN vs MCI, 0.963 ± 0.011 for MCI vs. AD, and 0.836 ± 0.085 for CN vs. AD. SHAP identified group-dependent proteomic signatures. No protein-MRI associations survived FDR correction for CN vs. MCI. In MCI vs. AD, higher cortisol was associated with lower left precuneus and superior parietal volumes, while higher osteopontin was associated with lower left paracentral and accumbens volumes. In CN vs. AD, higher vitronectin was associated with lower posterior corpus callosum volume.
CONCLUSION: These findings suggest that plasma proteomics capture group-specific systemic biological signals across the AD continuum. Linking ML-prioritized plasma proteins to regional brain structure provides neuroanatomical context for blood-based biomarker discovery.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
ADRA2B genetic polymorphism modulates vagus nerve stimulation response.
bioRxiv : the preprint server for biology pii:2026.11.03.763718.
INTRODUCTION: Given interest in vagus nerve stimulation (VNS) as a potential therapy for Alzheimer's disease, due to its hypothesized influence on the noradrenergic (NA) system, there is a need to understand the pronounced individual differences in responsiveness to VNS in aging. We tested whether a genetic polymorphism related to NA signaling, the Δ301-303 deletion in the ADRA2B receptor, modulates transcutaneous auricular (taVNS) effects on task-related pupillary responses or pupil-linked cortical activity in noradrenergic projection territory.
METHODS: Forty-one adults (61% deletion carriers; ages 19-79) performed a visual oddball task during a sham-controlled single-blind crossover taVNS trial. Of these people, 25 (68% deletion carriers) also performed the same task with simultaneous fMRI.
RESULTS: ADRA2B genotype predicted the taVNS effect on oddball pupillary responses (t(37) = 3.03, p = .004, d = 0.84). Deletion carrier responses were more likely to increase, while non-carrier responses decreased. Carriers showed stronger spatial alignment between pupil-BOLD coupling and cortical norepinephrine transporter (NET) expression (t(22) = 2.82, p = .010, adjusted d = 1.21). This difference was selective to NET among 19 PET maps (all other p > .11). The individual effect of taVNS predicted NET alignment of pupil-BOLD coupling (ρ = .45, p = .023).
CONCLUSIONS: ADRA2B Δ301-303 deletion status, which is thought to increase NA availability, predicts the direction of the pupillary response to taVNS and how tightly pupil-linked BOLD activity aligns with cortical noradrenergic projection territory.
Additional Links: PMID-43060143
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060143,
year = {2026},
author = {Riley, E and Mabry, SA and MacMillan, MK and Ko, L and Middleton, FA and De Rosa, E and Anderson, AK},
title = {ADRA2B genetic polymorphism modulates vagus nerve stimulation response.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.03.763718},
pmid = {43060143},
issn = {2692-8205},
abstract = {INTRODUCTION: Given interest in vagus nerve stimulation (VNS) as a potential therapy for Alzheimer's disease, due to its hypothesized influence on the noradrenergic (NA) system, there is a need to understand the pronounced individual differences in responsiveness to VNS in aging. We tested whether a genetic polymorphism related to NA signaling, the Δ301-303 deletion in the ADRA2B receptor, modulates transcutaneous auricular (taVNS) effects on task-related pupillary responses or pupil-linked cortical activity in noradrenergic projection territory.
METHODS: Forty-one adults (61% deletion carriers; ages 19-79) performed a visual oddball task during a sham-controlled single-blind crossover taVNS trial. Of these people, 25 (68% deletion carriers) also performed the same task with simultaneous fMRI.
RESULTS: ADRA2B genotype predicted the taVNS effect on oddball pupillary responses (t(37) = 3.03, p = .004, d = 0.84). Deletion carrier responses were more likely to increase, while non-carrier responses decreased. Carriers showed stronger spatial alignment between pupil-BOLD coupling and cortical norepinephrine transporter (NET) expression (t(22) = 2.82, p = .010, adjusted d = 1.21). This difference was selective to NET among 19 PET maps (all other p > .11). The individual effect of taVNS predicted NET alignment of pupil-BOLD coupling (ρ = .45, p = .023).
CONCLUSIONS: ADRA2B Δ301-303 deletion status, which is thought to increase NA availability, predicts the direction of the pupillary response to taVNS and how tightly pupil-linked BOLD activity aligns with cortical noradrenergic projection territory.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Subcellular Spatial Profiling Unveils Links Between Neuritic Plaques with Selective Tau Vulnerability in Alzheimer's Disease.
bioRxiv : the preprint server for biology pii:2026.11.05.764692.
Alzheimer's disease (AD) features widespread extracellular amyloid-β plaques but selective intraneuronal tau accumulation in cortical layers II/III and V, while layer IV remains relatively resistant. Here, we combined subcellular spatial transcriptomics with co-registered Aβ and pTau immunohistochemistry to determine why neurons exposed to comparable plaque-associated pathology differ in somatic pTau accumulation. Plaque-associated neuritic stress occurred similarly across layers, but layer IV neurons showed attenuated pTau accumulation and reduced somatic expression of a shared neurite-soma stress program involving DCTN1 , CALM3 , NORAD , and PIN1 . Trajectory analysis within layers identified tau-vulnerable and resistant neuronal states implicating calcium signaling, retrograde transport, and lysosomal function. Notably, astrocytic APOE -neuronal LRP1 co-expression increased significantly along the pTau-vulnerable trajectory, and APOE ε4 was associated with stronger coupling of local plaque pathology to pTau-associated molecular programs. These findings reveal neuronal programs and neuron-glia interactions underlying selective tau vulnerability and resistance in AD, highlighting potential tau-targeting therapeutics.
Additional Links: PMID-43060145
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060145,
year = {2026},
author = {Li, H and Gross, ER and Devine, A and Gundavelli, A and Prell, SA and Woodbury, ME and Gen, L and Doering, A and Held, A and Hyman, BT and Serrano-Pozo, A and Zwang, T and Bennett, RE and Das, S},
title = {Subcellular Spatial Profiling Unveils Links Between Neuritic Plaques with Selective Tau Vulnerability in Alzheimer's Disease.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.05.764692},
pmid = {43060145},
issn = {2692-8205},
abstract = {Alzheimer's disease (AD) features widespread extracellular amyloid-β plaques but selective intraneuronal tau accumulation in cortical layers II/III and V, while layer IV remains relatively resistant. Here, we combined subcellular spatial transcriptomics with co-registered Aβ and pTau immunohistochemistry to determine why neurons exposed to comparable plaque-associated pathology differ in somatic pTau accumulation. Plaque-associated neuritic stress occurred similarly across layers, but layer IV neurons showed attenuated pTau accumulation and reduced somatic expression of a shared neurite-soma stress program involving DCTN1 , CALM3 , NORAD , and PIN1 . Trajectory analysis within layers identified tau-vulnerable and resistant neuronal states implicating calcium signaling, retrograde transport, and lysosomal function. Notably, astrocytic APOE -neuronal LRP1 co-expression increased significantly along the pTau-vulnerable trajectory, and APOE ε4 was associated with stronger coupling of local plaque pathology to pTau-associated molecular programs. These findings reveal neuronal programs and neuron-glia interactions underlying selective tau vulnerability and resistance in AD, highlighting potential tau-targeting therapeutics.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Brain proteinopathies associated physiological changes leading to cognitive resilience in Alzheimer's disease.
bioRxiv : the preprint server for biology pii:2026.11.09.765496.
UNLABELLED: Alzheimer's disease (AD) pathology has been well characterized, however the molecular mechanisms underlying resilience to the disease remain understudied. With the growing evidence of individuals who are resilient to AD and generation of cross-cohort multiomics data, it has become feasible to understand these mechanisms. In this study, we integrated longitudinal cognitive assessments, regional neuropathology, and matched prefrontal proteomic and metabolomic profiles across donors from two independent cohorts. We identified that asymptomatic AD (AsymAD) brains exhibited amyloid burdens comparable to AD but had fewer compact plaques, lower regional tau burden, and more restricted TDP-43 pathology. Across matched stages of amyloid, tau, and TDP-43 pathology, AsymAD was consistently distinguished from AD by preservation of mitochondrial translation and bioenergetics, synaptic programs, glutamatergic metabolites, and polyunsaturated membrane lipids. Longitudinal cognitive assessments further separated resilient from vulnerable AsymAD individuals despite comparable amyloid and TDP-43 burden, with vulnerability associated with greater neurofibrillary tangle accumulation. Both AsymAD groups retained a prefrontal proteome close to that of cognitively normal individuals, apart from amyloid-associated proteins, whereas mitochondrial, synaptic, and immune changes were largely confined to AD.
HIGHLIGHTS: AsymAD carries AD-level amyloid with lesser compact plaques, tau, and TDP-43The mitochondrial, lipid, synaptic functions separate AsymAD from AD at every pathology stageResilient and vulnerable AsymAD differ in tangles, not amyloid or TDP-43AsymAD keeps a control-like prefrontal proteome.
Additional Links: PMID-43060152
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060152,
year = {2026},
author = {Mandal, P and Baloni, P},
title = {Brain proteinopathies associated physiological changes leading to cognitive resilience in Alzheimer's disease.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.09.765496},
pmid = {43060152},
issn = {2692-8205},
abstract = {UNLABELLED: Alzheimer's disease (AD) pathology has been well characterized, however the molecular mechanisms underlying resilience to the disease remain understudied. With the growing evidence of individuals who are resilient to AD and generation of cross-cohort multiomics data, it has become feasible to understand these mechanisms. In this study, we integrated longitudinal cognitive assessments, regional neuropathology, and matched prefrontal proteomic and metabolomic profiles across donors from two independent cohorts. We identified that asymptomatic AD (AsymAD) brains exhibited amyloid burdens comparable to AD but had fewer compact plaques, lower regional tau burden, and more restricted TDP-43 pathology. Across matched stages of amyloid, tau, and TDP-43 pathology, AsymAD was consistently distinguished from AD by preservation of mitochondrial translation and bioenergetics, synaptic programs, glutamatergic metabolites, and polyunsaturated membrane lipids. Longitudinal cognitive assessments further separated resilient from vulnerable AsymAD individuals despite comparable amyloid and TDP-43 burden, with vulnerability associated with greater neurofibrillary tangle accumulation. Both AsymAD groups retained a prefrontal proteome close to that of cognitively normal individuals, apart from amyloid-associated proteins, whereas mitochondrial, synaptic, and immune changes were largely confined to AD.
HIGHLIGHTS: AsymAD carries AD-level amyloid with lesser compact plaques, tau, and TDP-43The mitochondrial, lipid, synaptic functions separate AsymAD from AD at every pathology stageResilient and vulnerable AsymAD differ in tangles, not amyloid or TDP-43AsymAD keeps a control-like prefrontal proteome.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies.
bioRxiv : the preprint server for biology pii:2026.11.09.765484.
Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau -MAPT-). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silen cing c onnected interfering o ligonucleotides against M APT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.
Additional Links: PMID-43060157
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060157,
year = {2026},
author = {Sgourdou, P and Vrettos, N and Hoxha, K and Baffic, T and Lee, EB and Xu, H and Lee, VM and Mourelatos, Z},
title = {SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.09.765484},
pmid = {43060157},
issn = {2692-8205},
abstract = {Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau -MAPT-). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silen cing c onnected interfering o ligonucleotides against M APT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Chronic FMNL2 overexpression is associated with changes in brain histology and exploratory behavior in adult zebrafish.
bioRxiv : the preprint server for biology pii:2026.11.09.765478.
Formin-like protein 2 (FMNL2) has been associated with Alzheimer's disease and cerebrovascular pathology and regulates gliovascular remodeling following amyloid exposure. However, the consequences of sustained FMNL2 elevation remain unclear. We generated a transgenic zebrafish line expressing human FMNL2 under the her4.1 promoter and examined adult brain histology and behavior under baseline conditions and following acute amyloid-β42 (Aβ42) exposure. Histological analyses assessed FMNL2 immunoreactivity, overlap between the glial marker BLBP and endothelial tight-junction marker ZO1, synaptic vesicle protein SV2 labeling, and microglial counts. Exploratory behavior was evaluated using the novel tank test and free-movement pattern Y-maze. Compared with uninjected wild-type controls, uninjected FMNL2-overexpressing fish showed higher FMNL2 immunoreactivity, lower BLBP-ZO1 overlap, fewer normalized SV2 puncta, and higher counts of total and morphologically activated microglia. Acute Aβ42 exposure in wild-type animals produced changes in the same direction across these histological endpoints. No significant additional histological changes were detected following Aβ42 exposure in the overexpression background. In the novel tank test, uninjected FMNL2-overexpressing fish had a higher composite boldness index than uninjected wild-type controls. These findings indicate that sustained FMNL2 overexpression is associated with histological changes resembling several responses to acute Aβ42 exposure, together with altered exploratory behavior. They support further investigation of persistent FMNL2 elevation as a contributor to altered glial-vascular organization and cellular responses relevant to Alzheimer's disease.
Additional Links: PMID-43060174
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060174,
year = {2026},
author = {Lyu, C and Tayran, H and Bhattarai, P and Yilmaz, E and Kizil, C},
title = {Chronic FMNL2 overexpression is associated with changes in brain histology and exploratory behavior in adult zebrafish.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.09.765478},
pmid = {43060174},
issn = {2692-8205},
abstract = {Formin-like protein 2 (FMNL2) has been associated with Alzheimer's disease and cerebrovascular pathology and regulates gliovascular remodeling following amyloid exposure. However, the consequences of sustained FMNL2 elevation remain unclear. We generated a transgenic zebrafish line expressing human FMNL2 under the her4.1 promoter and examined adult brain histology and behavior under baseline conditions and following acute amyloid-β42 (Aβ42) exposure. Histological analyses assessed FMNL2 immunoreactivity, overlap between the glial marker BLBP and endothelial tight-junction marker ZO1, synaptic vesicle protein SV2 labeling, and microglial counts. Exploratory behavior was evaluated using the novel tank test and free-movement pattern Y-maze. Compared with uninjected wild-type controls, uninjected FMNL2-overexpressing fish showed higher FMNL2 immunoreactivity, lower BLBP-ZO1 overlap, fewer normalized SV2 puncta, and higher counts of total and morphologically activated microglia. Acute Aβ42 exposure in wild-type animals produced changes in the same direction across these histological endpoints. No significant additional histological changes were detected following Aβ42 exposure in the overexpression background. In the novel tank test, uninjected FMNL2-overexpressing fish had a higher composite boldness index than uninjected wild-type controls. These findings indicate that sustained FMNL2 overexpression is associated with histological changes resembling several responses to acute Aβ42 exposure, together with altered exploratory behavior. They support further investigation of persistent FMNL2 elevation as a contributor to altered glial-vascular organization and cellular responses relevant to Alzheimer's disease.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Disease aging clocks in the plasma proteome stratify risk and track preclinical progression.
Research square pii:rs.3.rs-10675323.
Aging is the strongest risk factor for most chronic diseases, yet people of the same chronological age differ in how far disease processes have advanced. Existing plasma proteomic clocks estimate chronological age, or the age of a single organ, but none targets the pathway from aging to a specific disease. Here we developed disease aging clocks by deriving the plasma proteomic composite that maximizes the age-mediated component of disease risk and applied the framework to 31 age-related diseases in 44,526 UK Biobank participants. The resulting disease age gap separated 10-year incidence up to 20-fold among individuals of the same chronological age, and each additional year of gap raised the hazard of type 2 diabetes by 24%, chronic kidney disease by 21% and Alzheimer's disease (AD) by 17%. Among participants who went on to develop disease, the gap was larger closer to diagnosis in 19 of 20 diseases, indicating that it reports preclinical stage rather than fixed susceptibility. Across these 20 diseases, 56% of the gap was orthogonal to chronological and organ-specific clocks. Applied without refitting to Stanford Alzheimer's Disease Research Center participants (n=501), the AD clock was elevated in AD and Lewy body disease but not Parkinson's disease, and tracked plasma biomarkers, cognition and neuroimaging features. Disease aging clocks provide a blood-based measure of the stage of a specific aging-to-disease process years before diagnosis, with potential applications in prevention-trial enrichment and longitudinal disease monitoring.
Additional Links: PMID-43060219
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060219,
year = {2026},
author = {He, Z and Park, J and Tan, J and Wen, R and Wang, J and Ying, K and Guen, YL and Mormino, E and Henderson, V and Wyss-Coray, T},
title = {Disease aging clocks in the plasma proteome stratify risk and track preclinical progression.},
journal = {Research square},
volume = {},
number = {},
pages = {},
doi = {10.21203/rs.3.rs-10675323/v1},
pmid = {43060219},
issn = {2693-5015},
abstract = {Aging is the strongest risk factor for most chronic diseases, yet people of the same chronological age differ in how far disease processes have advanced. Existing plasma proteomic clocks estimate chronological age, or the age of a single organ, but none targets the pathway from aging to a specific disease. Here we developed disease aging clocks by deriving the plasma proteomic composite that maximizes the age-mediated component of disease risk and applied the framework to 31 age-related diseases in 44,526 UK Biobank participants. The resulting disease age gap separated 10-year incidence up to 20-fold among individuals of the same chronological age, and each additional year of gap raised the hazard of type 2 diabetes by 24%, chronic kidney disease by 21% and Alzheimer's disease (AD) by 17%. Among participants who went on to develop disease, the gap was larger closer to diagnosis in 19 of 20 diseases, indicating that it reports preclinical stage rather than fixed susceptibility. Across these 20 diseases, 56% of the gap was orthogonal to chronological and organ-specific clocks. Applied without refitting to Stanford Alzheimer's Disease Research Center participants (n=501), the AD clock was elevated in AD and Lewy body disease but not Parkinson's disease, and tracked plasma biomarkers, cognition and neuroimaging features. Disease aging clocks provide a blood-based measure of the stage of a specific aging-to-disease process years before diagnosis, with potential applications in prevention-trial enrichment and longitudinal disease monitoring.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Delayed-centrifugation blood collection tube for remote blood biomarker assessment.
medRxiv : the preprint server for health sciences pii:2026.10.30.26366958.
INTRODUCTION: Plasma phosphorylated tau 217 (p-tau217) and amyloid-β 42 (Aβ42) are advancing toward clinical use for Alzheimer's disease (AD), but their reliability can be impacted by preanalytical handling. Although alternative collection tubes with distinct stabilization strategies-P100 (protease inhibitor) and HEMAcollect (hemolysis/platelet-activation minimization)-have been developed to stabilize plasma proteins, how well they preserve these markers remains unresolved; we therefore compared both against fresh standard EDTA tubes.
METHODS: In 40 participants, plasma p-tau217 and Aβ42 were measured (Lumipulse) in paired fresh EDTA, P100, and HEMAcollect samples after 5-day ambient storage. We assessed concentration change, rank-order preservation (Spearman ρ), percentage difference, and diagnostic classification under the p-tau217/Aβ42 ratio and p-tau217 alone.
RESULTS: P100 preserved p-tau217 favorably, with high rank-order correlation (ρ=0.98) and a modest median change (+12.1%), and its classification agreement with fresh EDTA reached 97.5% using p-tau217 alone. HEMAcollect showed greater p-tau217 signal loss (-57.5%). Aβ42 was reduced in both tubes (-72.8% P100; -95.5% HEMAcollect) with loss of rank order, so neither preserved the p-tau217/Aβ42 ratio.
DISCUSSION: Stability was tube- and analyte-specific, and P100 consistently outperformed HEMAcollect-preserving p-tau217 rank order while HEMAcollect reduced signal across analytes. Although neither tube preserved the Aβ42-dependent ratio, P100 shows potential for p-tau217-based workflows. Preanalytical stability must be established analyte by analyte before alternative tubes enter clinical AD diagnosis.
Additional Links: PMID-43060272
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060272,
year = {2026},
author = {Lee, YR and Raj, A and Lopez, OL and Zeng, X and Karikari, TK},
title = {Delayed-centrifugation blood collection tube for remote blood biomarker assessment.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.30.26366958},
pmid = {43060272},
abstract = {INTRODUCTION: Plasma phosphorylated tau 217 (p-tau217) and amyloid-β 42 (Aβ42) are advancing toward clinical use for Alzheimer's disease (AD), but their reliability can be impacted by preanalytical handling. Although alternative collection tubes with distinct stabilization strategies-P100 (protease inhibitor) and HEMAcollect (hemolysis/platelet-activation minimization)-have been developed to stabilize plasma proteins, how well they preserve these markers remains unresolved; we therefore compared both against fresh standard EDTA tubes.
METHODS: In 40 participants, plasma p-tau217 and Aβ42 were measured (Lumipulse) in paired fresh EDTA, P100, and HEMAcollect samples after 5-day ambient storage. We assessed concentration change, rank-order preservation (Spearman ρ), percentage difference, and diagnostic classification under the p-tau217/Aβ42 ratio and p-tau217 alone.
RESULTS: P100 preserved p-tau217 favorably, with high rank-order correlation (ρ=0.98) and a modest median change (+12.1%), and its classification agreement with fresh EDTA reached 97.5% using p-tau217 alone. HEMAcollect showed greater p-tau217 signal loss (-57.5%). Aβ42 was reduced in both tubes (-72.8% P100; -95.5% HEMAcollect) with loss of rank order, so neither preserved the p-tau217/Aβ42 ratio.
DISCUSSION: Stability was tube- and analyte-specific, and P100 consistently outperformed HEMAcollect-preserving p-tau217 rank order while HEMAcollect reduced signal across analytes. Although neither tube preserved the Aβ42-dependent ratio, P100 shows potential for p-tau217-based workflows. Preanalytical stability must be established analyte by analyte before alternative tubes enter clinical AD diagnosis.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Anticholinergic Medications and Health in Adults with Autism or Intellectual Disability.
medRxiv : the preprint server for health sciences pii:2026.10.26.26366518.
OBJECTIVE: Contributors to autistic adults' elevated risk for negative aging-related outcomes, including Alzheimer's disease and related dementias (ADRD), falls, and mortality remain underexplored. One candidate factor is exposure to medications with anticholinergic (AC) effects. Thus, this study assessed prevalence of medications with AC effects, and their associations with ADRD, falls, and mortality across four groups: autism-only, autism+intellectual disability (ID), ID-only, and controls.
METHODS: We conducted a retrospective cohort study of 2017-2019 US linked Medicare and Medicaid claims data for 40+ year-olds. Autism, ID, ADRD, and falls were identified using validated algorithms, and mortality was based on Medicare/Medicaid death indicators. Medications were coded using a comprehensive AC potency scale. AC medication exposure effects and interactions between AC potency and group were examined using modified Poisson regressions. Sensitivity analyses to address indication bias excluded persons prescribed antidepressant and/or antipsychotic medication(s).
RESULTS: All three clinical groups experienced significantly greater AC medication exposure (autism+ID: 92.5%>ID-only: 88.6%>autism-only: 80.0%) than non-autistic/non-ID controls (61.3%). Additionally, AC medications were more frequently associated with ADRD, falls, and mortality in all of these groups. Stepwise associations between AC potency levels and ADRD, falls, and mortality were found, and these effects were more prominent for persons with autism and/or ID relative to the control sample.
INTERPRETATION: This study provides a foundational examination of exposure to AC medication effects and their associations with aging-related outcomes in middle-age and older autistic adults and adults with ID. AC medication exposure represents one potential modifiable risk factor for negative aging-related outcomes in these groups.
Additional Links: PMID-43060300
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060300,
year = {2026},
author = {McQuaid, GA and Tao, S and Shea, LL and Wallace, GL},
title = {Anticholinergic Medications and Health in Adults with Autism or Intellectual Disability.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.26.26366518},
pmid = {43060300},
abstract = {OBJECTIVE: Contributors to autistic adults' elevated risk for negative aging-related outcomes, including Alzheimer's disease and related dementias (ADRD), falls, and mortality remain underexplored. One candidate factor is exposure to medications with anticholinergic (AC) effects. Thus, this study assessed prevalence of medications with AC effects, and their associations with ADRD, falls, and mortality across four groups: autism-only, autism+intellectual disability (ID), ID-only, and controls.
METHODS: We conducted a retrospective cohort study of 2017-2019 US linked Medicare and Medicaid claims data for 40+ year-olds. Autism, ID, ADRD, and falls were identified using validated algorithms, and mortality was based on Medicare/Medicaid death indicators. Medications were coded using a comprehensive AC potency scale. AC medication exposure effects and interactions between AC potency and group were examined using modified Poisson regressions. Sensitivity analyses to address indication bias excluded persons prescribed antidepressant and/or antipsychotic medication(s).
RESULTS: All three clinical groups experienced significantly greater AC medication exposure (autism+ID: 92.5%>ID-only: 88.6%>autism-only: 80.0%) than non-autistic/non-ID controls (61.3%). Additionally, AC medications were more frequently associated with ADRD, falls, and mortality in all of these groups. Stepwise associations between AC potency levels and ADRD, falls, and mortality were found, and these effects were more prominent for persons with autism and/or ID relative to the control sample.
INTERPRETATION: This study provides a foundational examination of exposure to AC medication effects and their associations with aging-related outcomes in middle-age and older autistic adults and adults with ID. AC medication exposure represents one potential modifiable risk factor for negative aging-related outcomes in these groups.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Autophagy activator AA-20 engages CDK5 to promote lipophagy and improve neurodegeneration-associated phenotypes.
bioRxiv : the preprint server for biology pii:2026.10.30.760220.
UNLABELLED: Lipophagy, the selective degradation of lipid droplets (LDs) by autophagy, has the potential to ameliorate neurodegenerative diseases such as Parkinson's (PD) and Alzheimer's (AD), wherein LD accumulation has been linked to the exacerbation of the proteinopathy component of neurodegeneration. Pharmacological lipophagy inducers remain scarce. We previously identified AA-20 as a novel autophagy activator that acts independently of mTORC1 inhibition, thereby providing a means of stimulating autophagy while avoiding the immunosuppressive side effects associated with direct mTORC1 inhibition. Prior work also showed that AA-20 treatment reduces PolyQ aggregate levels in several C. elegans tissues. Here, we demonstrate that AA-20 enhances LD recruitment to autophagosomes and promotes LD degradation via lysosomal acid lipase activation in murine hippocampal neuronal cells, consistent with lipophagy activation. In human Swedish Amyloid Precursor Protein mutated cerebral organoids, two weeks of AA-20 treatment normalized aberrant lipidomic profiles by selectively reducing various disease-associated lipids, while also correcting the AD-associated electrical hyperexcitability phenotype. Moreover, we identified cyclin-dependent kinase 5 (CDK5), a neuronal kinase linked to AD hyperexcitability and PD pathology, as a target of AA-20. AA-20-induced autophagy and lipid clearance in HT22 cells require CDK5. In a neuronal seeding model of α-synuclein pathology, AA-20 reduced pS129-α-synuclein levels. Collectively, these findings indicate AA-20 can promote lipophagic clearance of LDs and mitigate multiple cellular phenotypes associated with lipidopathy and proteinopathy in neurodegenerative disease models.
SIGNIFICANCE: Neurodegenerative diseases such as Alzheimer's and Parkinson's are associated with impaired autophagy and abnormal lipid droplet (LD) accumulation. Few small molecules enhance neuronal lipid clearance without inhibiting mTORC1, but chronic blockade of which is associated with immunosuppressive and metabolic side effects. This study shows that AA-20, an mTORC1-independent autophagy activator, promotes lipophagic LD clearance in neuronal cells and reduces selected disease-associated lipids in human Alzheimer's cerebral organoids in a lysosomal acid lipase-dependent manner. AA-20 binds CDK5 and appears to modulate, rather than classically inhibit, this neuron-enriched kinase. In an exploratory Parkinson's neuron model, AA-20 also reduced pathological α-synuclein phosphorylation. These findings support further investigation of AA-20 as a tool to probe neuronal lipid clearance and neurodegeneration-associated phenotypes.
Additional Links: PMID-43060333
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060333,
year = {2026},
author = {Tan, EP and Ambaye, L and Mahul-Mellier, AL and Zhang, Y and Martínez-Botía, P and Labra, SR and Massey, LA and Gao, Z and Ahmed, Z and Nugroho, K and Ash, C and Ren, W and Cole, CM and Wu, Y and Ly, S and Compher, J and Almaraz, M and Lederberg, O and Matthewson, A and Rhoades, D and Cuoco, CA and Garza, D and Powers, ET and Paulo, JA and Finley, D and Gygi, SP and Petrascheck, M and Lipton, SA and Hansen, M and Forli, S and Prado, MA and Lashuel, HA and Kelly, JW},
title = {Autophagy activator AA-20 engages CDK5 to promote lipophagy and improve neurodegeneration-associated phenotypes.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.30.760220},
pmid = {43060333},
issn = {2692-8205},
abstract = {UNLABELLED: Lipophagy, the selective degradation of lipid droplets (LDs) by autophagy, has the potential to ameliorate neurodegenerative diseases such as Parkinson's (PD) and Alzheimer's (AD), wherein LD accumulation has been linked to the exacerbation of the proteinopathy component of neurodegeneration. Pharmacological lipophagy inducers remain scarce. We previously identified AA-20 as a novel autophagy activator that acts independently of mTORC1 inhibition, thereby providing a means of stimulating autophagy while avoiding the immunosuppressive side effects associated with direct mTORC1 inhibition. Prior work also showed that AA-20 treatment reduces PolyQ aggregate levels in several C. elegans tissues. Here, we demonstrate that AA-20 enhances LD recruitment to autophagosomes and promotes LD degradation via lysosomal acid lipase activation in murine hippocampal neuronal cells, consistent with lipophagy activation. In human Swedish Amyloid Precursor Protein mutated cerebral organoids, two weeks of AA-20 treatment normalized aberrant lipidomic profiles by selectively reducing various disease-associated lipids, while also correcting the AD-associated electrical hyperexcitability phenotype. Moreover, we identified cyclin-dependent kinase 5 (CDK5), a neuronal kinase linked to AD hyperexcitability and PD pathology, as a target of AA-20. AA-20-induced autophagy and lipid clearance in HT22 cells require CDK5. In a neuronal seeding model of α-synuclein pathology, AA-20 reduced pS129-α-synuclein levels. Collectively, these findings indicate AA-20 can promote lipophagic clearance of LDs and mitigate multiple cellular phenotypes associated with lipidopathy and proteinopathy in neurodegenerative disease models.
SIGNIFICANCE: Neurodegenerative diseases such as Alzheimer's and Parkinson's are associated with impaired autophagy and abnormal lipid droplet (LD) accumulation. Few small molecules enhance neuronal lipid clearance without inhibiting mTORC1, but chronic blockade of which is associated with immunosuppressive and metabolic side effects. This study shows that AA-20, an mTORC1-independent autophagy activator, promotes lipophagic LD clearance in neuronal cells and reduces selected disease-associated lipids in human Alzheimer's cerebral organoids in a lysosomal acid lipase-dependent manner. AA-20 binds CDK5 and appears to modulate, rather than classically inhibit, this neuron-enriched kinase. In an exploratory Parkinson's neuron model, AA-20 also reduced pathological α-synuclein phosphorylation. These findings support further investigation of AA-20 as a tool to probe neuronal lipid clearance and neurodegeneration-associated phenotypes.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Suvorexant Inversely Affects Phosphorylated Tau in Human Cerebrospinal Fluid and Plasma.
medRxiv : the preprint server for health sciences pii:2026.11.03.26367196.
Alzheimer disease (AD) is characterized by amyloid-β plaques and neurofibrillary tangles of tau. Suvorexant, a dual orexin receptor antagonist, was previously shown to acutely reduce the ratio of phosphorylated tau-181 to unphosphorylated tau-181 (pT181/T181) in cerebrospinal fluid (CSF). However, its effects on plasma pT181/T181 and broader proteomic networks remain unknown. Here, we conducted a secondary analysis of samples from a randomized, placebo-controlled trial of 25 participants receiving placebo or suvorexant 20 mg. Paired CSF and plasma samples were collected longitudinally via indwelling intrathecal and intravenous catheters. Plasma AD biomarkers were quantified by mass spectrometry, and proteomic profiling was performed using the SomaScan 11K assay on samples from hours 0, 16, and 24. Suvorexant increased pT181/T181 in plasma while decreasing it in CSF between 08:00-16:00. At the pathway level, suvorexant increased the extracellular abundance of proteins associated with translation, RNA binding, cytoskeletal organization and endosomal sorting, centrally at 16 hours and peripherally at 24 hours, and decreased cytokine and receptor-ligand signaling and serine protease activity in plasma at 24 hours. As plasma biomarkers are increasingly used for clinical screening and trial enrollment, factors that influence their levels, including medications, must be identified and their effects on interpretation understood.
Additional Links: PMID-43060339
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060339,
year = {2026},
author = {Pedersen, TJ and Yu, J and Li, A and Ibanez, L and Bubu, OM and Lucey, BP},
title = {Suvorexant Inversely Affects Phosphorylated Tau in Human Cerebrospinal Fluid and Plasma.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.03.26367196},
pmid = {43060339},
abstract = {Alzheimer disease (AD) is characterized by amyloid-β plaques and neurofibrillary tangles of tau. Suvorexant, a dual orexin receptor antagonist, was previously shown to acutely reduce the ratio of phosphorylated tau-181 to unphosphorylated tau-181 (pT181/T181) in cerebrospinal fluid (CSF). However, its effects on plasma pT181/T181 and broader proteomic networks remain unknown. Here, we conducted a secondary analysis of samples from a randomized, placebo-controlled trial of 25 participants receiving placebo or suvorexant 20 mg. Paired CSF and plasma samples were collected longitudinally via indwelling intrathecal and intravenous catheters. Plasma AD biomarkers were quantified by mass spectrometry, and proteomic profiling was performed using the SomaScan 11K assay on samples from hours 0, 16, and 24. Suvorexant increased pT181/T181 in plasma while decreasing it in CSF between 08:00-16:00. At the pathway level, suvorexant increased the extracellular abundance of proteins associated with translation, RNA binding, cytoskeletal organization and endosomal sorting, centrally at 16 hours and peripherally at 24 hours, and decreased cytokine and receptor-ligand signaling and serine protease activity in plasma at 24 hours. As plasma biomarkers are increasingly used for clinical screening and trial enrollment, factors that influence their levels, including medications, must be identified and their effects on interpretation understood.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Shared genetic architecture between Alzheimer's disease and blood pressure implicates ACE and NBEAL1 in individuals of European ancestry.
Research square pii:rs.3.rs-11269850.
Background Vascular dysfunction is increasingly recognized as a contributor to Alzheimer's disease (AD), yet the genetic mechanisms linking blood pressure (BP) and AD remain incompletely understood. We investigated shared genetic architecture between AD and systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) to identify locus-specific mechanisms connecting vascular regulation and neurodegeneration. Results We analyzed genome-wide association study summary statistics from individuals of European ancestry using global and local genetic correlation and conjunctional false discovery rate (conjFDR), followed by cis-Mendelian randomization (cis-MR), functional annotation, expression quantitative trait locus associations, and AD-specific multi-omic evidence. AD showed modest negative global genetic correlations with BP but significant local genetic correlation at eight regions. ConjFDR identified 42 high-confidence variants across 22 independent LD regions, with PRKD3 , NBEAL1 , NDUFAF6 , SPI1 , and the APOE region supported by both local genetic correlation and conjFDR. Cis-MR provided evidence for effects of BP on AD at multiple regions, with ACE and the APOE region showing significant effects for all three BP traits. Integrative analysis most strongly prioritized the APOE region, with convergent evidence at ACE and NBEAL1 and additional signals implicating immune and mitochondrial pathways. Conclusions The genetic relationship between AD and BP is characterized by heterogeneous, locus-specific overlap not fully captured by genome-wide genetic correlation. Convergent evidence implicates APOE , ACE , NBEAL1 , and other loci involved in vascular, immune, and mitochondrial biology, supporting multiple, partially BP-trait-specific mechanisms linking vascular regulation to AD.
Additional Links: PMID-43060357
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060357,
year = {2026},
author = {Ray, N and Yang, D and Yang, Y and Kumar, A and Kurup, J and Kannappan, B and Loaiza, J and Rosario, PD and Bush, W and Beecham, G and Reitz, C},
title = {Shared genetic architecture between Alzheimer's disease and blood pressure implicates ACE and NBEAL1 in individuals of European ancestry.},
journal = {Research square},
volume = {},
number = {},
pages = {},
doi = {10.21203/rs.3.rs-11269850/v1},
pmid = {43060357},
issn = {2693-5015},
abstract = {Background Vascular dysfunction is increasingly recognized as a contributor to Alzheimer's disease (AD), yet the genetic mechanisms linking blood pressure (BP) and AD remain incompletely understood. We investigated shared genetic architecture between AD and systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) to identify locus-specific mechanisms connecting vascular regulation and neurodegeneration. Results We analyzed genome-wide association study summary statistics from individuals of European ancestry using global and local genetic correlation and conjunctional false discovery rate (conjFDR), followed by cis-Mendelian randomization (cis-MR), functional annotation, expression quantitative trait locus associations, and AD-specific multi-omic evidence. AD showed modest negative global genetic correlations with BP but significant local genetic correlation at eight regions. ConjFDR identified 42 high-confidence variants across 22 independent LD regions, with PRKD3 , NBEAL1 , NDUFAF6 , SPI1 , and the APOE region supported by both local genetic correlation and conjFDR. Cis-MR provided evidence for effects of BP on AD at multiple regions, with ACE and the APOE region showing significant effects for all three BP traits. Integrative analysis most strongly prioritized the APOE region, with convergent evidence at ACE and NBEAL1 and additional signals implicating immune and mitochondrial pathways. Conclusions The genetic relationship between AD and BP is characterized by heterogeneous, locus-specific overlap not fully captured by genome-wide genetic correlation. Convergent evidence implicates APOE , ACE , NBEAL1 , and other loci involved in vascular, immune, and mitochondrial biology, supporting multiple, partially BP-trait-specific mechanisms linking vascular regulation to AD.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Sex-specific gene and isoform expression characterizes hippocampal aging in rhesus macaques.
bioRxiv : the preprint server for biology pii:2026.11.04.764396.
Aging produces widespread transcriptomic alterations that extend beyond changes in gene expression to include changes at the isoform level. Declining splicing fidelity, including increased intron retention and aberrant isoform expression, has been proposed to contribute to cellular dysfunction; however, the extent and biological significance of isoform-specific changes in the aging brain remain poorly understood. Age-related cognitive decline has also been associated with neuroinflammation and the development of a chronic inflammatory state, or "inflammaging," within the brain. Here, we used short- and long-read RNA sequencing to characterize gene- and isoform-level changes associated with hippocampal aging across sex in 24 rhesus macaques. We identified 594 age-associated differential isoform expression events, comprising both shared and sex-specific changes. Inflammatory pathways, including TNF-α-NF-κB signaling, interferon responses, and complement pathways, were enriched across both sexes. Weighted gene co-expression network analysis (WGCNA) further identified sex-specific modules associated with inflammatory, glial, mitochondrial, and hormone-responsive processes. Notably, several age-associated changes were detected at the isoform level despite limited or absent corresponding gene-level differences, highlighting transcript-level regulation as an additional dimension of brain aging that may be overlooked by gene-level analyses. To investigate the relationship between aging and Alzheimer's disease (AD), we independently performed WGCNA on the rhesus macaque cohort and a publicly available human hippocampal AD single-nucleus RNA-sequencing dataset (GSE268609). Cross-species module preservation and gene overlap analyses identified shared genes between age-associated and AD-associated networks, with pathway enrichment implicating glial function, inflammation, and mitochondrial biology. Together, these findings highlight sex-associated differences in hippocampal transcriptomic aging, underscore the importance of isoform-level regulation, and identify shared transcriptional signatures between normal aging and AD-associated pathways.
Additional Links: PMID-43060389
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060389,
year = {2026},
author = {Harper-Alexander, V and Peterson, S and Sadikova, S and Kohama, S and Ram, DR},
title = {Sex-specific gene and isoform expression characterizes hippocampal aging in rhesus macaques.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.04.764396},
pmid = {43060389},
issn = {2692-8205},
abstract = {Aging produces widespread transcriptomic alterations that extend beyond changes in gene expression to include changes at the isoform level. Declining splicing fidelity, including increased intron retention and aberrant isoform expression, has been proposed to contribute to cellular dysfunction; however, the extent and biological significance of isoform-specific changes in the aging brain remain poorly understood. Age-related cognitive decline has also been associated with neuroinflammation and the development of a chronic inflammatory state, or "inflammaging," within the brain. Here, we used short- and long-read RNA sequencing to characterize gene- and isoform-level changes associated with hippocampal aging across sex in 24 rhesus macaques. We identified 594 age-associated differential isoform expression events, comprising both shared and sex-specific changes. Inflammatory pathways, including TNF-α-NF-κB signaling, interferon responses, and complement pathways, were enriched across both sexes. Weighted gene co-expression network analysis (WGCNA) further identified sex-specific modules associated with inflammatory, glial, mitochondrial, and hormone-responsive processes. Notably, several age-associated changes were detected at the isoform level despite limited or absent corresponding gene-level differences, highlighting transcript-level regulation as an additional dimension of brain aging that may be overlooked by gene-level analyses. To investigate the relationship between aging and Alzheimer's disease (AD), we independently performed WGCNA on the rhesus macaque cohort and a publicly available human hippocampal AD single-nucleus RNA-sequencing dataset (GSE268609). Cross-species module preservation and gene overlap analyses identified shared genes between age-associated and AD-associated networks, with pathway enrichment implicating glial function, inflammation, and mitochondrial biology. Together, these findings highlight sex-associated differences in hippocampal transcriptomic aging, underscore the importance of isoform-level regulation, and identify shared transcriptional signatures between normal aging and AD-associated pathways.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
TailEnrich enables discovery of dysregulated genes through disease sample enrichment testing.
bioRxiv : the preprint server for biology pii:2026.11.04.764457.
UNLABELLED: Identifying differentially expressed genes is fundamental to elucidating the molecular mecha nisms underlying complex diseases. However, in complex disorders such as Alzheimer's disease (AD), the genes exhibiting dysregulated expression may vary among patient subsets, reflecting the heterogeneity of the underlying pathological processes. Consequently, pathogenic genes are profoundly dysregulated in only a subset of patients. Conventional differential expression tools, such as DESeq2 and edgeR, are primarily designed to detect population-level expression shifts and may have limited power to identify subgroup-specific dysregulation. To overcome this limitation, we developed TailEnrich, a novel com putational method that discovers dysregulated genes within patient subsets. TailEnrich independently tests the extreme left (downregulated) or right (upregulated) tails of a gene's expression distribution for disease sample enrichment. We quantify this enrichment using a new metric, i.e. the PE (Percentage of Enriched disease samples) score. On simulated datasets, TailEnrich demonstrates markedly improved accuracy over DESeq2 and edgeR in identifying dysregulated genes specific to patient subsets. Applied to AD gene expression data, TailEnrich uncovers a distinct, biologically relevant set of genes within key pathological pathways that are missed by mean shift-based approaches. TailEnrich provides a novel method for identifying dysregulated genes, and readily extends to other omics data including genomic variants and proteomics to uncover pathogenic genes in complex diseases.
TailEnrich is implemented in R. The source code and documenta tion are freely available at https://github.com/Sanke926/Tailenrich .
Additional Links: PMID-43060468
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060468,
year = {2026},
author = {Li, H and Liu, Y and Lin, C and Wang, S and Pan, H and Wang, S},
title = {TailEnrich enables discovery of dysregulated genes through disease sample enrichment testing.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.04.764457},
pmid = {43060468},
issn = {2692-8205},
abstract = {UNLABELLED: Identifying differentially expressed genes is fundamental to elucidating the molecular mecha nisms underlying complex diseases. However, in complex disorders such as Alzheimer's disease (AD), the genes exhibiting dysregulated expression may vary among patient subsets, reflecting the heterogeneity of the underlying pathological processes. Consequently, pathogenic genes are profoundly dysregulated in only a subset of patients. Conventional differential expression tools, such as DESeq2 and edgeR, are primarily designed to detect population-level expression shifts and may have limited power to identify subgroup-specific dysregulation. To overcome this limitation, we developed TailEnrich, a novel com putational method that discovers dysregulated genes within patient subsets. TailEnrich independently tests the extreme left (downregulated) or right (upregulated) tails of a gene's expression distribution for disease sample enrichment. We quantify this enrichment using a new metric, i.e. the PE (Percentage of Enriched disease samples) score. On simulated datasets, TailEnrich demonstrates markedly improved accuracy over DESeq2 and edgeR in identifying dysregulated genes specific to patient subsets. Applied to AD gene expression data, TailEnrich uncovers a distinct, biologically relevant set of genes within key pathological pathways that are missed by mean shift-based approaches. TailEnrich provides a novel method for identifying dysregulated genes, and readily extends to other omics data including genomic variants and proteomics to uncover pathogenic genes in complex diseases.
TailEnrich is implemented in R. The source code and documenta tion are freely available at https://github.com/Sanke926/Tailenrich .},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Identification of novel compounds from Olea Europaea targeting hDus2 as potential anticancer agents: a molecular docking and molecular dynamics study.
Frontiers in oncology, 16:1845700.
INTRODUCTION: Leukemia, a type of blood cancer, ranks among the top causes of cancer-related fatalities. Human tRNA-dihydrouridine synthase 2 (hDus2) catalyzes the conversion of uridine to dihydrouridine in the tRNA and is overexpressed in cancer cells, facilitating the translational process required for cancer cell growth. Inhibition of hDus2 reduces cancer cell growth and viability while increasing apoptosis sensitivity under stress, making it an excellent cancer target. Olea Europaea is known to be abundant in flavonoids, polyphenols, vitamins, and antioxidants, and shows immense potential in providing health benefits. The varied properties of these compounds are very significant in the prevention of disorders such as Alzheimer's and Cancer.
METHODOLOGY: Olea Europaea extract was tested for anti-cancer activity, followed by identification of potential leads using in silico methods. The compounds from the OliveNet database were screened against the hDus2 enzyme. The identified compounds were further validated using Molecular Dynamics (MD) Simulation.
RESULTS: Molecular docking studies with the Glide module revealed that several compounds showed high affinity for hDus2. The top five compounds out of six hundred seventy six compounds were selected for molecular dynamics simulations to study their structural stability and conformational dynamics in the presence of solvent molecules.
CONCLUSION: Binding free energy calculations revealed that all complexes were stable, with P166 and P161 exhibiting the highest binding potential against hDus2. These findings lay the foundation for the development of novel anti-cancer therapeutics targeting leukemia.
Additional Links: PMID-43060482
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060482,
year = {2026},
author = {Mukhija, M and Chandra, A and Devi, K and Chaudhuri, S and Bhattacharya, B and Sharma, T and Goel, VK},
title = {Identification of novel compounds from Olea Europaea targeting hDus2 as potential anticancer agents: a molecular docking and molecular dynamics study.},
journal = {Frontiers in oncology},
volume = {16},
number = {},
pages = {1845700},
pmid = {43060482},
issn = {2234-943X},
abstract = {INTRODUCTION: Leukemia, a type of blood cancer, ranks among the top causes of cancer-related fatalities. Human tRNA-dihydrouridine synthase 2 (hDus2) catalyzes the conversion of uridine to dihydrouridine in the tRNA and is overexpressed in cancer cells, facilitating the translational process required for cancer cell growth. Inhibition of hDus2 reduces cancer cell growth and viability while increasing apoptosis sensitivity under stress, making it an excellent cancer target. Olea Europaea is known to be abundant in flavonoids, polyphenols, vitamins, and antioxidants, and shows immense potential in providing health benefits. The varied properties of these compounds are very significant in the prevention of disorders such as Alzheimer's and Cancer.
METHODOLOGY: Olea Europaea extract was tested for anti-cancer activity, followed by identification of potential leads using in silico methods. The compounds from the OliveNet database were screened against the hDus2 enzyme. The identified compounds were further validated using Molecular Dynamics (MD) Simulation.
RESULTS: Molecular docking studies with the Glide module revealed that several compounds showed high affinity for hDus2. The top five compounds out of six hundred seventy six compounds were selected for molecular dynamics simulations to study their structural stability and conformational dynamics in the presence of solvent molecules.
CONCLUSION: Binding free energy calculations revealed that all complexes were stable, with P166 and P161 exhibiting the highest binding potential against hDus2. These findings lay the foundation for the development of novel anti-cancer therapeutics targeting leukemia.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Personalized Prediction of Differences in fMRI Connectivity Estimates Across Preprocessing Pipelines.
bioRxiv : the preprint server for biology pii:2026.11.04.763874.
Longitudinal functional MRI of the human brain is valuable for tracking changes in functional connectivity (FC) associated with disease progression or treatment response. Even so, measured FC values depend on preprocessing, and nuisance regression and temporal filtering affect individuals differently. We examined whether we could use earlier scans to predict how preprocessing would affect a later scan. In 69 ADNI (Alzheimer's Disease Neuroimaging Initiative) participants scanned three times, we measured how nuisance regression and filtering, alone and in sequence, changed the measured FC. A ridge regression model combined these responses with baseline FC from the third scan to predict the effect of reversing the processing order. Just four coefficients were shared across 79,800 connections. In leave-one-participant-out testing, mean squared error was 0.012, compared with 0.017 for predicting the same average response for everyone. It outperformed the best of seven alternative predictions chosen for each participant (0.013; normalized gain 0.069, 95% bootstrap interval 0.006-0.134), with lower error in 44 of 69 participants. About half the benefit of using each person's earlier responses, rather than the average across participants, came from which connections changed. This advantage persisted after accounting for acquisition variables. The ADNI-trained model reduced mean error in ten Midnight Scan Club participants without refitting. These results support using personal preprocessing history to predict changes in connectivity estimates on newly acquired scans.
Additional Links: PMID-43060527
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060527,
year = {2026},
author = {Maximov, Y and Volkov, A and Chattopadhyay, T and Thompson, PM and Gabitov, I},
title = {Personalized Prediction of Differences in fMRI Connectivity Estimates Across Preprocessing Pipelines.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.04.763874},
pmid = {43060527},
issn = {2692-8205},
abstract = {Longitudinal functional MRI of the human brain is valuable for tracking changes in functional connectivity (FC) associated with disease progression or treatment response. Even so, measured FC values depend on preprocessing, and nuisance regression and temporal filtering affect individuals differently. We examined whether we could use earlier scans to predict how preprocessing would affect a later scan. In 69 ADNI (Alzheimer's Disease Neuroimaging Initiative) participants scanned three times, we measured how nuisance regression and filtering, alone and in sequence, changed the measured FC. A ridge regression model combined these responses with baseline FC from the third scan to predict the effect of reversing the processing order. Just four coefficients were shared across 79,800 connections. In leave-one-participant-out testing, mean squared error was 0.012, compared with 0.017 for predicting the same average response for everyone. It outperformed the best of seven alternative predictions chosen for each participant (0.013; normalized gain 0.069, 95% bootstrap interval 0.006-0.134), with lower error in 44 of 69 participants. About half the benefit of using each person's earlier responses, rather than the average across participants, came from which connections changed. This advantage persisted after accounting for acquisition variables. The ADNI-trained model reduced mean error in ten Midnight Scan Club participants without refitting. These results support using personal preprocessing history to predict changes in connectivity estimates on newly acquired scans.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Midlife nonlinearities across scale in Biondi body amyloid formation in the human choroid plexus.
bioRxiv : the preprint server for biology pii:2026.11.04.764372.
Human choroid plexus epithelial cells (CPECs), which produce cerebrospinal fluid and form the blood-cerebrospinal fluid barrier, accumulate discrete intracellular amyloid inclusions called Biondi bodies (BBs). Using systematic manual and machine learning approaches on the choroid plexus glomus, we determined the percentages of CPECs containing thioflavin S-stained BBs as well as BB load and spatial distributions in whole slide images from 77 cases across the human lifespan. On average, BB prevalence was near zero until age 40, rose steeply in the 5th and 6th decades, and exceeded 50% after age 70. As prevalence plateaued, BB load continued to rise with age. Accelerated BB accumulation was seen in two cases of diabetic ketoacidosis, including a 16-year-old, while an 85-year-old with the relatively rare APOE2/E2 genotype had fewer BBs than expected. BB prevalence in the choroid plexus glomus was not associated with Alzheimer's disease, but was lower in females than males. Notably, spatial clustering of BBs was universal across cases while nearest-neighbor analyses suggested cell-to-cell, prion-like BB spread that can account for the nonlinearities seen at tissue and population scales. The abrupt, nonlinear BB accumulation during midlife coincides with or precedes other common aging-associated neuropathologies of the human brain, consistent with broad BB and ChP contributions to brain aging and disease.
Additional Links: PMID-43060539
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060539,
year = {2026},
author = {Neel, MJ and Vukalovich, N and Porahang, P and Zhao, C and Huang, W and Ghahremani, S and Lin, A and Sandhu, O and Nguyen, B and Pejhanfar, K and Zolfaghari, E and Shin, E and Church, CA and Ricks-Oddie, JL and Ringman, JM and Guzman, S and Chang, PD and Johnson, BA and Monuki, ES},
title = {Midlife nonlinearities across scale in Biondi body amyloid formation in the human choroid plexus.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.04.764372},
pmid = {43060539},
issn = {2692-8205},
abstract = {Human choroid plexus epithelial cells (CPECs), which produce cerebrospinal fluid and form the blood-cerebrospinal fluid barrier, accumulate discrete intracellular amyloid inclusions called Biondi bodies (BBs). Using systematic manual and machine learning approaches on the choroid plexus glomus, we determined the percentages of CPECs containing thioflavin S-stained BBs as well as BB load and spatial distributions in whole slide images from 77 cases across the human lifespan. On average, BB prevalence was near zero until age 40, rose steeply in the 5th and 6th decades, and exceeded 50% after age 70. As prevalence plateaued, BB load continued to rise with age. Accelerated BB accumulation was seen in two cases of diabetic ketoacidosis, including a 16-year-old, while an 85-year-old with the relatively rare APOE2/E2 genotype had fewer BBs than expected. BB prevalence in the choroid plexus glomus was not associated with Alzheimer's disease, but was lower in females than males. Notably, spatial clustering of BBs was universal across cases while nearest-neighbor analyses suggested cell-to-cell, prion-like BB spread that can account for the nonlinearities seen at tissue and population scales. The abrupt, nonlinear BB accumulation during midlife coincides with or precedes other common aging-associated neuropathologies of the human brain, consistent with broad BB and ChP contributions to brain aging and disease.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Caudate nucleus aging and its association with brain disorders.
bioRxiv : the preprint server for biology pii:2026.10.28.762543.
The caudate nucleus supports cognition and goal-directed behavior, undergoes age-associated changes, and is implicated in substance use, psychiatric, and neurodegenerative disorders. However, how aging alters its diverse cell types and how such changes relate to diseases remains poorly understood. To address these questions, we assembled single nucleus transcriptomic atlases of the caudate tissue, comprising 963,842 nuclei from 178 human donors, including controls and individuals with alcohol use disorder (AUD) or opioid use disorder (OUD), and 83,699 nuclei from six healthy rhesus macaques. We also curated 3,139 bulk RNA-seq profiles from the caudate and other brain regions spanning controls and multiple diagnostic groups, as well as paired RNA and chromatin accessibility profiles from 257,524 caudate nuclei across 161 control and AUD donors. These datasets enabled comparisons across age, species, brain regions, and diagnostic groups. We found shared glial aging features in humans and macaques, whereas neuronal changes were more divergent. Inferred neuron-to-neuron communication declined with age, with greater declines in AUD. Both transcriptional and chromatin accessibility profiles showed nonlinear age-associated patterns, with pronounced changes in later adulthood. In donors with AUD, age-associated changes appeared earlier, with altered trajectories in lipid metabolism, mitochondrial function, and neuronal signaling. Across comparisons involving AUD, OUD, bipolar disorder, schizophrenia, and Alzheimer disease, mitochondrial function and fatty acid metabolism emerged as consensus features linking caudate aging to diseases, although the direction and extent of overlap varied by disorder and brain region. Together, these findings define cellular and regulatory features of primate caudate aging and reveal shared and context-dependent relationships between aging and brain disorders.
Additional Links: PMID-43060593
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060593,
year = {2026},
author = {Guo, S and Yang, X and Dong, Y and Xu, J and Sangjizhuoma, A and Wichmann, T and Galvan, A and Smith, Y and He, J},
title = {Caudate nucleus aging and its association with brain disorders.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.10.28.762543},
pmid = {43060593},
issn = {2692-8205},
abstract = {The caudate nucleus supports cognition and goal-directed behavior, undergoes age-associated changes, and is implicated in substance use, psychiatric, and neurodegenerative disorders. However, how aging alters its diverse cell types and how such changes relate to diseases remains poorly understood. To address these questions, we assembled single nucleus transcriptomic atlases of the caudate tissue, comprising 963,842 nuclei from 178 human donors, including controls and individuals with alcohol use disorder (AUD) or opioid use disorder (OUD), and 83,699 nuclei from six healthy rhesus macaques. We also curated 3,139 bulk RNA-seq profiles from the caudate and other brain regions spanning controls and multiple diagnostic groups, as well as paired RNA and chromatin accessibility profiles from 257,524 caudate nuclei across 161 control and AUD donors. These datasets enabled comparisons across age, species, brain regions, and diagnostic groups. We found shared glial aging features in humans and macaques, whereas neuronal changes were more divergent. Inferred neuron-to-neuron communication declined with age, with greater declines in AUD. Both transcriptional and chromatin accessibility profiles showed nonlinear age-associated patterns, with pronounced changes in later adulthood. In donors with AUD, age-associated changes appeared earlier, with altered trajectories in lipid metabolism, mitochondrial function, and neuronal signaling. Across comparisons involving AUD, OUD, bipolar disorder, schizophrenia, and Alzheimer disease, mitochondrial function and fatty acid metabolism emerged as consensus features linking caudate aging to diseases, although the direction and extent of overlap varied by disorder and brain region. Together, these findings define cellular and regulatory features of primate caudate aging and reveal shared and context-dependent relationships between aging and brain disorders.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Network analysis of mouse brain proteomes resolves molecular and cellular endophenotypes of aging and Aβ pathology.
bioRxiv : the preprint server for biology pii:2026.11.05.764669.
Aging and Alzheimer's disease (AD) pathology exert both shared and distinct effects on the brain, yet their relative contributions to molecular alterations remain poorly defined. Here we performed tandem mass tag proteomics across the lifespan in wild-type and 5xFAD mice and integrated these data with human brain proteomic networks to resolve aging- and amyloid-β (Aβ)-associated molecular programs. We quantified 8,535 proteins and identified 51 co-expression modules representing neuronal, mitochondrial, glial, vascular and proteostatic pathways. Aging emerged as the predominant driver of proteomic remodeling, with widespread alterations in RNA metabolism, protein translation, and neuronal pathways occurring independently of Aβ pathology. In contrast, Aβ selectively modified a subset of age-dependent processes, including suppression of mitochondrial ATP biosynthetic machinery and amplification of astrocytic and microglial activation states. These key aging and disease-related molecular signatures were highly conserved in human AD brain proteomes. Together, our findings establish aging as the primary determinant of brain proteome organization while revealing specific mechanisms through which Aβ pathology reshapes age-associated biological processes. Our results also highlight molecular mechanisms of human aging and AD pathology that can be modeled in mouse models.
Additional Links: PMID-43060597
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060597,
year = {2026},
author = {Rayaprolu, S and Malepati, S and Dammer, EB and Langdon, K and Kumari, R and Brandelli, AD and Espinosa-Garcia, C and Duong, DD and Srivastava, U and Kumar, P and Tfaily, A and Chen, J and Zhou, X and Li, Y and Chaudhary, AF and Liang, S and Seyfried, NT and Rangaraju, S},
title = {Network analysis of mouse brain proteomes resolves molecular and cellular endophenotypes of aging and Aβ pathology.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.05.764669},
pmid = {43060597},
issn = {2692-8205},
abstract = {Aging and Alzheimer's disease (AD) pathology exert both shared and distinct effects on the brain, yet their relative contributions to molecular alterations remain poorly defined. Here we performed tandem mass tag proteomics across the lifespan in wild-type and 5xFAD mice and integrated these data with human brain proteomic networks to resolve aging- and amyloid-β (Aβ)-associated molecular programs. We quantified 8,535 proteins and identified 51 co-expression modules representing neuronal, mitochondrial, glial, vascular and proteostatic pathways. Aging emerged as the predominant driver of proteomic remodeling, with widespread alterations in RNA metabolism, protein translation, and neuronal pathways occurring independently of Aβ pathology. In contrast, Aβ selectively modified a subset of age-dependent processes, including suppression of mitochondrial ATP biosynthetic machinery and amplification of astrocytic and microglial activation states. These key aging and disease-related molecular signatures were highly conserved in human AD brain proteomes. Together, our findings establish aging as the primary determinant of brain proteome organization while revealing specific mechanisms through which Aβ pathology reshapes age-associated biological processes. Our results also highlight molecular mechanisms of human aging and AD pathology that can be modeled in mouse models.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Dopamine Synthesis Capacity and Tau Pathology Differentially Modulate Rest-to-Task Functional Network Dynamics.
bioRxiv : the preprint server for biology pii:2026.11.04.764247.
UNLABELLED: Optimal cognition relies on large-scale functional brain networks which balance segregation at rest with selective integration during task performance. In aging, these network dynamics are altered. We examined two prominent features of brain aging: dysregulated dopamine function and Alzheimer's disease (AD)-related pathology to examine impacts on brain network dynamics. Young adults and cognitively unimpaired older adults completed resting-state and task-based fMRI and PET imaging of dopamine synthesis capacity ([ [18] F]fluoro-m-L-tyrosine). Older adults were classified as β-amyloid negative/positive using [ [11] C]Pittsburgh Compound-B PET (PiB-or PiB+) and underwent tau-PET scanning ([ [18] F]flortaucipir). Greater rest-to-task network stability and task-related network segregation were associated with better subsequent memory. Compared to young adults, PiB+ older adults showed reduced network stability and both PiB+ and PiB-older adults showed reduced segregation during rest. Higher ventral striatal dopamine synthesis capacity was associated with greater stability within associative networks in young adults, but this relationship was attenuated in older adults and absent in PiB+ participants. In PiB+ older adults, higher tau burden was associated with a task-induced collapse of network segregation across large-scale networks. These findings reveal dissociable influences of dopamine and tau on rest-to-task network organization, highlighting the value of integrating neuromodulatory and pathological markers in aging research.
AUTHOR SUMMARY: As we age, our brains become less efficient at balancing network segregation at rest with selective integration during task states. In this study, we combine brain imaging methods to examine how dopamine, a key neuromodulator, and tau pathology, a hallmark of Alzheimer's disease, influence large-scale brain network dynamics. We show that dopamine supports stable and well-organized brain networks while tau pathology disrupts this organization during a cognitive task. These opposing influences help explain why some individuals maintain cognitive resilience while others show early network dysfunction, providing new insight into mechanisms of cognitive aging and age-related pathology.
Additional Links: PMID-43060632
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060632,
year = {2026},
author = {Morin, TM and Chen, HY and Aghasoltan, S and Hsu, M and Jagust, WJ and Berry, AS},
title = {Dopamine Synthesis Capacity and Tau Pathology Differentially Modulate Rest-to-Task Functional Network Dynamics.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.04.764247},
pmid = {43060632},
issn = {2692-8205},
abstract = {UNLABELLED: Optimal cognition relies on large-scale functional brain networks which balance segregation at rest with selective integration during task performance. In aging, these network dynamics are altered. We examined two prominent features of brain aging: dysregulated dopamine function and Alzheimer's disease (AD)-related pathology to examine impacts on brain network dynamics. Young adults and cognitively unimpaired older adults completed resting-state and task-based fMRI and PET imaging of dopamine synthesis capacity ([ [18] F]fluoro-m-L-tyrosine). Older adults were classified as β-amyloid negative/positive using [ [11] C]Pittsburgh Compound-B PET (PiB-or PiB+) and underwent tau-PET scanning ([ [18] F]flortaucipir). Greater rest-to-task network stability and task-related network segregation were associated with better subsequent memory. Compared to young adults, PiB+ older adults showed reduced network stability and both PiB+ and PiB-older adults showed reduced segregation during rest. Higher ventral striatal dopamine synthesis capacity was associated with greater stability within associative networks in young adults, but this relationship was attenuated in older adults and absent in PiB+ participants. In PiB+ older adults, higher tau burden was associated with a task-induced collapse of network segregation across large-scale networks. These findings reveal dissociable influences of dopamine and tau on rest-to-task network organization, highlighting the value of integrating neuromodulatory and pathological markers in aging research.
AUTHOR SUMMARY: As we age, our brains become less efficient at balancing network segregation at rest with selective integration during task states. In this study, we combine brain imaging methods to examine how dopamine, a key neuromodulator, and tau pathology, a hallmark of Alzheimer's disease, influence large-scale brain network dynamics. We show that dopamine supports stable and well-organized brain networks while tau pathology disrupts this organization during a cognitive task. These opposing influences help explain why some individuals maintain cognitive resilience while others show early network dysfunction, providing new insight into mechanisms of cognitive aging and age-related pathology.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Broad Cognitive and Motivational Enhancement through M 4 -Selective Muscarinic Modulation.
bioRxiv : the preprint server for biology pii:2026.11.05.764685.
The muscarinic M 4 subtype of acetylcholine receptors is part of agonist compounds considered treatment options for Schizophrenia and Alzheimers disease, but how M 4 -subtype selective modulation affects cognition and motivation is largely unknown due to dose-limiting side effects, a scarcity of receptor-selective compounds, and missing multi-domain assessments of cognition. Here, we surmount these constraints by utilizing a M 4 -selective positive allosteric modulator (PAM) to assess in nonhuman primates a broad array of endpoints spanning motivational effort control and multiple executive function domains. We found broad dose-dependent performance improvements of set shifting indexing cognitive flexibility, visual search indexing selective attention, antisaccade performance indexing inhibitory control, visuospatial maze learning, and temporal order serial object learning, while working memory span was non-systematically modulated. In addition, the M 4 PAM reduced effort avoidance in an effort-based choice task documenting a pro-motivational effect. Task-composite performance scores showed pro-cognitive effects across multiple doses and an effective dose range for individual subjects in the absence of adverse dose-limiting cholinergic side effects. Together, the broad pro-cognitive and pro-motivational multi-task profile of M 4 PAM modulation suggests that the M 4 receptor is a master regulator of executive cognitive functioning, possibly acting on domain-general neural processes across the prefrontal-striatal circuits.
Additional Links: PMID-43060640
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060640,
year = {2026},
author = {Wen, X and Shehreen, S and Neumann, A and Temple, KJ and Lindsley, CW and Jones, CK and Womelsdorf, T},
title = {Broad Cognitive and Motivational Enhancement through M 4 -Selective Muscarinic Modulation.},
journal = {bioRxiv : the preprint server for biology},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.05.764685},
pmid = {43060640},
issn = {2692-8205},
abstract = {The muscarinic M 4 subtype of acetylcholine receptors is part of agonist compounds considered treatment options for Schizophrenia and Alzheimers disease, but how M 4 -subtype selective modulation affects cognition and motivation is largely unknown due to dose-limiting side effects, a scarcity of receptor-selective compounds, and missing multi-domain assessments of cognition. Here, we surmount these constraints by utilizing a M 4 -selective positive allosteric modulator (PAM) to assess in nonhuman primates a broad array of endpoints spanning motivational effort control and multiple executive function domains. We found broad dose-dependent performance improvements of set shifting indexing cognitive flexibility, visual search indexing selective attention, antisaccade performance indexing inhibitory control, visuospatial maze learning, and temporal order serial object learning, while working memory span was non-systematically modulated. In addition, the M 4 PAM reduced effort avoidance in an effort-based choice task documenting a pro-motivational effect. Task-composite performance scores showed pro-cognitive effects across multiple doses and an effective dose range for individual subjects in the absence of adverse dose-limiting cholinergic side effects. Together, the broad pro-cognitive and pro-motivational multi-task profile of M 4 PAM modulation suggests that the M 4 receptor is a master regulator of executive cognitive functioning, possibly acting on domain-general neural processes across the prefrontal-striatal circuits.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Tau PET Braak staging across the Alzheimer Disease continuum using Flortaucipir and MK6240.
medRxiv : the preprint server for health sciences pii:2026.11.01.26367034.
Tau positron emission tomography (PET) staging is increasingly used to stratify Alzheimer's disease (AD), yet cross-tracer interchangeability remains unestablished. In a prospective head-to-head study of 682 individuals across the aging-to-AD continuum, we compared tau PET Braak staging derived from [ [18] F]Flortaucipir and [ [18] F]MK6240. While both tracers showed high internal adherence to hierarchical Braak patterns (89-92%), cross-tracer agreement was limited (43%, weighted κ = 0.54) and fell to 14- 23% at early-to-intermediate stages, a key window for therapeutic intervention. Discordance was strongly directional: in over 90% of discordant cases [ [18] F]MK6240 assigned a higher stage, on average approximately one stage above [ [18] F]Flortaucipir. [ [18] F]MK6240 upstaging was associated with greater Aβ burden, adverse plasma biomarker profiles, and worse cognitive performance. Stage-frequency benchmarking against an external neuropathological cohort (N = 4,422) revealed that PET staging lags neuropathology by ∼2 Braak stages for [ [18] F]MK6240 and ∼3 for [ [18] F]Flortaucipir in the early phases of disease, with progressive convergence at later stages. Tau PET Braak staging is internally coherent within tracers but not interchangeable across them, with [ [18] F]MK6240 systematically assigning higher stages than [ [18] F]Flortaucipir. This biologically meaningful discordance, most pronounced at early stages, has direct implications for patient selection and staging for clinical trials and practice, necessitating tracer- aware harmonization strategies.
Additional Links: PMID-43060650
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060650,
year = {2026},
author = {Rocha, A and Soares, C and Scop Medeiros, M and Ruppert, E and Macedo, AC and Lussier, FZ and Povala, G and Bellaver, B and Ferreira, PCL and Bauer-Negrini, G and Amaral, L and Rodrigues, M and Oliveira-Junior, M and Mroue, R and de Oliveira Franco, Á and Tissot, C and Ferrari-Souza, JP and Rahmouni, N and Evelhoch, JL and Betthauser, TJ and Tudorascu, DL and Karikari, TK and Masdeu, JC and Fortea, J and Soleimani-Meigooni, DN and Lowe, V and Oh, H and Pascual, B and Gordon, BA and Rosa-Neto, P and Baker, S and Pascoal, TA and , },
title = {Tau PET Braak staging across the Alzheimer Disease continuum using Flortaucipir and MK6240.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.01.26367034},
pmid = {43060650},
abstract = {Tau positron emission tomography (PET) staging is increasingly used to stratify Alzheimer's disease (AD), yet cross-tracer interchangeability remains unestablished. In a prospective head-to-head study of 682 individuals across the aging-to-AD continuum, we compared tau PET Braak staging derived from [ [18] F]Flortaucipir and [ [18] F]MK6240. While both tracers showed high internal adherence to hierarchical Braak patterns (89-92%), cross-tracer agreement was limited (43%, weighted κ = 0.54) and fell to 14- 23% at early-to-intermediate stages, a key window for therapeutic intervention. Discordance was strongly directional: in over 90% of discordant cases [ [18] F]MK6240 assigned a higher stage, on average approximately one stage above [ [18] F]Flortaucipir. [ [18] F]MK6240 upstaging was associated with greater Aβ burden, adverse plasma biomarker profiles, and worse cognitive performance. Stage-frequency benchmarking against an external neuropathological cohort (N = 4,422) revealed that PET staging lags neuropathology by ∼2 Braak stages for [ [18] F]MK6240 and ∼3 for [ [18] F]Flortaucipir in the early phases of disease, with progressive convergence at later stages. Tau PET Braak staging is internally coherent within tracers but not interchangeable across them, with [ [18] F]MK6240 systematically assigning higher stages than [ [18] F]Flortaucipir. This biologically meaningful discordance, most pronounced at early stages, has direct implications for patient selection and staging for clinical trials and practice, necessitating tracer- aware harmonization strategies.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
A multi-scale cell-type resolved map of trans -regulatory architecture in the aging human brain.
medRxiv : the preprint server for health sciences pii:2026.11.05.26367384.
Mapping genetic effects on distal genes and regulatory programs is essential for understanding how genetic variation influences complex diseases; yet trans -QTL discovery remains limited by weak effect sizes, extensive multiple testing and poor reproducibility. Here, we introduce TransMap , a generalizable computational framework that combines multi-scale trans -QTL mapping with multi-phenotype genetic colocalization to improve the discovery and interpretation of distal regulatory variants. Beyond individual trans -eGenes, TransMap constructs local co-regulatory program phenotypes that account for background expression variation to improve the detection of weak, coordinated distal genetic effects. Across a broad range of simulation settings, TransMap achieved 9.2-36.7% higher trans -QTL discovery power than existing methods while maintaining well-controlled type I error rates. We applied TransMap to bulk and single-nucleus transcriptomic profiles from the aging human brain in the ADSP Functional Genomics Consortium (FunGen-AD), further integrating proteomic, glycoproteomic and metabolomic biomarker measurements (average N= 476 donors). Genome-wide fine-mapping of TransMap single-gene and program-level QTL yielded variant annotations with 2.75-2.88x heritability enrichment across 57 complex diseases and traits (average N= 307K), with complementary heritability information captured across regulatory scales. Multi-phenotype colocalization identified 49,532 trans -regulatory events supported by shared genetic signals with cis -eQTL or biomarker-QTL, including 1,825 candidate cis-trans-biomarker regulatory configurations. TransMap further revealed an asymmetric cross-cell-type regulatory architecture in which neuronal cis -regulatory signals preferentially associate with coordinated glial trans -regulatory responses, supported by co-culture experiments and spatial transcriptomics. Alzheimer's disease (AD) GWAS-prioritized colocalization identified trans -regulatory associations in 115 AD-associated loci, including a KNOP1 cis -eQTL associated in trans with a microglial regulatory program containing MS4A4E , with additional support from statistical mediation analysis. TransMap provides a multi-scale, cell-type-resolved atlas of trans -regulatory variation and a generalizable framework for elucidating the regulatory architecture of complex diseases.
Additional Links: PMID-43060671
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060671,
year = {2026},
author = {Cao, X and Wang, Y and Sun, H and Feng, R and Zhang, H and Li, Y and Lee, H and Karaahmet, B and Li, B and Gersbach, C and Crawford, G and Taga, M and Beeri, MS and Buchman, AS and Klein, HU and de Jager, PL and Bennett, D and , and Wang, G and Dey, KK},
title = {A multi-scale cell-type resolved map of trans -regulatory architecture in the aging human brain.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.05.26367384},
pmid = {43060671},
abstract = {Mapping genetic effects on distal genes and regulatory programs is essential for understanding how genetic variation influences complex diseases; yet trans -QTL discovery remains limited by weak effect sizes, extensive multiple testing and poor reproducibility. Here, we introduce TransMap , a generalizable computational framework that combines multi-scale trans -QTL mapping with multi-phenotype genetic colocalization to improve the discovery and interpretation of distal regulatory variants. Beyond individual trans -eGenes, TransMap constructs local co-regulatory program phenotypes that account for background expression variation to improve the detection of weak, coordinated distal genetic effects. Across a broad range of simulation settings, TransMap achieved 9.2-36.7% higher trans -QTL discovery power than existing methods while maintaining well-controlled type I error rates. We applied TransMap to bulk and single-nucleus transcriptomic profiles from the aging human brain in the ADSP Functional Genomics Consortium (FunGen-AD), further integrating proteomic, glycoproteomic and metabolomic biomarker measurements (average N= 476 donors). Genome-wide fine-mapping of TransMap single-gene and program-level QTL yielded variant annotations with 2.75-2.88x heritability enrichment across 57 complex diseases and traits (average N= 307K), with complementary heritability information captured across regulatory scales. Multi-phenotype colocalization identified 49,532 trans -regulatory events supported by shared genetic signals with cis -eQTL or biomarker-QTL, including 1,825 candidate cis-trans-biomarker regulatory configurations. TransMap further revealed an asymmetric cross-cell-type regulatory architecture in which neuronal cis -regulatory signals preferentially associate with coordinated glial trans -regulatory responses, supported by co-culture experiments and spatial transcriptomics. Alzheimer's disease (AD) GWAS-prioritized colocalization identified trans -regulatory associations in 115 AD-associated loci, including a KNOP1 cis -eQTL associated in trans with a microglial regulatory program containing MS4A4E , with additional support from statistical mediation analysis. TransMap provides a multi-scale, cell-type-resolved atlas of trans -regulatory variation and a generalizable framework for elucidating the regulatory architecture of complex diseases.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Music-Synchronized Gamma Light Stimulation Strengthens Theta-Gamma Coupling in Older Adults with Cognitive Impairment: Results from a Randomized Feasibility Trial.
medRxiv : the preprint server for health sciences pii:2026.11.06.26367319.
Noninvasive clinical innovations for restoring gamma activity via sound and light stimulation have the potential to improve memory and cognitive abilities in Alzheimer's disease. We assessed whether pairing music with theta- and gamma-band light changes memory-supporting neural dynamics, and whether those changes track cognition. In an ongoing randomized feasibility trial, 38 older adults with cognitive impairment completed eight weeks of an audiovisual intervention. The treatment group (n = 19) listened to self-selected music while viewing light stimulation that consisted of a 39-Hz gamma-band signal modulated by delta- and theta-band musical rhythms. The control group (n = 19) listened to podcasts while viewing synchronized lights without the gamma frequency (delta-band only). Before and after the 8-week intervention, participants completed a face-name association task and the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog). Individuals in the treatment group showed significant improvements on a face-name association task and the ADAS-Cog. Cluster-based permutation testing showed a larger increase in phase-amplitude coupling between acoustic theta phase and frontal EEG gamma amplitude in the treatment group compared to the control group. Across participants, increases in stimulus-driven theta to EEG-gamma phase-amplitude coupling were associated with improvements in memory. These preliminary results suggest that theta-gamma stimulation delivered through music and lights strengthens cross-frequency coupling, and may correspondingly strengthen associative memory.
Additional Links: PMID-43060675
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060675,
year = {2026},
author = {Kubit, BM and Asthagiri, A and Lopez, KL and Wang, J and Parrish, C and Trebour, B and Zhao, ZA and Yesil, D and Toivonen, A and Jacobowitz, A and Quigley, B and Wu, EX and Kim, JC and Large, E and Loui, P},
title = {Music-Synchronized Gamma Light Stimulation Strengthens Theta-Gamma Coupling in Older Adults with Cognitive Impairment: Results from a Randomized Feasibility Trial.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.06.26367319},
pmid = {43060675},
abstract = {Noninvasive clinical innovations for restoring gamma activity via sound and light stimulation have the potential to improve memory and cognitive abilities in Alzheimer's disease. We assessed whether pairing music with theta- and gamma-band light changes memory-supporting neural dynamics, and whether those changes track cognition. In an ongoing randomized feasibility trial, 38 older adults with cognitive impairment completed eight weeks of an audiovisual intervention. The treatment group (n = 19) listened to self-selected music while viewing light stimulation that consisted of a 39-Hz gamma-band signal modulated by delta- and theta-band musical rhythms. The control group (n = 19) listened to podcasts while viewing synchronized lights without the gamma frequency (delta-band only). Before and after the 8-week intervention, participants completed a face-name association task and the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog). Individuals in the treatment group showed significant improvements on a face-name association task and the ADAS-Cog. Cluster-based permutation testing showed a larger increase in phase-amplitude coupling between acoustic theta phase and frontal EEG gamma amplitude in the treatment group compared to the control group. Across participants, increases in stimulus-driven theta to EEG-gamma phase-amplitude coupling were associated with improvements in memory. These preliminary results suggest that theta-gamma stimulation delivered through music and lights strengthens cross-frequency coupling, and may correspondingly strengthen associative memory.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Memory Self-Awareness Phenotypes are Associated with Alzheimer's Disease Biomarker Burden and Clinical Progression in Amnestic Mild Cognitive Impairment.
medRxiv : the preprint server for health sciences pii:2026.11.03.26367187.
BACKGROUND: Altered memory self-awareness is common in mild cognitive impairment (MCI), but its relationship to Alzheimer's disease (AD) pathology and progression remains unclear.
METHODS: Using 590 amnestic MCI ADNI participants, memory self-awareness was derived from participant-informant discrepancies on the memory subdomain of the Everyday Cognition questionnaire. Heightened awareness and unawareness subscores were calculated, and k-means clustering identified four phenotypes. Associations with cerebrospinal fluid (CSF) and positron emission tomography (PET) were examined, and clinical progression was assessed using Cox models.
RESULTS: Aware and Unaware groups showed lower CSF amyloid-β, and higher CSF phosphorylated tau and PET amyloid. The Unaware phenotype was associated with increased progression risk (hazard ratio 2.41, 95% CI 1.48-3.92), whereas the Worried Well phenotype showed reduced risk (hazard ratio 0.58, 95% CI 0.34-0.99).
CONCLUSIONS: Multidimensional assessment of memory self-awareness identifies biologically and prognostically distinct subgroups within MCI and may improve risk stratification in prodromal AD.
Additional Links: PMID-43060725
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060725,
year = {2026},
author = {Enbar-Salo, N and Palmer, P and Munro, C and Dubbelman, M and Aaronson, A and Nosheny, R and Gatchel, J and Marshall, GA and Vannini, P and , },
title = {Memory Self-Awareness Phenotypes are Associated with Alzheimer's Disease Biomarker Burden and Clinical Progression in Amnestic Mild Cognitive Impairment.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.03.26367187},
pmid = {43060725},
abstract = {BACKGROUND: Altered memory self-awareness is common in mild cognitive impairment (MCI), but its relationship to Alzheimer's disease (AD) pathology and progression remains unclear.
METHODS: Using 590 amnestic MCI ADNI participants, memory self-awareness was derived from participant-informant discrepancies on the memory subdomain of the Everyday Cognition questionnaire. Heightened awareness and unawareness subscores were calculated, and k-means clustering identified four phenotypes. Associations with cerebrospinal fluid (CSF) and positron emission tomography (PET) were examined, and clinical progression was assessed using Cox models.
RESULTS: Aware and Unaware groups showed lower CSF amyloid-β, and higher CSF phosphorylated tau and PET amyloid. The Unaware phenotype was associated with increased progression risk (hazard ratio 2.41, 95% CI 1.48-3.92), whereas the Worried Well phenotype showed reduced risk (hazard ratio 0.58, 95% CI 0.34-0.99).
CONCLUSIONS: Multidimensional assessment of memory self-awareness identifies biologically and prognostically distinct subgroups within MCI and may improve risk stratification in prodromal AD.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
PRISM-AD quantifies clinical and genetic contributions to cognitive risk prediction.
medRxiv : the preprint server for health sciences pii:2026.11.03.26367206.
BACKGROUND: Older adults with high inherited Alzheimer's disease (AD) susceptibility can still be cognitively normal (CN). An overall risk estimate alone does not show the cognitive and genetic contributions within a forecast.
OBJECTIVE: To quantify clinical and genetic contributions to cognitive prognosis.
METHODS: PRISM-AD combined nonlinear clinical functions and a polygenic risk score (PRS) term in 4,435 European-ancestry participants. Participant-level internal validation evaluated first recorded mild cognitive impairment (MCI) after CN in 908 participants and AD dementia after MCI in 714, within three or five years. Separately fitted comparators used identical inputs. Post hoc clinical-course comparisons used regression with robust standard errors and Benjamini-Hochberg (BH) correction.
RESULTS: PRISM-AD using current assessments achieved average precision of 0.2996 and 0.4094 for three- and five-year CN-to-MCI, with estimates close to logistic regression. No PRISM-AD PRS increment met BH q < 0.05. Three-year first-MCI forecasts characterized risk contributions in 893 initially CN participants. A retrospective comparison over available follow-up included 95 participants with later AD and 701 with CN at their last diagnostic assessment. Modeled genetic factors were higher in later AD in nine of ten shared cognitive-risk deciles. After adjustment for modeled cognitive risk and fold, the genetic-factor ratio was 1.135 (nominal 95% CI, 1.073 to 1.201, BH q < 0.001).
CONCLUSIONS: Higher genetic contributions were associated with later AD at comparable modeled cognitive risk. These exploratory profiles require independent validation before use in cognitive follow-up or prevention research.
Additional Links: PMID-43060740
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060740,
year = {2026},
author = {Dai, Y and Wood, CS and Jiang, X and Hsu, YC},
title = {PRISM-AD quantifies clinical and genetic contributions to cognitive risk prediction.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.03.26367206},
pmid = {43060740},
abstract = {BACKGROUND: Older adults with high inherited Alzheimer's disease (AD) susceptibility can still be cognitively normal (CN). An overall risk estimate alone does not show the cognitive and genetic contributions within a forecast.
OBJECTIVE: To quantify clinical and genetic contributions to cognitive prognosis.
METHODS: PRISM-AD combined nonlinear clinical functions and a polygenic risk score (PRS) term in 4,435 European-ancestry participants. Participant-level internal validation evaluated first recorded mild cognitive impairment (MCI) after CN in 908 participants and AD dementia after MCI in 714, within three or five years. Separately fitted comparators used identical inputs. Post hoc clinical-course comparisons used regression with robust standard errors and Benjamini-Hochberg (BH) correction.
RESULTS: PRISM-AD using current assessments achieved average precision of 0.2996 and 0.4094 for three- and five-year CN-to-MCI, with estimates close to logistic regression. No PRISM-AD PRS increment met BH q < 0.05. Three-year first-MCI forecasts characterized risk contributions in 893 initially CN participants. A retrospective comparison over available follow-up included 95 participants with later AD and 701 with CN at their last diagnostic assessment. Modeled genetic factors were higher in later AD in nine of ten shared cognitive-risk deciles. After adjustment for modeled cognitive risk and fold, the genetic-factor ratio was 1.135 (nominal 95% CI, 1.073 to 1.201, BH q < 0.001).
CONCLUSIONS: Higher genetic contributions were associated with later AD at comparable modeled cognitive risk. These exploratory profiles require independent validation before use in cognitive follow-up or prevention research.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Stage-Specific Roles of Plasma GFAP in Linking Amyloid Cascade in Alzheimer Disease.
medRxiv : the preprint server for health sciences pii:2026.11.03.26366374.
INTRODUCTION: Astrocytic reactivity, measured by plasma glial fibrillary acidic protein (GFAP), is robustly elevated across the Alzheimer disease (AD) continuum, yet its relationship with the amyloid cascade remains poorly understood.
METHODS: We integrated plasma GFAP with multimodal AD biomarkers including cerebrospinal fluid (CSF) or plasma Aβ (Aβ42/40), Aβ and tau positron emission tomography (PET), structural MRI, and clinical severity, across a discovery cohort (Knight Alzheimer Disease Research Center, n=278) and an independent replication cohort (Alzheimer's Disease Neuroimaging Initiative, n=236).
RESULTS: In both cohorts, plasma GFAP mediated the association of soluble Aβ42/40 (CSF in the Knight ADRC; plasma in ADNI) with Aβ PET, as well as the association of Aβ PET with tau PET in the overall samples, which remained significant after false discovery rate (FDR) correction. Among tau-negative individuals, GFAP mediated the association between CSF Aβ42/40 and Aβ PET in Knight ADRC, but this effect did not survive FDR correction with plasma Aβ42/40 in ADNI. In Aβ-positive individuals, GFAP mediated the association between Aβ PET and tau PET burden in both cohorts, but survived correction only in ADNI. Interaction findings were partially replicated across cohorts. Exploratory plasma proteomics further revealed a GFAP-associated protein network enriched for extracellular matrix (ECM)-immune remodeling network.
DISCUSSION: These findings reveal stage-specific associations of plasma GFAP with the amyloid cascade and implicate an astrocyte-centered ECM-inflammatory axis, which may inform future diagnostic panels or targeted therapies.
CLINICAL TRIAL REGISTRATION: Alzheimer's Disease Neuroimaging Initiative 3, ClinicalTrials.gov, NCT02854033 .
Additional Links: PMID-43060752
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060752,
year = {2026},
author = {Niu, X and Sun, Q and Wisch, JK and Jiang, M and Luna, A and Hoagey, DA and Schindler, SE and Cruchaga, C and Gordon, BA and Wang, Y and Benzinger, TLS and , and Wang, Q},
title = {Stage-Specific Roles of Plasma GFAP in Linking Amyloid Cascade in Alzheimer Disease.},
journal = {medRxiv : the preprint server for health sciences},
volume = {},
number = {},
pages = {},
doi = {10.64898/2026.11.03.26366374},
pmid = {43060752},
abstract = {INTRODUCTION: Astrocytic reactivity, measured by plasma glial fibrillary acidic protein (GFAP), is robustly elevated across the Alzheimer disease (AD) continuum, yet its relationship with the amyloid cascade remains poorly understood.
METHODS: We integrated plasma GFAP with multimodal AD biomarkers including cerebrospinal fluid (CSF) or plasma Aβ (Aβ42/40), Aβ and tau positron emission tomography (PET), structural MRI, and clinical severity, across a discovery cohort (Knight Alzheimer Disease Research Center, n=278) and an independent replication cohort (Alzheimer's Disease Neuroimaging Initiative, n=236).
RESULTS: In both cohorts, plasma GFAP mediated the association of soluble Aβ42/40 (CSF in the Knight ADRC; plasma in ADNI) with Aβ PET, as well as the association of Aβ PET with tau PET in the overall samples, which remained significant after false discovery rate (FDR) correction. Among tau-negative individuals, GFAP mediated the association between CSF Aβ42/40 and Aβ PET in Knight ADRC, but this effect did not survive FDR correction with plasma Aβ42/40 in ADNI. In Aβ-positive individuals, GFAP mediated the association between Aβ PET and tau PET burden in both cohorts, but survived correction only in ADNI. Interaction findings were partially replicated across cohorts. Exploratory plasma proteomics further revealed a GFAP-associated protein network enriched for extracellular matrix (ECM)-immune remodeling network.
DISCUSSION: These findings reveal stage-specific associations of plasma GFAP with the amyloid cascade and implicate an astrocyte-centered ECM-inflammatory axis, which may inform future diagnostic panels or targeted therapies.
CLINICAL TRIAL REGISTRATION: Alzheimer's Disease Neuroimaging Initiative 3, ClinicalTrials.gov, NCT02854033 .},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Anatomical Interfaces as a Complementary Substrate for Structural MRI Representation in Alzheimer's Disease.
Research square pii:rs.3.rs-11067124.
Background Structural MRI analysis of Alzheimer's disease (AD) commonly relies on region-of-interest (ROI) summaries or voxel-level deep networks, neither of which explicitly quantifies the physical interfaces shared by adjacent brain regions. We investigated whether these anatomical interfaces provide structural information complementary to conventional regional measures. Methods T1-weighted MRI was segmented into 79 anatomical regions using a pretrained nnU-Net. Each region was represented as a graph node with six morpho-textural descriptors, while edges were defined only between regions sharing voxel-level face contact and characterized by Structural Contact and Boundary Appearance features. Results Correlation analyses showed generally limited redundancy between node- and interface-level descriptors, supporting partially distinct representational information. Node-controlled analyses further showed that selected interface features remained significantly associated with disease stage after adjustment for the morpho-textural characteristics of both connected regions, indicating that interface-level variation was not fully reducible to regional abnormalities. White matter hypointensity interfaces repeatedly emerged among the retained stage-associated effects. Selected Structural Contact features also showed convergent associations with clinical severity across CDR-SB, ADAS-Cog13, and MMSE. Representation ablation demonstrated that disrupting anatomical adjacency or removing interface attributes reduced classification performance, supporting the contribution of anatomically organized relational information. The full representation also improved multi-class classification relative to conventional ROI-vector and voxel-level baselines, with this advantage preserved on the independent NACC cohort without fine-tuning. Conclusions These findings indicate that anatomical interfaces provide measurable and complementary structural information beyond conventional region-wise morphometry, offering an interpretable framework for representing inter-regional structural relationships in neurodegenerative disease.
Additional Links: PMID-43060763
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060763,
year = {2026},
author = {Gi, Y and Lim, H and Park, S and Lee, J and Park, S and Jung, AH and Baek, SH and Kim, JH and Kim, BJ and Yoon, M},
title = {Anatomical Interfaces as a Complementary Substrate for Structural MRI Representation in Alzheimer's Disease.},
journal = {Research square},
volume = {},
number = {},
pages = {},
doi = {10.21203/rs.3.rs-11067124/v1},
pmid = {43060763},
issn = {2693-5015},
abstract = {Background Structural MRI analysis of Alzheimer's disease (AD) commonly relies on region-of-interest (ROI) summaries or voxel-level deep networks, neither of which explicitly quantifies the physical interfaces shared by adjacent brain regions. We investigated whether these anatomical interfaces provide structural information complementary to conventional regional measures. Methods T1-weighted MRI was segmented into 79 anatomical regions using a pretrained nnU-Net. Each region was represented as a graph node with six morpho-textural descriptors, while edges were defined only between regions sharing voxel-level face contact and characterized by Structural Contact and Boundary Appearance features. Results Correlation analyses showed generally limited redundancy between node- and interface-level descriptors, supporting partially distinct representational information. Node-controlled analyses further showed that selected interface features remained significantly associated with disease stage after adjustment for the morpho-textural characteristics of both connected regions, indicating that interface-level variation was not fully reducible to regional abnormalities. White matter hypointensity interfaces repeatedly emerged among the retained stage-associated effects. Selected Structural Contact features also showed convergent associations with clinical severity across CDR-SB, ADAS-Cog13, and MMSE. Representation ablation demonstrated that disrupting anatomical adjacency or removing interface attributes reduced classification performance, supporting the contribution of anatomically organized relational information. The full representation also improved multi-class classification relative to conventional ROI-vector and voxel-level baselines, with this advantage preserved on the independent NACC cohort without fine-tuning. Conclusions These findings indicate that anatomical interfaces provide measurable and complementary structural information beyond conventional region-wise morphometry, offering an interpretable framework for representing inter-regional structural relationships in neurodegenerative disease.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Interpreting Functional Connectivity in Alzheimer's Disease as Cognitive Processes: Multinomial Processing Trees and the Common Model of Cognition.
Research square pii:rs.3.rs-10981827.
Cognitive process models and brain connectivity analyses both provide a higher resolution into what cognitive functions are engaged during cognitive tasks than traditional methods. However, the two methods are typically applied in isolation. Our goal is to combine them, and ask which impaired cognitive functions are associated with a specific connectivity signature. Participants were 1,127 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI), of varying cognitive status at their last included time point: Cognitively Normal = 554, Mild Cognitive Impairment = 386, Alzheimer's Disease = 187. We combine Bayesian multinomial processing tree (MPT) cognitive modelling with resting-state functional connectivity analysis guided by the Common Model of Cognition. MPT modelling showed that Learned and Delayed Retrieval processes had the largest diagnostic differences (η[2] ≈ 0.40), while Short-term Retrieval was unaffected. MPT parameters were correlated with widespread brain connectivity changes. However, brain connectivity changes were collinear, and mostly attributable to the diagnostic group. The exception was the Delayed Retrieval process parameter, which was associated with functional connectivity between areas associated with Working Memory and areas associated with Long-Term Memory, even when corrected for all other parameters. Combining the two analyses allowed us to link a function defined at the neural level to a function defined at the behavioral level. This article describes the potential and current limits of joining the two classes of models.
Additional Links: PMID-43060770
Full Text:
Publisher:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060770,
year = {2026},
author = {Potthoff, RD and Steffen, S and van Rentergem, JA and Sibert, C},
title = {Interpreting Functional Connectivity in Alzheimer's Disease as Cognitive Processes: Multinomial Processing Trees and the Common Model of Cognition.},
journal = {Research square},
volume = {},
number = {},
pages = {},
doi = {10.21203/rs.3.rs-10981827/v1},
pmid = {43060770},
issn = {2693-5015},
abstract = {Cognitive process models and brain connectivity analyses both provide a higher resolution into what cognitive functions are engaged during cognitive tasks than traditional methods. However, the two methods are typically applied in isolation. Our goal is to combine them, and ask which impaired cognitive functions are associated with a specific connectivity signature. Participants were 1,127 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI), of varying cognitive status at their last included time point: Cognitively Normal = 554, Mild Cognitive Impairment = 386, Alzheimer's Disease = 187. We combine Bayesian multinomial processing tree (MPT) cognitive modelling with resting-state functional connectivity analysis guided by the Common Model of Cognition. MPT modelling showed that Learned and Delayed Retrieval processes had the largest diagnostic differences (η[2] ≈ 0.40), while Short-term Retrieval was unaffected. MPT parameters were correlated with widespread brain connectivity changes. However, brain connectivity changes were collinear, and mostly attributable to the diagnostic group. The exception was the Delayed Retrieval process parameter, which was associated with functional connectivity between areas associated with Working Memory and areas associated with Long-Term Memory, even when corrected for all other parameters. Combining the two analyses allowed us to link a function defined at the neural level to a function defined at the behavioral level. This article describes the potential and current limits of joining the two classes of models.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Blood-brain barrier-penetrant pharmacological strategies for neuroinflammation in Alzheimer's disease: small molecules and engineered peptides.
Frontiers in pharmacology, 17:1983306.
Recognition of Alzheimer's disease (AD) as a neuroinflammatory disorder, alongside amyloid-β and tau pathology, necessitates the development of innovative therapies capable of overcoming blood-brain barrier (BBB)-mediated limitations to brain drug delivery. This review discusses current efforts to develop BBB-permeable small molecules and peptide-based therapies targeting the neuroimmune modulators TREM2, the NLRP3 inflammasome, RIPK1, and the cGAS-STING signaling pathway, with consideration of the concept of the neurovascular paradox. Despite promising recent developments, the trade-off between permeability, selectivity, and cytotoxicity remains a significant issue. The current findings indicate that BBB penetration, the timing of microglial targeting, immunosuppressive effects, and neuroimmune homeostasis should be considered when seeking to modulate neuroinflammation effectively. Novel delivery systems, such as those using cell-penetrating peptide shuttles and antibody-based transport systems, may help address BBB limitations, and biomarker-guided treatment is increasingly important. Overall, this review reframes brain drug delivery not only as a function of pharmacokinetic parameters but also as part of a system integrating neurovascular physiology, neuroimmunology, and medicinal chemistry.
Additional Links: PMID-43060827
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060827,
year = {2026},
author = {Fatima, F and Sajid, MI and Shirazi, AN and Sohaib, SN and Khan, FA and Shahzadi, HR and El-Sayed, NS and Tiwari, RK and Parang, K},
title = {Blood-brain barrier-penetrant pharmacological strategies for neuroinflammation in Alzheimer's disease: small molecules and engineered peptides.},
journal = {Frontiers in pharmacology},
volume = {17},
number = {},
pages = {1983306},
pmid = {43060827},
issn = {1663-9812},
abstract = {Recognition of Alzheimer's disease (AD) as a neuroinflammatory disorder, alongside amyloid-β and tau pathology, necessitates the development of innovative therapies capable of overcoming blood-brain barrier (BBB)-mediated limitations to brain drug delivery. This review discusses current efforts to develop BBB-permeable small molecules and peptide-based therapies targeting the neuroimmune modulators TREM2, the NLRP3 inflammasome, RIPK1, and the cGAS-STING signaling pathway, with consideration of the concept of the neurovascular paradox. Despite promising recent developments, the trade-off between permeability, selectivity, and cytotoxicity remains a significant issue. The current findings indicate that BBB penetration, the timing of microglial targeting, immunosuppressive effects, and neuroimmune homeostasis should be considered when seeking to modulate neuroinflammation effectively. Novel delivery systems, such as those using cell-penetrating peptide shuttles and antibody-based transport systems, may help address BBB limitations, and biomarker-guided treatment is increasingly important. Overall, this review reframes brain drug delivery not only as a function of pharmacokinetic parameters but also as part of a system integrating neurovascular physiology, neuroimmunology, and medicinal chemistry.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Midsagittal Corpus Callosum Parameterization: A Framework for Spatially Detailed Diffusion MR Imaging Analysis.
ArXiv pii:2611.19066.
The corpus callosum (CC) is the largest white matter structure in the human brain and plays a central role in interhemispheric communication. Diffusion MR imaging is widely used to investigate microstructural organization, but commonly used analysis approaches have important limitations. Voxel-based methods rely heavily on accurate inter-subject registration and smoothing choices, tract-based spatial statistics (TBSS) restricts the analysis to a narrow white matter skeleton, and parcellation approaches reduce spatial detail by averaging diffusion measures over relatively large regions. In this work, we introduce a parameterization framework for the analysis of the midsagittal CC that resamples the structure using a standardized grid of points, establishing a geometric correspondence across individuals without explicit inter-subject registration. In a test-retest dataset, the method provided stable measurements while covering most of the midsagittal CC, and sensitivity analyses showed that results in the central CC changed little under perturbations of the input CC mask, whereas peripheral regions were more sensitive. The framework was further evaluated in group analyses of aging and Alzheimer's disease in datasets that differ in acquisition protocol and spatial resolution. Effect-size maps and quantitative comparisons showed that its results were largely consistent with TBSS and parcellation-based analyses in the overall spatial pattern of effects, while also revealing additional spatially localized differences. These findings suggest that the parameterization provides a simple, computationally efficient, and spatially detailed approach for investigating midsagittal CC microstructure, offering a structure-specific complement to whole-brain and region-based methods.
Additional Links: PMID-43060846
Full Text:
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43060846,
year = {2026},
author = {Santana, C and Lebel, C and Frayne, R and Rittner, L},
title = {Midsagittal Corpus Callosum Parameterization: A Framework for Spatially Detailed Diffusion MR Imaging Analysis.},
journal = {ArXiv},
volume = {},
number = {},
pages = {},
pmid = {43060846},
issn = {2331-8422},
abstract = {The corpus callosum (CC) is the largest white matter structure in the human brain and plays a central role in interhemispheric communication. Diffusion MR imaging is widely used to investigate microstructural organization, but commonly used analysis approaches have important limitations. Voxel-based methods rely heavily on accurate inter-subject registration and smoothing choices, tract-based spatial statistics (TBSS) restricts the analysis to a narrow white matter skeleton, and parcellation approaches reduce spatial detail by averaging diffusion measures over relatively large regions. In this work, we introduce a parameterization framework for the analysis of the midsagittal CC that resamples the structure using a standardized grid of points, establishing a geometric correspondence across individuals without explicit inter-subject registration. In a test-retest dataset, the method provided stable measurements while covering most of the midsagittal CC, and sensitivity analyses showed that results in the central CC changed little under perturbations of the input CC mask, whereas peripheral regions were more sensitive. The framework was further evaluated in group analyses of aging and Alzheimer's disease in datasets that differ in acquisition protocol and spatial resolution. Effect-size maps and quantitative comparisons showed that its results were largely consistent with TBSS and parcellation-based analyses in the overall spatial pattern of effects, while also revealing additional spatially localized differences. These findings suggest that the parameterization provides a simple, computationally efficient, and spatially detailed approach for investigating midsagittal CC microstructure, offering a structure-specific complement to whole-brain and region-based methods.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Shared mechanisms and therapeutic horizons: exploring the potential interplay between benign prostatic hyperplasia/lower urinary tract symptoms and Alzheimer's disease.
Frontiers in neurology, 17:1817059.
Alzheimer's disease (AD) and benign prostatic hyperplasia (BPH) are two prevalent age-related disorders with significant global healthcare burdens. Traditionally viewed as distinct conditions, emerging evidence suggests that they may share common pathophysiological mechanisms, including chronic inflammation, endocrine dysregulation, metabolic dysfunction, cardiovascular impairment, and sleep disturbances. This review synthesizes current epidemiological, mechanistic, and therapeutic insights linking BPH and AD, with a focus on their overlapping risk factors and molecular pathways. Although most of the currently available evidence is observational and cannot establish causality, understanding these interactions could inform novel preventive and therapeutic strategies to mitigate the dual burden of neurodegenerative and urological conditions in older populations.
Additional Links: PMID-43061084
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43061084,
year = {2026},
author = {Song, M and Liu, A and Liang, H and Yang, Q and Zhang, B and Cui, J and Qiu, Y},
title = {Shared mechanisms and therapeutic horizons: exploring the potential interplay between benign prostatic hyperplasia/lower urinary tract symptoms and Alzheimer's disease.},
journal = {Frontiers in neurology},
volume = {17},
number = {},
pages = {1817059},
pmid = {43061084},
issn = {1664-2295},
mesh = {Humans ; *Prostatic Hyperplasia/epidemiology/therapy/physiopathology/metabolism/complications ; *Alzheimer Disease/epidemiology/therapy/physiopathology/metabolism/complications ; Male ; *Lower Urinary Tract Symptoms/epidemiology/therapy/physiopathology/metabolism ; },
abstract = {Alzheimer's disease (AD) and benign prostatic hyperplasia (BPH) are two prevalent age-related disorders with significant global healthcare burdens. Traditionally viewed as distinct conditions, emerging evidence suggests that they may share common pathophysiological mechanisms, including chronic inflammation, endocrine dysregulation, metabolic dysfunction, cardiovascular impairment, and sleep disturbances. This review synthesizes current epidemiological, mechanistic, and therapeutic insights linking BPH and AD, with a focus on their overlapping risk factors and molecular pathways. Although most of the currently available evidence is observational and cannot establish causality, understanding these interactions could inform novel preventive and therapeutic strategies to mitigate the dual burden of neurodegenerative and urological conditions in older populations.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Prostatic Hyperplasia/epidemiology/therapy/physiopathology/metabolism/complications
*Alzheimer Disease/epidemiology/therapy/physiopathology/metabolism/complications
Male
*Lower Urinary Tract Symptoms/epidemiology/therapy/physiopathology/metabolism
RevDate: 2026-11-20
CmpDate: 2026-11-20
Gene therapy and RNA-directed medicines in Alzheimer's disease: toward a precision framework for clinical translation.
Frontiers in aging neuroscience, 18:2011267.
BACKGROUND: Gene transfer and RNA-directed medicines offer distinct approaches to modifying disease-relevant biology in Alzheimer's disease (AD). Existing precision drug-development frameworks require adaptation to account for persistent expression, anatomical distribution, and platform-specific limits on dose adjustment.
OBJECTIVE: To propose a modality-specific framework organized around molecular target, biological subgroup, anatomical and cellular delivery, and disease stage, with common requirements for target engagement, clinically meaningful outcomes, and long-term safety.
METHODS: A targeted appraisal of selected clinical, translational, and registry sources was used to develop and illustrate the framework, without a systematic review or quantitative synthesis.
RESULTS: The retrieved clinical programs illustrate core domains of the suggested framework: nerve growth factor (NGF) studies showed persistent expression, but postmortem findings in three phase I participants revealed limitations in anatomical delivery; apolipoprotein E (APOE) ε2 gene addition in APOE ε4 homozygotes represents a genotype-directed intervention, whereas brain-derived neurotrophic factor delivery targets vulnerable memory circuits; tau-directed antisense oligonucleotides and RNA-interference approaches targeting tau or amyloid precursor protein expand the range of molecular targets and platforms. The conference-reported phase II CELIA trial findings, consisting of a missed primary dose-response endpoint despite biomarker reductions and exploratory secondary clinical findings, highlight why target engagement and efficacy require separate evaluation. When designing trials in this field, there must be explicitly defined relationships among mechanism, population, exposure, timing, and outcomes before interpreting results.
CONCLUSION: The proposed framework is in its early developmental phase, and its value depends on prospective evaluation, platform-appropriate measures of biological activity, as well as on reassessment of delivery assumptions and therapeutic mechanisms following negative findings.
Additional Links: PMID-43061116
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43061116,
year = {2026},
author = {Vasiliu, O},
title = {Gene therapy and RNA-directed medicines in Alzheimer's disease: toward a precision framework for clinical translation.},
journal = {Frontiers in aging neuroscience},
volume = {18},
number = {},
pages = {2011267},
pmid = {43061116},
issn = {1663-4365},
abstract = {BACKGROUND: Gene transfer and RNA-directed medicines offer distinct approaches to modifying disease-relevant biology in Alzheimer's disease (AD). Existing precision drug-development frameworks require adaptation to account for persistent expression, anatomical distribution, and platform-specific limits on dose adjustment.
OBJECTIVE: To propose a modality-specific framework organized around molecular target, biological subgroup, anatomical and cellular delivery, and disease stage, with common requirements for target engagement, clinically meaningful outcomes, and long-term safety.
METHODS: A targeted appraisal of selected clinical, translational, and registry sources was used to develop and illustrate the framework, without a systematic review or quantitative synthesis.
RESULTS: The retrieved clinical programs illustrate core domains of the suggested framework: nerve growth factor (NGF) studies showed persistent expression, but postmortem findings in three phase I participants revealed limitations in anatomical delivery; apolipoprotein E (APOE) ε2 gene addition in APOE ε4 homozygotes represents a genotype-directed intervention, whereas brain-derived neurotrophic factor delivery targets vulnerable memory circuits; tau-directed antisense oligonucleotides and RNA-interference approaches targeting tau or amyloid precursor protein expand the range of molecular targets and platforms. The conference-reported phase II CELIA trial findings, consisting of a missed primary dose-response endpoint despite biomarker reductions and exploratory secondary clinical findings, highlight why target engagement and efficacy require separate evaluation. When designing trials in this field, there must be explicitly defined relationships among mechanism, population, exposure, timing, and outcomes before interpreting results.
CONCLUSION: The proposed framework is in its early developmental phase, and its value depends on prospective evaluation, platform-appropriate measures of biological activity, as well as on reassessment of delivery assumptions and therapeutic mechanisms following negative findings.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Neuroprotective and Neuroregenerative Effects of FGF-9 and Small Molecules Induced Neural Progenitor Cells in Chemically Induced Rat Model of Alzheimer's Disease.
Stem cells international, 2026:5123338.
Growth factors and small molecules are critical regulators of neural differentiation of stem cells, playing a pivotal role in modulating cellular signaling pathways that promote neurogenesis and enhance cell survival. Their combined application offers significant protective effects in Alzheimer's disease (AD) by facilitating the generation of neural progenitor cells (NPCs) capable of neuroprotection and regeneration in damaged neural tissues. This study aimed to generate NPCs from umbilical cord-derived mesenchymal stem cells (UC-MSCs) using small molecules CHIR99021, valproic acid (VPA), and fibroblast growth factor 9 (FGF-9) to evaluate their therapeutic efficacy in a rat model of neurodegeneration. Neural differentiation was induced in UC-MSCs using CHIR99021, VPA, and FGF-9 and assessed for minimal cytotoxicity and characterization through MTT assay, RT-PCR analysis, and immunocytochemistry. For in vivo studies, 25 healthy adult male albino Wistar rats were chemically induced with AlCl3 neurodegeneration. Treatment groups, including normal saline negative control, AlCl3 positive control, MSCs, neural induction media (NIM), CHIR + VPA, and CHIR + VPA + FGF-9 treated groups were assessed for behavioral assessments to evaluate cognitive and anxiety-related behaviors, followed by molecular and histopathological analysis of brain tissue. Gene expression analysis in NPCs treated with CHIR + VPA + FGF-9 demonstrated significant upregulation of neural progenitor genes: Nestin, Sox-2, and GFAP along with activation of key neurogenic signaling pathway markers Hes 1 and FGFr-3 with statistical significance (p < 0.001), respectively. The CHIR + VPA + FGF-9 induced NPCs exhibited elevated expression of neurotrophic factors NTF, BDNF, and GDNF (p < 0.001, respectively), supporting their neuroprotective and regenerative potential. Molecular analysis showed a decline in the expression of neurodegenerative pathological: MAPT-1 (p < 0.01) and inflammatory markers: NFkB (p < 0.05) and TNF-α (p < 0.01). Histological and immunohistochemical findings demonstrated reduced neuronal degeneration and enhanced neuronal survival in the hippocampus. Furthermore, protein expression of amyloid precursor protein (APP) was decreased (p < 0.001 vs. AlCl3) and cell proliferation marker (Ki67) was elevated (p < 0.001 vs. AlCl3) in NPCs-treated animals. These findings suggest that FGF-9, CHIR99021, and VPA-induced NPCs exert neuroprotective and neuroregenerative effects, highlighting their potential as a favorable therapeutic approach for AD.
Additional Links: PMID-43061297
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43061297,
year = {2026},
author = {Khan, L and Sahibdad, I and Ullah, N and Mehmood, S and Ullah, S and Ahmed, N and Hasan, JA},
title = {Neuroprotective and Neuroregenerative Effects of FGF-9 and Small Molecules Induced Neural Progenitor Cells in Chemically Induced Rat Model of Alzheimer's Disease.},
journal = {Stem cells international},
volume = {2026},
number = {},
pages = {5123338},
pmid = {43061297},
issn = {1687-966X},
abstract = {Growth factors and small molecules are critical regulators of neural differentiation of stem cells, playing a pivotal role in modulating cellular signaling pathways that promote neurogenesis and enhance cell survival. Their combined application offers significant protective effects in Alzheimer's disease (AD) by facilitating the generation of neural progenitor cells (NPCs) capable of neuroprotection and regeneration in damaged neural tissues. This study aimed to generate NPCs from umbilical cord-derived mesenchymal stem cells (UC-MSCs) using small molecules CHIR99021, valproic acid (VPA), and fibroblast growth factor 9 (FGF-9) to evaluate their therapeutic efficacy in a rat model of neurodegeneration. Neural differentiation was induced in UC-MSCs using CHIR99021, VPA, and FGF-9 and assessed for minimal cytotoxicity and characterization through MTT assay, RT-PCR analysis, and immunocytochemistry. For in vivo studies, 25 healthy adult male albino Wistar rats were chemically induced with AlCl3 neurodegeneration. Treatment groups, including normal saline negative control, AlCl3 positive control, MSCs, neural induction media (NIM), CHIR + VPA, and CHIR + VPA + FGF-9 treated groups were assessed for behavioral assessments to evaluate cognitive and anxiety-related behaviors, followed by molecular and histopathological analysis of brain tissue. Gene expression analysis in NPCs treated with CHIR + VPA + FGF-9 demonstrated significant upregulation of neural progenitor genes: Nestin, Sox-2, and GFAP along with activation of key neurogenic signaling pathway markers Hes 1 and FGFr-3 with statistical significance (p < 0.001), respectively. The CHIR + VPA + FGF-9 induced NPCs exhibited elevated expression of neurotrophic factors NTF, BDNF, and GDNF (p < 0.001, respectively), supporting their neuroprotective and regenerative potential. Molecular analysis showed a decline in the expression of neurodegenerative pathological: MAPT-1 (p < 0.01) and inflammatory markers: NFkB (p < 0.05) and TNF-α (p < 0.01). Histological and immunohistochemical findings demonstrated reduced neuronal degeneration and enhanced neuronal survival in the hippocampus. Furthermore, protein expression of amyloid precursor protein (APP) was decreased (p < 0.001 vs. AlCl3) and cell proliferation marker (Ki67) was elevated (p < 0.001 vs. AlCl3) in NPCs-treated animals. These findings suggest that FGF-9, CHIR99021, and VPA-induced NPCs exert neuroprotective and neuroregenerative effects, highlighting their potential as a favorable therapeutic approach for AD.},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
CD8[+] T cells drive neuroinflammation and cognitive decline in Alzheimer's disease.
Frontiers in immunology, 17:1990281.
Alzheimer's disease (AD) is the most common neurodegenerative disease in the world, and its pathogenesis is very complex, posing a serious threat to human health. The reciprocal regulation of the nervous and immune systems plays a key role in driving AD progression, although the specific mechanisms remain to be elucidated. In recent years, attention has increasingly focused on the role of adaptive immune cells in AD. Among them, CD8[+] T cells have been found to infiltrate the brain parenchyma of AD patients, and this phenomenon is closely associated with neuronal injury and cognitive decline. This review first outlines the epidemiology and pathomechanisms of AD and systematically summarizes CD8[+] T cell activation, cytotoxicity, migration, and function. It emphasizes the dual potential role of these cells in AD. These cells may exacerbate neuronal injury and cognitive dysfunction through multiple pathways, including direct cytotoxicity, release of pro-inflammatory cytokines, disruption of the blood-brain barrier, and inhibition of neuroplasticity. However, under specific microenvironmental conditions, CD8[+] T cells may also exert immunomodulatory functions and confer potential protective effects. This review also discusses related therapeutic strategies based on these mechanisms. Finally, we discuss the difficulties currently facing research and future directions for clinical translation. We believe that in-depth exploration of the immunoregulatory mechanisms of CD8[+] T cells in AD can provide theoretical foundations and new perspectives for developing innovative immunotherapies targeting neuroinflammation and cognitive impairment in AD.
Additional Links: PMID-43061396
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43061396,
year = {2026},
author = {Xie, Z and Lu, Y and Qiu, Y and Deng, Q and Zhang, J and Zhou, H and Zhang, X},
title = {CD8[+] T cells drive neuroinflammation and cognitive decline in Alzheimer's disease.},
journal = {Frontiers in immunology},
volume = {17},
number = {},
pages = {1990281},
pmid = {43061396},
issn = {1664-3224},
mesh = {Humans ; *Alzheimer Disease/immunology/metabolism/therapy ; *CD8-Positive T-Lymphocytes/immunology/metabolism ; Animals ; *Neuroinflammatory Diseases/immunology ; *Cognitive Dysfunction/immunology ; Blood-Brain Barrier/immunology ; Lymphocyte Activation ; Brain/immunology/pathology/metabolism ; },
abstract = {Alzheimer's disease (AD) is the most common neurodegenerative disease in the world, and its pathogenesis is very complex, posing a serious threat to human health. The reciprocal regulation of the nervous and immune systems plays a key role in driving AD progression, although the specific mechanisms remain to be elucidated. In recent years, attention has increasingly focused on the role of adaptive immune cells in AD. Among them, CD8[+] T cells have been found to infiltrate the brain parenchyma of AD patients, and this phenomenon is closely associated with neuronal injury and cognitive decline. This review first outlines the epidemiology and pathomechanisms of AD and systematically summarizes CD8[+] T cell activation, cytotoxicity, migration, and function. It emphasizes the dual potential role of these cells in AD. These cells may exacerbate neuronal injury and cognitive dysfunction through multiple pathways, including direct cytotoxicity, release of pro-inflammatory cytokines, disruption of the blood-brain barrier, and inhibition of neuroplasticity. However, under specific microenvironmental conditions, CD8[+] T cells may also exert immunomodulatory functions and confer potential protective effects. This review also discusses related therapeutic strategies based on these mechanisms. Finally, we discuss the difficulties currently facing research and future directions for clinical translation. We believe that in-depth exploration of the immunoregulatory mechanisms of CD8[+] T cells in AD can provide theoretical foundations and new perspectives for developing innovative immunotherapies targeting neuroinflammation and cognitive impairment in AD.},
}
MeSH Terms:
show MeSH Terms
hide MeSH Terms
Humans
*Alzheimer Disease/immunology/metabolism/therapy
*CD8-Positive T-Lymphocytes/immunology/metabolism
Animals
*Neuroinflammatory Diseases/immunology
*Cognitive Dysfunction/immunology
Blood-Brain Barrier/immunology
Lymphocyte Activation
Brain/immunology/pathology/metabolism
RevDate: 2026-11-20
Aging and neurodegenerative diseases: emerging technologies and therapeutics.
Military Medical Research, 13(1):100079.
Additional Links: PMID-43061545
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43061545,
year = {2026},
author = {Shetty, AK and Mandhyan, PM},
title = {Aging and neurodegenerative diseases: emerging technologies and therapeutics.},
journal = {Military Medical Research},
volume = {13},
number = {1},
pages = {100079},
pmid = {43061545},
issn = {2054-9369},
}
RevDate: 2026-11-20
CmpDate: 2026-11-20
Bypassing the Blood-Brain Barrier: A Dual-Axis Framework for Parkinson's Disease Utilizing Glymphatic-Lymphatic Clearance and In Situ Chaperone Synthesis.
Cureus, 18(10):e118265.
Parkinson's disease (PD) is characterized neuropathologically by loss of dopaminergic neurons in the substantia nigra pars compacta and by aggregation of misfolded alpha-synuclein into Lewy bodies and Lewy neurites, which is proposed to propagate in a prion-like manner following a stereotyped, stage-dependent pattern described by Braak staging. Because any circulating agent intended to act within the central nervous system (CNS) must cross the blood-brain barrier, this review proposes active craniospinal tensioning (ACT), a mechanical, non-pharmacological route to disease modification acting on cerebrospinal fluid (CSF) and cerebral venous pressure dynamics. ACT combines two concurrent mechanisms converging on a single venous-side target within Monro-Kellie/Queckenstedt pressure continuity: suboccipital venous occlusion-rebound, proposed to raise and release craniospinal CSF pressure to accelerate venous-side glymphatic efflux, and dural pull-recoil, a reverse Queckenstedt effect in which spinal elongation is proposed to generate a CSF-side pressure gradient with a coupled venous component. The proposed disease-modifying route is clearance of transiting extracellular alpha-synuclein from the perivascular and interstitial space before it templates a neighboring cell. The claim is scoped to the CNS phase of PD, excluding peripheral vagal or olfactory transport, with its most direct anatomical rationale at the dorsal motor nucleus of the vagus (DMV), one of the two earliest CNS sites of Lewy pathology in Braak staging and adjacent to ACT's craniocervical site of action, where ACT is proposed to act on onward extracellular spread rather than on arrival. A secondary, hypothesis-generating axis, cerebral venous preconditioning (CVPC), proposes that the same cycle produces venule- and capillary-wall strain sufficient to activate heat shock factor 1 (HSF-1) within the neurovascular unit, beginning at the vessel wall, independent of oxygen tension, with a possible contribution from hypoxia-inducible factor 1-alpha (HIF-1α) left open; the mechanical route alone is proposed as sufficient. Validation is staged, with diffusion tensor image analysis along the perivascular space (DTI-ALPS) and neuromelanin-sensitive magnetic resonance imaging with quantitative susceptibility mapping (QSM) of the substantia nigra as dual falsification endpoints over at least two years, and any disease-modification claim deferred to a randomized, delayed-start trial. This framework is entirely theoretical, requires clinical validation, and extends a dual-axis template already applied to Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Additional Links: PMID-43061646
PubMed:
Citation:
show bibtex listing
hide bibtex listing
@article {pmid43061646,
year = {2026},
author = {Chen, HW},
title = {Bypassing the Blood-Brain Barrier: A Dual-Axis Framework for Parkinson's Disease Utilizing Glymphatic-Lymphatic Clearance and In Situ Chaperone Synthesis.},
journal = {Cureus},
volume = {18},
number = {10},
pages = {e118265},
pmid = {43061646},
issn = {2168-8184},
abstract = {Parkinson's disease (PD) is characterized neuropathologically by loss of dopaminergic neurons in the substantia nigra pars compacta and by aggregation of misfolded alpha-synuclein into Lewy bodies and Lewy neurites, which is proposed to propagate in a prion-like manner following a stereotyped, stage-dependent pattern described by Braak staging. Because any circulating agent intended to act within the central nervous system (CNS) must cross the blood-brain barrier, this review proposes active craniospinal tensioning (ACT), a mechanical, non-pharmacological route to disease modification acting on cerebrospinal fluid (CSF) and cerebral venous pressure dynamics. ACT combines two concurrent mechanisms converging on a single venous-side target within Monro-Kellie/Queckenstedt pressure continuity: suboccipital venous occlusion-rebound, proposed to raise and release craniospinal CSF pressure to accelerate venous-side glymphatic efflux, and dural pull-recoil, a reverse Queckenstedt effect in which spinal elongation is proposed to generate a CSF-side pressure gradient with a coupled venous component. The proposed disease-modifying route is clearance of transiting extracellular alpha-synuclein from the perivascular and interstitial space before it templates a neighboring cell. The claim is scoped to the CNS phase of PD, excluding peripheral vagal or olfactory transport, with its most direct anatomical rationale at the dorsal motor nucleus of the vagus (DMV), one of the two earliest CNS sites of Lewy pathology in Braak staging and adjacent to ACT's craniocervical site of action, where ACT is proposed to act on onward extracellular spread rather than on arrival. A secondary, hypothesis-generating axis, cerebral venous preconditioning (CVPC), proposes that the same cycle produces venule- and capillary-wall strain sufficient to activate heat shock factor 1 (HSF-1) within the neurovascular unit, beginning at the vessel wall, independent of oxygen tension, with a possible contribution from hypoxia-inducible factor 1-alpha (HIF-1α) left open; the mechanical route alone is proposed as sufficient. Validation is staged, with diffusion tensor image analysis along the perivascular space (DTI-ALPS) and neuromelanin-sensitive magnetic resonance imaging with quantitative susceptibility mapping (QSM) of the substantia nigra as dual falsification endpoints over at least two years, and any disease-modification claim deferred to a randomized, delayed-start trial. This framework is entirely theoretical, requires clinical validation, and extends a dual-axis template already applied to Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).},
}
▼ ▼ LOAD NEXT 100 CITATIONS
RJR Experience and Expertise
Researcher
Robbins holds BS, MS, and PhD degrees in the life sciences. He served as a tenured faculty member in the Zoology and Biological Science departments at Michigan State University. He is currently exploring the intersection between genomics, microbial ecology, and biodiversity — an area that promises to transform our understanding of the biosphere.
Educator
Robbins has extensive experience in college-level education: At MSU he taught introductory biology, genetics, and population genetics. At JHU, he was an instructor for a special course on biological database design. At FHCRC, he team-taught a graduate-level course on the history of genetics. At Bellevue College he taught medical informatics.
Administrator
Robbins has been involved in science administration at both the federal and the institutional levels. At NSF he was a program officer for database activities in the life sciences, at DOE he was a program officer for information infrastructure in the human genome project. At the Fred Hutchinson Cancer Research Center, he served as a vice president for fifteen years.
Technologist
Robbins has been involved with information technology since writing his first Fortran program as a college student. At NSF he was the first program officer for database activities in the life sciences. At JHU he held an appointment in the CS department and served as director of the informatics core for the Genome Data Base. At the FHCRC he was VP for Information Technology.
Publisher
While still at Michigan State, Robbins started his first publishing venture, founding a small company that addressed the short-run publishing needs of instructors in very large undergraduate classes. For more than 20 years, Robbins has been operating The Electronic Scholarly Publishing Project, a web site dedicated to the digital publishing of critical works in science, especially classical genetics.
Speaker
Robbins is well-known for his speaking abilities and is often called upon to provide keynote or plenary addresses at international meetings. For example, in July, 2012, he gave a well-received keynote address at the Global Biodiversity Informatics Congress, sponsored by GBIF and held in Copenhagen. The slides from that talk can be seen HERE.
Facilitator
Robbins is a skilled meeting facilitator. He prefers a participatory approach, with part of the meeting involving dynamic breakout groups, created by the participants in real time: (1) individuals propose breakout groups; (2) everyone signs up for one (or more) groups; (3) the groups with the most interested parties then meet, with reports from each group presented and discussed in a subsequent plenary session.
Designer
Robbins has been engaged with photography and design since the 1960s, when he worked for a professional photography laboratory. He now prefers digital photography and tools for their precision and reproducibility. He designed his first web site more than 20 years ago and he personally designed and implemented this web site. He engages in graphic design as a hobby.
RJR Picks from Around the Web (updated 11 MAY 2018 )
Old Science
Weird Science
Treating Disease with Fecal Transplantation
Fossils of miniature humans (hobbits) discovered in Indonesia
Paleontology
Dinosaur tail, complete with feathers, found preserved in amber.
Astronomy
Mysterious fast radio burst (FRB) detected in the distant universe.
Big Data & Informatics
Big Data: Buzzword or Big Deal?
Hacking the genome: Identifying anonymized human subjects using publicly available data.